{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "toc_visible": true,
      "machine_shape": "hm",
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU",
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "f21302207e0146d7be7734e6d9cfcfd8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_4f4265ac12dc483f87f559b131f32b76",
              "IPY_MODEL_1419cf2aef4343a49555b4b01d06230e",
              "IPY_MODEL_47f61aca78004636b9bb48f5d86f1594"
            ],
            "layout": "IPY_MODEL_4a89a05fa79d4104bc3e723ec49b23e1"
          }
        },
        "4f4265ac12dc483f87f559b131f32b76": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_58a25e5ba197445397598cac5539a1fe",
            "placeholder": "​",
            "style": "IPY_MODEL_59193fdd30134684a5d02d3788da6715",
            "value": "Fetching 1 files: 100%"
          }
        },
        "1419cf2aef4343a49555b4b01d06230e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b22865d149ba4ce99986bf0df507c13a",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_291f02dbd90741899def31d164a37f56",
            "value": 1
          }
        },
        "47f61aca78004636b9bb48f5d86f1594": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0e8810540e6643728ee71b2142ef5fca",
            "placeholder": "​",
            "style": "IPY_MODEL_6ee403ddc58e49e39df8cb3cdae317dc",
            "value": " 1/1 [00:00&lt;00:00, 89.27it/s]"
          }
        },
        "4a89a05fa79d4104bc3e723ec49b23e1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "58a25e5ba197445397598cac5539a1fe": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "59193fdd30134684a5d02d3788da6715": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "b22865d149ba4ce99986bf0df507c13a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "291f02dbd90741899def31d164a37f56": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "0e8810540e6643728ee71b2142ef5fca": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6ee403ddc58e49e39df8cb3cdae317dc": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "446b49a3fb294014ab5f731280626527": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_8a4360f56e51436a846ed008d84a61ea",
              "IPY_MODEL_95782e837a384a588d11f50469cc7231",
              "IPY_MODEL_9ee925afe77c4dca94a2cbd205683035"
            ],
            "layout": "IPY_MODEL_284002f8dce5412dba9b1cec6a234bbc"
          }
        },
        "8a4360f56e51436a846ed008d84a61ea": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9e4aa572fef44fd9b53e8453520d2469",
            "placeholder": "​",
            "style": "IPY_MODEL_be91ac0a99684828a1db722d1f210eac",
            "value": "Fetching 1 files: 100%"
          }
        },
        "95782e837a384a588d11f50469cc7231": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7315c82c6020408aaa85ee72844a6cee",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_7108cd99da8e409a917dfe85ea04849f",
            "value": 1
          }
        },
        "9ee925afe77c4dca94a2cbd205683035": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_107aeded299b4fdf87d996c9323c5ddd",
            "placeholder": "​",
            "style": "IPY_MODEL_4e75b56b93b1441eabac0591e124d9e9",
            "value": " 1/1 [00:00&lt;00:00, 79.29it/s]"
          }
        },
        "284002f8dce5412dba9b1cec6a234bbc": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9e4aa572fef44fd9b53e8453520d2469": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "be91ac0a99684828a1db722d1f210eac": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "7315c82c6020408aaa85ee72844a6cee": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7108cd99da8e409a917dfe85ea04849f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "107aeded299b4fdf87d996c9323c5ddd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4e75b56b93b1441eabac0591e124d9e9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "![JohnSnowLabs](https://nlp.johnsnowlabs.com/assets/images/logo.png)"
      ],
      "metadata": {
        "id": "nGgSSiRW-kja"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "[![Open In Colab](https://colab.research.google.com/assets/colab-badge.svg)](https://colab.research.google.com/github/JohnSnowLabs/spark-nlp-workshop/blob/master/tutorials/Certification_Trainings/Public/22.2_Retrieval_Augmented_Generation_with_Spark_NLP.ipynb)"
      ],
      "metadata": {
        "id": "ds4CQnjg-mDh"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "# **Retrieval Augmented Generation with Spark NLP**"
      ],
      "metadata": {
        "id": "kAZFl5iOHvej"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## **🎬 Colab Setup**"
      ],
      "metadata": {
        "id": "mGdnCnAYNedV"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from getpass import getpass\n",
        "OPENAI_API_KEY = getpass('Please enter your open_api_key:')\n",
        "# If you do not have an OpenAI key, you can skip the OpenAI section below and continue using open-source LLMs."
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ro9zd-gdDN7l",
        "outputId": "ccdf949d-1b62-4c9b-8623-780925eb3748"
      },
      "execution_count": 1,
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Please enter your open_api_key:··········\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "id": "4WQLLrIUA9cg"
      },
      "outputs": [],
      "source": [
        "!pip install -q johnsnowlabs\n",
        "#!pip install -q pyspark==3.4.1 spark-nlp\n",
        "!pip install -q langchain openai tiktoken faiss-cpu\n",
        "!pip install -q ctransformers\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 237
        },
        "id": "KzMHa0HdA9ch",
        "outputId": "4ec11497-959e-46f4-d005-4e883a8cefc3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Spark NLP Version : 5.3.1\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<pyspark.sql.session.SparkSession at 0x7c9a5a304730>"
            ],
            "text/html": [
              "\n",
              "            <div>\n",
              "                <p><b>SparkSession - in-memory</b></p>\n",
              "                \n",
              "        <div>\n",
              "            <p><b>SparkContext</b></p>\n",
              "\n",
              "            <p><a href=\"http://289719c0e135:4040\">Spark UI</a></p>\n",
              "\n",
              "            <dl>\n",
              "              <dt>Version</dt>\n",
              "                <dd><code>v3.4.0</code></dd>\n",
              "              <dt>Master</dt>\n",
              "                <dd><code>local[*]</code></dd>\n",
              "              <dt>AppName</dt>\n",
              "                <dd><code>Spark NLP</code></dd>\n",
              "            </dl>\n",
              "        </div>\n",
              "        \n",
              "            </div>\n",
              "        "
            ]
          },
          "metadata": {},
          "execution_count": 3
        }
      ],
      "source": [
        "import sparknlp\n",
        "from sparknlp.base import *\n",
        "from sparknlp.annotator import *\n",
        "\n",
        "from pyspark.sql import SparkSession\n",
        "from pyspark.sql import functions as F\n",
        "from pyspark.ml import Pipeline, PipelineModel\n",
        "\n",
        "import pandas as pd\n",
        "\n",
        "import warnings\n",
        "warnings.filterwarnings('ignore')\n",
        "\n",
        "params = {\"spark.driver.memory\":\"16G\",\n",
        "          \"spark.kryoserializer.buffer.max\":\"2000M\",\n",
        "          \"spark.driver.maxResultSize\":\"2000M\"}\n",
        "\n",
        "spark = sparknlp.start(params=params, gpu=True)\n",
        "\n",
        "print(\"Spark NLP Version :\", sparknlp.version())\n",
        "\n",
        "spark"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# RAG Architecture\n",
        "A typical RAG application has two main components:\n",
        "\n",
        "**Indexing**: a pipeline for ingesting data from a source and indexing it. This usually happens offline.\n",
        "- `Load`: First we need to load our data. This is done with DocumentLoaders.\n",
        "- `Split`: Text splitters break large Documents into smaller chunks. This is useful both for indexing data and for passing it in to a model, since large chunks are harder to search over and won’t fit in a model’s finite context window.\n",
        "- `Store`: We need somewhere to store and index our splits, so that they can later be searched over. This is often done using a VectorStore and Embeddings model.\n",
        "\n",
        "**Retrieval and generation**: the actual RAG chain, which takes the user query at run time and retrieves the relevant data from the index, then passes that to the model.\n",
        "[source](https://python.langchain.com/docs/use_cases/question_answering/)\n"
      ],
      "metadata": {
        "id": "VAqSLhcEGQ4X"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "![image.png](data:image/png;base64,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)\n",
        "\n",
        "[image source](https://towardsdatascience.com/retrieval-augmented-generation-rag-from-theory-to-langchain-implementation-4e9bd5f6a4f2)"
      ],
      "metadata": {
        "id": "XfMfAOvwHbS1"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Dataset"
      ],
      "metadata": {
        "id": "Reer1xrH-z_8"
      }
    },
    {
      "cell_type": "code",
      "execution_count": 4,
      "metadata": {
        "id": "3nC4eEb55ZYH"
      },
      "outputs": [],
      "source": [
        "! wget -q https://github.com/JohnSnowLabs/spark-nlp-workshop/raw/master/healthcare-nlp/data/diabetes_txt_files.zip"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import shutil\n",
        "\n",
        "filename = \"./diabetes_txt_files.zip\"\n",
        "extract_dir = \"./\"\n",
        "archive_format = \"zip\"\n",
        "\n",
        "shutil.unpack_archive(filename, extract_dir, archive_format)"
      ],
      "metadata": {
        "id": "mjfOcm9e-2k6"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "multi_doc = spark.read.text(\"./diabetes_txt_files\", wholetext=True).toDF(\"text\")\n",
        "multi_doc = multi_doc.withColumn(\"filename\", F.input_file_name())\\\n",
        "                      .withColumn(\"filename\",F.split('filename', '/'))\\\n",
        "                      .withColumn('filename', F.col('filename')[F.size('filename') -1])\n",
        "multi_doc.show(10, truncate=100)\n",
        "\n",
        "print(\"document count:\", multi_doc.count())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "8dApNIcn-3gr",
        "outputId": "937f7766-9d54-4674-946d-f0990982a793"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "+----------------------------------------------------------------------------------------------------+-----------------------+\n",
            "|                                                                                                text|               filename|\n",
            "+----------------------------------------------------------------------------------------------------+-----------------------+\n",
            "|Diabetes mellitus is a group of diseases associated with various metabolic disorders, the main fe...|PMC4020724_abstract.txt|\n",
            "|Objective: The peer interaction–based online model has been influential in the recent development...|PMC7432193_abstract.txt|\n",
            "|Gestational diabetes mellitus (GDM) is associated with developing type 2 diabetes, but very few s...|PMC5770032_abstract.txt|\n",
            "|A diagnosis of diabetes or hyperglycemia should be confirmed prior to ordering, dispensing, or ad...|PMC6104264_abstract.txt|\n",
            "|The aim of this study was to describe the characteristics and outcomes of pregnancies in a nation...|PMC7054376_abstract.txt|\n",
            "|Gestational diabetes insipidus (DI) is a rare complication of pregnancy, usually developing in th...|PMC4626653_abstract.txt|\n",
            "|Among nonpregnant individuals, diabetes mellitus and high body mass index increase the risk of CO...|PMC8686449_abstract.txt|\n",
            "|Many studies have explored the relationship between diabetes mellitus (DM) and tuberculosis (TB) ...|PMC5597214_abstract.txt|\n",
            "|Fasting in the Islamic month of Ramadan is obligatory for all sane, healthy adult Muslims. The le...|PMC7480213_abstract.txt|\n",
            "|Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infect...|PMC7664589_abstract.txt|\n",
            "+----------------------------------------------------------------------------------------------------+-----------------------+\n",
            "only showing top 10 rows\n",
            "\n",
            "document count: 1000\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Documet Splitting\n"
      ],
      "metadata": {
        "id": "E2OamqcmF8p7"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def DocumetSplitter(spark_df,input_col = \"text\", chunk_size= 100,  chunk_overlap = 10):\n",
        "    from sparknlp.annotator import DocumentAssembler, DocumentCharacterTextSplitter\n",
        "    from pyspark.ml import Pipeline\n",
        "\n",
        "    document_assembler = DocumentAssembler()\\\n",
        "        .setInputCol(input_col)\\\n",
        "        .setOutputCol(\"document\")\n",
        "\n",
        "    character_text_splitter = DocumentCharacterTextSplitter() \\\n",
        "        .setInputCols([\"document\"]) \\\n",
        "        .setOutputCol(\"splits\") \\\n",
        "        .setChunkSize(chunk_size) \\\n",
        "        .setChunkOverlap(chunk_overlap) \\\n",
        "        .setExplodeSplits(True)\\\n",
        "        .setSplitPatterns([\"\\n\\n\", \"\\n\", \" \"])\n",
        "\n",
        "    pipeline = Pipeline().setStages([\n",
        "            document_assembler,\n",
        "            character_text_splitter\n",
        "    ])\n",
        "\n",
        "    result_df = pipeline.fit(spark_df).transform(spark_df)\n",
        "\n",
        "    splitted_pd_df = result_df.selectExpr(\"splits.result[0] as splits\",\n",
        "                                          \"splits.metadata[0].document as splits_id\",\n",
        "                                          \"filename as document_id\",).toPandas()\n",
        "\n",
        "    return splitted_pd_df"
      ],
      "metadata": {
        "id": "NazI8sK_-4Xi"
      },
      "execution_count": 7,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "splitted_pd_df = DocumetSplitter(multi_doc.limit(100),\n",
        "                                 chunk_size = 1000,\n",
        "                                 chunk_overlap = 50)\n",
        "splitted_pd_df"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 423
        },
        "id": "NZ5R0SbLDkTl",
        "outputId": "41b87397-11df-4245-b2a9-0a0a571f8c3b"
      },
      "execution_count": 42,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                                                splits splits_id  \\\n",
              "0    Diabetes mellitus is a group of diseases assoc...         0   \n",
              "1     A scheme of the relationship between etiology...         1   \n",
              "2    The classification of glucose metabolism disor...         2   \n",
              "3    on the degree of hyperglycemia occurring as a ...         3   \n",
              "4    *Casual plasma glucose ≥200 mg/dL (≥11.1 mmol/...         4   \n",
              "..                                                 ...       ...   \n",
              "386  In 1992, 1,091 individuals were interviewed an...         1   \n",
              "387  These results suggest that particular efforts ...         2   \n",
              "388  To systematically review the risk factors for ...         0   \n",
              "389  A total of 24 case–control studies were includ...         1   \n",
              "390  Older age, body mass index, family history of ...         2   \n",
              "\n",
              "                 document_id  \n",
              "0    PMC4020724_abstract.txt  \n",
              "1    PMC4020724_abstract.txt  \n",
              "2    PMC4020724_abstract.txt  \n",
              "3    PMC4020724_abstract.txt  \n",
              "4    PMC4020724_abstract.txt  \n",
              "..                       ...  \n",
              "386  PMC6944834_abstract.txt  \n",
              "387  PMC6944834_abstract.txt  \n",
              "388  PMC7779280_abstract.txt  \n",
              "389  PMC7779280_abstract.txt  \n",
              "390  PMC7779280_abstract.txt  \n",
              "\n",
              "[391 rows x 3 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-e8c787a3-bd95-4b70-8774-cdf124c0f316\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>splits</th>\n",
              "      <th>splits_id</th>\n",
              "      <th>document_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>Diabetes mellitus is a group of diseases assoc...</td>\n",
              "      <td>0</td>\n",
              "      <td>PMC4020724_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>A scheme of the relationship between etiology...</td>\n",
              "      <td>1</td>\n",
              "      <td>PMC4020724_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>The classification of glucose metabolism disor...</td>\n",
              "      <td>2</td>\n",
              "      <td>PMC4020724_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>on the degree of hyperglycemia occurring as a ...</td>\n",
              "      <td>3</td>\n",
              "      <td>PMC4020724_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>*Casual plasma glucose ≥200 mg/dL (≥11.1 mmol/...</td>\n",
              "      <td>4</td>\n",
              "      <td>PMC4020724_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>386</th>\n",
              "      <td>In 1992, 1,091 individuals were interviewed an...</td>\n",
              "      <td>1</td>\n",
              "      <td>PMC6944834_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>387</th>\n",
              "      <td>These results suggest that particular efforts ...</td>\n",
              "      <td>2</td>\n",
              "      <td>PMC6944834_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>388</th>\n",
              "      <td>To systematically review the risk factors for ...</td>\n",
              "      <td>0</td>\n",
              "      <td>PMC7779280_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>389</th>\n",
              "      <td>A total of 24 case–control studies were includ...</td>\n",
              "      <td>1</td>\n",
              "      <td>PMC7779280_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>390</th>\n",
              "      <td>Older age, body mass index, family history of ...</td>\n",
              "      <td>2</td>\n",
              "      <td>PMC7779280_abstract.txt</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>391 rows × 3 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-e8c787a3-bd95-4b70-8774-cdf124c0f316')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-e8c787a3-bd95-4b70-8774-cdf124c0f316 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-e8c787a3-bd95-4b70-8774-cdf124c0f316');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-a115f0d2-efe4-460b-90ba-61edd600b306\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-a115f0d2-efe4-460b-90ba-61edd600b306')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-a115f0d2-efe4-460b-90ba-61edd600b306 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "  <div id=\"id_096a0872-8337-4826-bd50-b5c8f9ad500b\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('splitted_pd_df')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_096a0872-8337-4826-bd50-b5c8f9ad500b button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('splitted_pd_df');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "splitted_pd_df",
              "summary": "{\n  \"name\": \"splitted_pd_df\",\n  \"rows\": 391,\n  \"fields\": [\n    {\n      \"column\": \"splits\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 391,\n        \"samples\": [\n          \"\\u2002If any of the criteria for diabetic type (i) through to (iv) is observed at the initial examination, the patient is judged to be \\u2018diabetic type\\u2019. Re\\u2010examination is conducted on another day, and if \\u2018diabetic type\\u2019 is reconfirmed, diabetes mellitus is diagnosed. However, a diagnosis cannot be made only by the re\\u2010examination of HbA1c alone. Moreover, if the plasma glucose values (any of criteria [i], [ii], or [iii]) and the HbA1c (criterion [iv]) in the same blood sample both indicate diabetic type, diabetes mellitus is diagnosed based on the initial examination alone. If HbA1c is used, it is essential that the plasma glucose level (criteria [i], [ii] or [iii]) also indicates diabetic type for a diagnosis of diabetes mellitus. When diabetes mellitus is suspected, HbA1c should be measured at the same time as examination for plasma glucose.\",\n          \"before delivery or during the entire pregnancy, including missing variables using imputation or controlling for month of enrollment, the observed associations were comparable.\",\n          \"Teenage girls with childhood-onset type 1 diabetes in Wales are less likely to have children than teenage girls without diabetes. Teenage pregnancy in girls with type 1 diabetes, unlike in the background population, is not associated with social deprivation. In our cohort, glycaemic control was poor in both teenage and young adult mothers with type 1 diabetes. Pregnancy outcomes were comparable between teenage and young adult mothers with type 1 diabetes, but hospital admissions during the first year of life were five times more common among babies of teenage mothers with type 1 diabetes than those of young adult mothers with diabetes.\\nThe online version of this article (10.1007/s00125-019-05063-w) contains peer-reviewed but unedited supplementary material, which is available to authorised users.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"splits_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 13,\n        \"samples\": [\n          \"11\",\n          \"9\",\n          \"0\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"document_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 100,\n        \"samples\": [\n          \"PMC6907272_abstract.txt\",\n          \"PMC6944832_abstract.txt\",\n          \"PMC5411261_abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 42
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def LoadDocument(splitted_pd_df, page_content_column=\"splits\"):\n",
        "  # from langchain.document_loaders import PySparkDataFrameLoader\n",
        "  # loader = PySparkDataFrameLoader(spark, splitted_df,\n",
        "  #                                 page_content_column = page_content_column)\n",
        "  # splitted_docs = loader.load()\n",
        "\n",
        "  from langchain.document_loaders import DataFrameLoader\n",
        "  loader = DataFrameLoader(splitted_pd_df,\n",
        "                           page_content_column)\n",
        "  splitted_docs = loader.load()\n",
        "\n",
        "  return splitted_docs"
      ],
      "metadata": {
        "id": "DWxXmhL3D8Ww"
      },
      "execution_count": 43,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "splitted_docs = LoadDocument(splitted_pd_df, page_content_column=\"splits\")\n",
        "splitted_docs"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "I3wKUDg5FMwm",
        "outputId": "283e56f1-e137-4e27-deb7-30224fe2efb2"
      },
      "execution_count": 44,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetes mellitus is a group of diseases associated with various metabolic disorders, the main feature of which is chronic hyperglycemia due to insufficient insulin action. Its pathogenesis involves both genetic and environmental factors. The long‐term persistence of metabolic disorders can cause susceptibility to specific complications and also foster arteriosclerosis. Diabetes mellitus is associated with a broad range of clinical presentations, from being asymptomatic to ketoacidosis or coma, depending on the degree of metabolic disorder.\\nNote: Those that cannot at present be classified as any of the above are called unclassifiable.\\nThe occurrence of diabetes‐specific complications has not been confirmed in some of these conditions.\\nThe occurrence of diabetes‐specific complications has not been confirmed in some of these conditions.', metadata={'splits_id': '0', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='\\u2002A scheme of the relationship between etiology (mechanism) and patho‐physiological stages (states) of diabetes mellitus. Arrows pointing right represent worsening of glucose metabolism disorders (including onset of diabetes mellitus). Among the arrow lines,  indicates the condition classified as ‘diabetes mellitus’. Arrows pointing left represent improvement in the glucose metabolism disorder. The broken lines indicate events of low frequency. For example, in type\\u20032 diabetes mellitus, infection can lead to ketoacidosis and require temporary insulin treatment for survival. Also, once diabetes mellitus has developed, it is treated as diabetes mellitus regardless of improvement in glucose metabolism, therefore, the arrow lines pointing left are filled in black. In such cases, a broken line is used, because complete normalization of glucose metabolism is rare.', metadata={'splits_id': '1', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='The classification of glucose metabolism disorders is principally derived from etiology, and includes staging of pathophysiology based on the degree of deficiency of insulin action. These disorders are classified into four groups: (i) type\\u20031 diabetes mellitus; (ii) type\\u20032 diabetes mellitus; (iii) diabetes mellitus due to other specific mechanisms or diseases; and (iv) gestational diabetes mellitus. Type\\u20031 diabetes is characterized by destruction of pancreatic β‐cells. Type\\u20032 diabetes is characterized by combinations of decreased insulin secretion and decreased insulin sensitivity (insulin resistance). Glucose metabolism disorders in category (iii) are divided into two subgroups; subgroup\\u2003A is diabetes in which a genetic abnormality has been identified, and subgroup\\u2003B is diabetes associated with other pathologic disorders or clinical conditions. The staging of glucose metabolism includes normal, borderline and diabetic stages depending on the degree of hyperglycemia occurring as a', metadata={'splits_id': '2', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='on the degree of hyperglycemia occurring as a result of the lack of insulin action or clinical condition. The diabetic stage is then subdivided into three substages: non‐insulin‐ requiring, insulin‐requiring for glycemic control, and insulin‐dependent for survival. The two former conditions are called non‐insulin‐dependent diabetes and the latter is known as insulin‐dependent diabetes. In each individual, these stages may vary according to the deterioration or the improvement of the metabolic state, either spontaneously or by treatment.', metadata={'splits_id': '3', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='*Casual plasma glucose ≥200\\u2003mg/dL (≥11.1\\u2003mmol/L) and HbA1c≥6.5% are also regarded as to indicate diabetic type.\\nEven for normal type, if 1‐h value is 180\\u2003mg/dL (10.0\\u2003mmol/L), the risk of progression to diabetes mellitus is greater than for <180\\u2003mg/dL (10.0\\u2003mmol/L) and should be treated as with borderline type (follow‐up observation, etc.). Fasting plasma glucose level of 100–109\\u2003mg/dL (5.5–6.0\\u2003mmol/L) is called ‘high‐normal’: within the range of normal fasting plasma glucose.\\nPlasma glucose level after glucose load in oral glucose tolerance test (OGTT) is not included in casual plasma glucose levels. The value for HbA1c (%) is indicated with 0.4% added to HbA1c (JDS) (%).\\n*The value for HbA1c (%) is indicated with 0.4% added to HbA1c (JDS) (%). **Hyperglycemia must be confirmed in a non‐stressful condition. OGTT, oral glucose tolerance test.\\n*The value for HbA1c (%) is indicated with 0.4% added to HbA1c (JDS) (%).', metadata={'splits_id': '4', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='(IADPSG Consensus Panel, Reference 42, partly modified with permission of Diabetes Care).\\n\\u2002Flow chart outlining steps in the clinical diagnosis of diabetes mellitus. *The value for HbA1c (%) is indicated with 0.4% added to HbA1c (JDS) (%).', metadata={'splits_id': '5', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='Categories of the State of Glycemia:\\u2002 Confirmation of chronic hyperglycemia is essential for the diagnosis of diabetes mellitus. When plasma glucose levels are used to determine the categories of glycemia, patients are classified as having a diabetic type if they meet one of the following criteria: (i) fasting plasma glucose level of ≥126\\u2003mg/dL (≥7.0\\u2003mmol/L); (ii) 2‐h value of ≥200\\u2003mg/dL (≥11.1\\u2003mmol/L) in 75\\u2003g oral glucose tolerance test (OGTT); or (iii) casual plasma glucose level of ≥200\\u2003mg/dL (≥11.1\\u2003mmol/L). Normal type is defined as fasting plasma glucose level of <110\\u2003mg/dL (<6.1\\u2003mmol/L) and 2‐h value of <140\\u2003mg/dL (<7.8\\u2003mmol/L) in OGTT. Borderline type (neither diabetic nor normal type) is defined as falling between the diabetic and normal values. According to the current revision, in addition to the earlier listed plasma glucose values, hemoglobin A1c (HbA1c) has been given a more prominent position as one of the diagnostic criteria. That is, (iv) HbA1c≥6.5% is now also', metadata={'splits_id': '6', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='criteria. That is, (iv) HbA1c≥6.5% is now also considered to indicate diabetic type. The value of HbA1c, which is equivalent to the internationally used HbA1c (%) (HbA1c [NGSP]) defined by the NGSP (National Glycohemoglobin Standardization Program), is expressed by adding 0.4% to the HbA1c (JDS) (%) defined by the Japan Diabetes Society (JDS).', metadata={'splits_id': '7', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='Subjects with borderline type have a high rate of developing diabetes mellitus, and correspond to the combination of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) noted by the American Diabetes Association (ADA) and WHO. Although borderline cases show few of the specific complications of diabetes mellitus, the risk of arteriosclerosis is higher than those of normal type. When HbA1c is 6.0–6.4%, suspected diabetes mellitus cannot be excluded, and when HbA1c of 5.6–5.9% is included, it forms a group with a high risk for developing diabetes mellitus in the future, even if they do not have it currently.', metadata={'splits_id': '8', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='\\u2002If any of the criteria for diabetic type (i) through to (iv) is observed at the initial examination, the patient is judged to be ‘diabetic type’. Re‐examination is conducted on another day, and if ‘diabetic type’ is reconfirmed, diabetes mellitus is diagnosed. However, a diagnosis cannot be made only by the re‐examination of HbA1c alone. Moreover, if the plasma glucose values (any of criteria [i], [ii], or [iii]) and the HbA1c (criterion [iv]) in the same blood sample both indicate diabetic type, diabetes mellitus is diagnosed based on the initial examination alone. If HbA1c is used, it is essential that the plasma glucose level (criteria [i], [ii] or [iii]) also indicates diabetic type for a diagnosis of diabetes mellitus. When diabetes mellitus is suspected, HbA1c should be measured at the same time as examination for plasma glucose.', metadata={'splits_id': '9', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='\\u2002If the plasma glucose level indicates diabetic type (any of [i], [ii], or [iii]) and either of the following conditions exists, diabetes mellitus can be diagnosed immediately at the initial examination.\\n\\u2002The presence of typical symptoms of diabetes mellitus (thirst, polydipsia, polyuria, weight loss)\\n\\u2002The presence of definite diabetic retinopathy\\n\\u2002If it can be confirmed that the above conditions 1 or 2 existed in the past, diabetes mellitus can be diagnosed or suspected regardless of the current test results.\\n\\u2002If the diagnosis of diabetes cannot be established by these procedures, the patient is followed up and re‐examined after an appropriate interval.\\n\\u2002The physician should assess not only the presence or absence of diabetes, but also its etiology and glycemic stage, and the presence and absence of diabetic complications or associated conditions.\\nClinical Diagnosis:\\u2002', metadata={'splits_id': '10', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='Clinical Diagnosis:\\u2002  \\nEpidemiological Study:\\u2002 For the purpose of estimating the frequency of diabetes mellitus, ‘diabetes mellitus’ can be substituted for the determination of ‘diabetic type’ from a single examination. In this case, HbA1c≥6.5% alone can be defined as ‘diabetes mellitus’.\\nHealth Screening:\\u2002 It is important not to misdiagnose diabetes mellitus, and thus clinical information such as family history and obesity should be referred to at the time of screening in addition to an index for plasma glucose level.\\nGestational Diabetes Mellitus:\\u2002 There are two hyperglycemic disorders in pregnancy: (i) gestational diabetes mellitus (GDM); and (ii) diabetes mellitus. GDM is diagnosed if one or more of the following criteria is met in a 75\\u2003g OGTT during pregnancy:\\n\\u2002Fasting plasma glucose level of ≥92\\u2003mg/dL (5.1\\u2003mmol/L)\\n\\u20021‐h value of ≥180\\u2003mg/dL (10.0\\u2003mmol/L)\\n\\u20022‐h value of ≥153\\u2003mg/dL (8.5\\u2003mmol/L)', metadata={'splits_id': '11', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='\\u20022‐h value of ≥153\\u2003mg/dL (8.5\\u2003mmol/L)\\nHowever, diabetes mellitus that is diagnosed by the clinical diagnosis of diabetes mellitus defined earlier is excluded from GDM. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00074.x, 2010)', metadata={'splits_id': '12', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='Objective: The peer interaction–based online model has been influential in the recent development of diabetes management. This model “extends and innovates” the traditional mode of doctor–patient guidance, transforming it into a mode in which both doctor–patient guidance and patient–patient interaction coexist; this new mode has the added advantage of offering “extended continual intervention.” This study contributes to research on extending diabetes management models by investigating how patients with diabetes or prediabetes interact in online health communities, focusing on the interrelationship between self-efficacy characteristics and online participation during patient–patient interactions. Methods: In this cross-sectional study, participants with diabetes of various severities completed an electronic questionnaire, which was formulated with a revised classical scale. The questionnaire was disseminated through diabetes online health communities. Its content covered the', metadata={'splits_id': '0', 'document_id': 'PMC7432193_abstract.txt'}),\n",
              " Document(page_content='health communities. Its content covered the respondent’s general condition, self-evaluation of their self-efficacy, and participation in online health communities, specifically with respect to factors such as the time spent in online information each day, the number of groups joined, and the extent of interaction in diabetes online health communities, etc. The main observation indicators were the participants’ self-efficacy, their extent of online participation, and the characteristics of online health communities. Descriptive statistics, chi-square test, linear trend estimation, and ordinal logistic regression were used to explore the relationship between the three indicators. Results: The self-efficacy scores (  ± s) were 51.9 ± 9.12, and 59.1% of interviewed participants had self-efficacy scores greater than the mean. Overall, most participants (96%) considered online diabetes social platforms to be helpful. Groups differed with respect to interaction mode, which indicated that', metadata={'splits_id': '1', 'document_id': 'PMC7432193_abstract.txt'}),\n",
              " Document(page_content='respect to interaction mode, which indicated that people with high self-efficacy tend to employ various modes of interaction. Participants with high self-efficacy were also more likely to live in cities (p < 0.05) and be married (p < 0.05) and tended to spend more time paying attention to group information (p < 0.05), spend more time viewing group information (p < 0.05), and have a greater degree of interaction with group members (p < 0.05). Information sources for the different grades of participants was primarily obtained from social media. Conclusion: Among people with diabetes, the frequency and intensity of online interaction might positively affect self-efficacy and, by implication, diabetes self-management. Diabetics with high self-efficacy also tend to have positive online interaction and adopt different ways of interaction. In addition, the diabetes information sources of the respondents mainly come from social networks, most of the respondents think that online social', metadata={'splits_id': '2', 'document_id': 'PMC7432193_abstract.txt'}),\n",
              " Document(page_content='most of the respondents think that online social networking sites have a positive impact on diabetes self-management, which shows that social network plays an important role in diabetes information source of diabetics. However, the design of online health communities has room for improvement, specifically with respect to the provision of information that patients require. As an interesting side note, among people with diabetes or prediabetes, those who lived in urban area and were married, those who paid more attention to group information, and those who actively participated in interactions tended to have relatively high self-efficacy. The results suggest that people with diabetes have higher-quality self-care when they engage in online health community interactions; such benefits cannot be obtained from treatment in a hospital. In general, enhanced self-efficacy in people with diabetes enables them to more readily acquire diabetes-related knowledge. Online interaction with', metadata={'splits_id': '3', 'document_id': 'PMC7432193_abstract.txt'}),\n",
              " Document(page_content='knowledge. Online interaction with diabetics, who has the same experience, can not only get more information, but also have a sense of identity and belonging, which enhances self-efficacy and further urges them to actively participate in online interaction. Therefore, online health communities are an important supplement to the clinical treatment of diabetes mellitus and clinicians can take advantage of the educational function of online diabetes groups in their provision of tailored diabetes interventions and take into account the factors that affect the self-efficacy of diabetics (including the frequency and intensity of online interaction, age, marital status, residential area, etc.), to provide tailored diabetes interventions for diabetics. Such a use of online diabetes groups can strengthen diabetes self-management.', metadata={'splits_id': '4', 'document_id': 'PMC7432193_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes mellitus (GDM) is associated with developing type 2 diabetes, but very few studies have examined its effect on developing cardiovascular disease.', metadata={'splits_id': '0', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='We conducted a retrospective cohort study utilizing a large primary care database in the United Kingdom. From 1 February 1990 to 15 May 2016, 9,118 women diagnosed with GDM were identified and randomly matched with 37,281 control women by age and timing of pregnancy (up to 3 months). Adjusted incidence rate ratios (IRRs) with 95% confidence intervals (CIs) were calculated for cardiovascular risk factors and cardiovascular disease. Women with GDM were more likely to develop type 2 diabetes (IRR = 21.96; 95% CI 18.31–26.34) and hypertension (IRR = 1.85; 95% CI 1.59–2.16) after adjusting for age, Townsend (deprivation) quintile, body mass index, and smoking. For ischemic heart disease (IHD), the IRR was 2.78 (95% CI 1.37–5.66), and for cerebrovascular disease 0.95 (95% CI 0.51–1.77; p-value = 0.87), after adjusting for the above covariates and lipid-lowering medication and hypertension at baseline. Follow-up screening for type 2 diabetes and cardiovascular risk factors was poor.', metadata={'splits_id': '1', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='and cardiovascular risk factors was poor. Limitations include potential selective documentation of severe GDM for women in primary care, higher surveillance for outcomes in women diagnosed with GDM than control women, and a short median follow-up postpartum period, with a small number of outcomes for IHD and cerebrovascular disease.', metadata={'splits_id': '2', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='Women diagnosed with GDM were at very high risk of developing type 2 diabetes and had a significantly increased incidence of hypertension and IHD. Identifying this group of women in general practice and targeting cardiovascular risk factors could improve long-term outcomes.\\nKrishnarajah Nirantharakumar and colleagues present results from a cohort of women with gestational diabetes and identify these as a target group for preventative interventions for cardiovascular disease and type 2 diabetes.\\nThe prevalence of gestational diabetes mellitus (GDM) is increasing rapidly in most developed countries.\\nAlthough it is well documented that women diagnosed with GDM have a greatly increased lifetime risk of developing type 2 diabetes, there is a paucity of reports on its association with cardiovascular disease.', metadata={'splits_id': '3', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='Only 3 previous population-based cohort studies have reported on GDM and the long-term risk of cardiovascular events (including 1 utilizing a primary care database), and no studies have been reported from the United Kingdom (UK).\\nThis population-based retrospective cohort study utilized a large UK primary care database that included more than 9,000 women diagnosed with GDM between 1 February 1990 and 15 May 2016.\\nThe association between GDM and the development of type 2 diabetes, hypertension, and cardiovascular disease postpartum was examined.\\nWomen diagnosed with GDM were over 20 times more likely to develop type 2 diabetes, 2.8 times more likely to develop ischemic heart disease, and twice as likely to develop hypertension, although no association was found for cerebrovascular disease.\\nLess than 60% of women diagnosed with GDM were screened in primary care for type 2 diabetes in the first year postpartum, and the proportion screened rapidly declined after this period.', metadata={'splits_id': '4', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='Screening rates were also low for cardiovascular risk factors such as smoking, high body mass index, hypertension, and dyslipidemia, and were similar to the screening rates in control women.\\nGDM in women increases the risk for hypertension and ischemic heart disease in addition to type 2 diabetes.\\nAlthough the National Institute for Health and Care Excellence guidelines recommend annual screening for type 2 diabetes in women diagnosed with GDM, this study found that follow-up screening was poor for type 2 diabetes and other cardiovascular risk factors such as hypertension.\\nWomen diagnosed with GDM are an identifiable group of at-risk women and ideal for targeting preventative metabolic and cardiovascular interventions.\\nClinical guidelines should include postpartum screening and management for all cardiovascular risk factors in women diagnosed with GDM and not restrict it to diabetes.', metadata={'splits_id': '5', 'document_id': 'PMC5770032_abstract.txt'}),\n",
              " Document(page_content='A diagnosis of diabetes or hyperglycemia should be confirmed prior to ordering, dispensing, or administering insulin (A).\\nInsulin is the primary treatment in all patients with type 1 diabetes mellitus (T1DM) (A).\\nTypically, patients with T1DM will require initiation with multiple daily injections at the time of diagnosis. This is usually short-acting insulin or rapid-acting insulin analogue given 0 to 15\\xa0min before meals together with one or more daily separate injections of intermediate or long-acting insulin. Two or three premixed insulin injections per day may be used (A).\\nThe target glycated hemoglobin A1c (HbA1c) for all children with T1DM, including preschool children, is recommended to be <\\xa07.5% (<\\xa058\\xa0mmol/mol). The target is chosen aiming at minimizing hyperglycemia, severe hypoglycemia, hypoglycemic unawareness, and reducing the likelihood of development of long-term complications (B).', metadata={'splits_id': '0', 'document_id': 'PMC6104264_abstract.txt'}),\n",
              " Document(page_content='For patients prone to glycemic variability, glycemic control is best evaluated by a combination of results with self-monitoring of blood glucose (SMBG) (B).\\nIndications for exogenous insulin therapy in patients with type 2 diabetes mellitus (T2DM) include acute illness or surgery, pregnancy, glucose toxicity, contraindications to or failure to achieve goals with oral antidiabetic medications, and a need for flexible therapy (B).\\nIn T2DM patients, with regards to achieving glycemic goals, insulin is considered alone or in combination with oral agents when HbA1c is ≥\\xa07.5% (≥\\xa058\\xa0mmol/mol); and is essential for treatment in those with HbA1c\\xa0≥\\xa010% (≥\\xa086\\xa0mmol/mol), when diet, physical activity, and other antihyperglycemic agents have been optimally used (B).', metadata={'splits_id': '1', 'document_id': 'PMC6104264_abstract.txt'}),\n",
              " Document(page_content='The preferred method of insulin initiation in T2DM is to begin by adding a long-acting (basal) insulin or once-daily premixed/co-formulation insulin or twice-daily premixed insulin, alone or in combination with glucagon-like peptide-1 receptor agonist (GLP-1 RA) or in combination with other oral antidiabetic drugs (OADs) (B).\\nIf the desired glucose targets are not met, rapid-acting or short-acting (bolus or prandial) insulin can be added at mealtime to control the expected postprandial raise in glucose. An insulin regimen should be adopted and individualized but should, to the extent possible, closely resemble a natural physiologic state and avoid, to the extent possible, wide fluctuating glucose levels (C).', metadata={'splits_id': '2', 'document_id': 'PMC6104264_abstract.txt'}),\n",
              " Document(page_content='Blood glucose monitoring is an integral part of effective insulin therapy and should not be omitted in the patient’s care plan. Fasting plasma glucose (FPG) values should be used to titrate basal insulin, whereas both FPG and postprandial glucose (PPG) values should be used to titrate mealtime insulin (B).\\nMetformin combined with insulin is associated with decreased weight gain, lower insulin dose, and less hypoglycemia when compared with insulin alone (C).\\nOral medications should not be abruptly discontinued when starting insulin therapy because of the risk of rebound hyperglycemia (D).\\nAnalogue insulin is as effective as human insulin but is associated with less postprandial hyperglycemia and delayed hypoglycemia (B).', metadata={'splits_id': '3', 'document_id': 'PMC6104264_abstract.txt'}),\n",
              " Document(page_content='The shortest needles (currently the 4-mm pen and 6-mm syringe needles) are safe, effective, and less painful and should be the first-line choice in all patient categories; intramuscular (IM) injections should be avoided, especially with long-acting insulins, because severe hypoglycemia may result; lipohypertrophy is a frequent complication of therapy that distorts insulin absorption, and therefore, injections and infusions should not be given into these lesions and correct site rotation will help prevent them (A).\\nMany patients in East Africa reuse syringes for various reasons, including financial. This is not recommended by the manufacturer and there is an association between needle reuse and lipohypertrophy. However, patients who reuse needles should not be subjected to alarming claims of excessive morbidity from this practice (A).\\nHealth care authorities and planners should be alerted to the risks associated with syringe or pen needles 6\\xa0mm or longer in children (A).', metadata={'splits_id': '4', 'document_id': 'PMC6104264_abstract.txt'}),\n",
              " Document(page_content='The aim of this study was to describe the characteristics and outcomes of pregnancies in a national cohort of teenage (<20\\xa0years) and young adult women (≥20\\xa0years) with and without childhood-onset (<15\\xa0years) type 1 diabetes. We hypothesised that, owing to poor glycaemic control during the teenage years, pregnancy outcomes would be poorer in teenage mothers with type 1 diabetes than young adult mothers with type 1 diabetes and mothers without diabetes.', metadata={'splits_id': '0', 'document_id': 'PMC7054376_abstract.txt'}),\n",
              " Document(page_content='The Brecon Register of childhood-onset type 1 diabetes diagnosed in Wales since 1995 was linked to population-based datasets in the Secure Anonymised Information Linkage (SAIL) Databank, creating an electronic cohort (e-cohort) of legal births (live or stillbirths beyond 24\\xa0weeks’ gestation) to women aged less than 35\\xa0years between 1995 and 2013 in Wales. Teenage pregnancy rates were calculated based on the number of females in the same birth cohort in Wales. Pregnancy outcomes, including pre-eclampsia, preterm birth, low birthweight, macrosomia, congenital malformations, stillbirths and hospital admissions during the first year of life, were obtained from electronic records for the whole Welsh population. We used logistic and negative binomial regression to compare outcomes among teenage and young adult mothers with and without type 1 diabetes.', metadata={'splits_id': '1', 'document_id': 'PMC7054376_abstract.txt'}),\n",
              " Document(page_content='A total of 197,796 births were eligible for inclusion, including 330 to girls and women with childhood-onset type 1 diabetes, of whom 68 were teenagers (age 14–19\\xa0years, mean 17.9\\xa0years) and 262 were young adults (age 20–32\\xa0years, mean 24.0\\xa0years). The mean duration of diabetes was 14.3\\xa0years (9.7\\xa0years for teenagers; 15.5\\xa0years for young adults). Pregnancy rates were lower in teenagers with type 1 diabetes than in teenagers without diabetes (mean annual teenage pregnancy rate between 1999 and 2013: 8.6 vs 18.0 per 1000 teenage girls, respectively; p\\u2009<\\u20090.001). In the background population, teenage pregnancy was associated with deprivation (p\\u2009<\\u20090.001), but this was not the case for individuals with type 1 diabetes (p\\u2009=\\u20090.85). Glycaemic control was poor in teenage and young adult mothers with type 1 diabetes (mean HbA1c based on closest value to conception: 81.3 and 80.2\\xa0mmol/mol [9.6% and 9.5%], respectively, p\\u2009=\\u20090.78). Glycaemic control improved during pregnancy in both groups but to', metadata={'splits_id': '2', 'document_id': 'PMC7054376_abstract.txt'}),\n",
              " Document(page_content='improved during pregnancy in both groups but to a greater degree in young adults, who had significantly better glycaemic control than teenagers by the third trimester (mean HbA1c: 54.0 vs 67.4\\xa0mmol/mol [7.1% vs 8.3%], p\\u2009=\\u20090.01). All adverse outcomes were more common among mothers with type 1 diabetes than mothers without diabetes. Among those with type 1 diabetes, hospital admissions during the first year of life were more common among babies of teenage vs young adult mothers (adjusted OR 5.91 [95% CI 2.63, 13.25]). Other outcomes were no worse among teenage mothers with type 1 diabetes than among young adult mothers with diabetes.', metadata={'splits_id': '3', 'document_id': 'PMC7054376_abstract.txt'}),\n",
              " Document(page_content='Teenage girls with childhood-onset type 1 diabetes in Wales are less likely to have children than teenage girls without diabetes. Teenage pregnancy in girls with type 1 diabetes, unlike in the background population, is not associated with social deprivation. In our cohort, glycaemic control was poor in both teenage and young adult mothers with type 1 diabetes. Pregnancy outcomes were comparable between teenage and young adult mothers with type 1 diabetes, but hospital admissions during the first year of life were five times more common among babies of teenage mothers with type 1 diabetes than those of young adult mothers with diabetes.\\nThe online version of this article (10.1007/s00125-019-05063-w) contains peer-reviewed but unedited supplementary material, which is available to authorised users.', metadata={'splits_id': '4', 'document_id': 'PMC7054376_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes insipidus (DI) is a rare complication of pregnancy, usually developing in the third trimester and remitting spontaneously 4–6 weeks post-partum. It is mainly caused by excessive vasopressinase activity, an enzyme expressed by placental trophoblasts which metabolises arginine vasopressin (AVP). Its diagnosis is challenging, and the treatment requires desmopressin. A 38-year-old Chinese woman was referred in the 37th week of her first single-gestation due to polyuria, nocturia and polydipsia. She was known to have gestational diabetes mellitus diagnosed in the second trimester, well-controlled with diet. Her medical history was unremarkable. Physical examination demonstrated decreased skin turgor; her blood pressure was 102/63\\u200ammHg, heart rate 78\\u200abeats/min and weight 53\\u200akg (BMI 22.6\\u200akg/m2). Laboratory data revealed low urine osmolality 89\\u200amOsmol/kg (350–1000), serum osmolality 293\\u200amOsmol/kg (278–295), serum sodium 144\\u200ammol/l (135–145), potassium 4.1\\u200ammol/l (3.5–5.0),', metadata={'splits_id': '0', 'document_id': 'PMC4626653_abstract.txt'}),\n",
              " Document(page_content='(135–145), potassium 4.1\\u200ammol/l (3.5–5.0), urea 2.2\\u200ammol/l (2.5–6.7), glucose 3.5\\u200ammol/l and HbA1c 5.3%. Bilirubin, alanine transaminase, alkaline phosphatase and full blood count were normal. The patient was started on desmopressin with improvement in her symptoms, and normalisation of serum and urine osmolality (280 and 310\\u200amOsmol/kg respectively). A fetus was delivered at the 39th week without major problems. After delivery, desmopressin was stopped and she had no further evidence of polyuria, polydipsia or nocturia. Her sodium, serum/urine osmolality at 12-weeks post-partum were normal. A pituitary magnetic resonance imaging (MRI) revealed the neurohypophyseal T1-bright spot situated ectopically, with a normal adenohypophysis and infundibulum. She remains clinically well, currently breastfeeding, and off all medication. This case illustrates some challenges in the diagnosis and management of transient gestational DI.', metadata={'splits_id': '1', 'document_id': 'PMC4626653_abstract.txt'}),\n",
              " Document(page_content='Gestational DI is a rare complication of pregnancy occurring in two to four out of 100\\u200a000 pregnancies. It usually develops at the end of the second or third trimester of pregnancy and remits spontaneously 4–6 weeks after delivery.\\nGestational DI occurrence is related to excessive vasopressinase activity, an enzyme expressed by placental trophoblasts during pregnancy, which metabolises AVP. Its activity is proportional to the placental weight, explaining the higher vasopressinase activity in third trimester or in multiple pregnancies.\\nVasopressinase is metabolised by the liver, which most likely explains its higher concentrations in pregnant women with hepatic dysfunction, such acute fatty liver of pregnancy, HELLP syndrome, hepatitis and cirrhosis. Therefore, it is important to assess liver function in patients with gestational DI, and to be aware of the risk of DI in pregnant women with liver disease.', metadata={'splits_id': '2', 'document_id': 'PMC4626653_abstract.txt'}),\n",
              " Document(page_content='Serum and urine osmolality are essential for the diagnosis, but other tests such as serum sodium, glucose, urea, creatinine, liver function may be informative. The water deprivation test is normally not recommended during pregnancy because it may lead to significant dehydration, but a pituitary MRI should be performed at some point to exclude lesions in the hypothalamo-pituitary region.\\nThese patients should be monitored for vital signs, fluid balance, body weight, fetal status, renal and liver function, and treated with desmopressin. The recommended doses are similar or slightly higher than those recommended for central DI in non-pregnant women, and should be titrated individually.', metadata={'splits_id': '3', 'document_id': 'PMC4626653_abstract.txt'}),\n",
              " Document(page_content='Among nonpregnant individuals, diabetes mellitus and high body mass index increase the risk of COVID-19 and its severity.\\nThis study aimed to determine whether diabetes mellitus and high body mass index are risk factors for COVID-19 in pregnancy and whether gestational diabetes mellitus is associated with COVID-19 diagnosis.', metadata={'splits_id': '0', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='INTERCOVID was a multinational study conducted between March 2020 and February 2021 in 43 institutions from 18 countries, enrolling 2184 pregnant women aged ≥18 years; a total of 2071 women were included in the analyses. For each woman diagnosed with COVID-19, 2 nondiagnosed women delivering or initiating antenatal care at the same institution were also enrolled. The main exposures were preexisting diabetes mellitus, high body mass index (overweight or obesity was defined as a body mass index ≥25 kg/m2), and gestational diabetes mellitus in pregnancy. The main outcome was a confirmed diagnosis of COVID-19 based on a real-time polymerase chain reaction test, antigen test, antibody test, radiological pulmonary findings, or ≥2 predefined COVID-19 symptoms at any time during pregnancy or delivery. Relationships of exposures and COVID-19 diagnosis were assessed using generalized linear models with a Poisson distribution and log link function, with robust standard errors to account for', metadata={'splits_id': '1', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='with robust standard errors to account for model misspecification. Furthermore, we conducted sensitivity analyses: (1) restricted to those with a real-time polymerase chain reaction test or an antigen test in the last week of pregnancy, (2) restricted to those with a real-time polymerase chain reaction test or an antigen test during the entire pregnancy, (3) generating values for missing data using multiple imputation, and (4) analyses controlling for month of enrollment. In addition, among women who were diagnosed with COVID-19, we examined whether having gestational diabetes mellitus, diabetes mellitus, or high body mass index increased the risk of having symptomatic vs asymptomatic COVID-19.', metadata={'splits_id': '2', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='COVID-19 was associated with preexisting diabetes mellitus (risk ratio, 1.94; 95% confidence interval, 1.55–2.42), overweight or obesity (risk ratio, 1.20; 95% confidence interval, 1.06–1.37), and gestational diabetes mellitus (risk ratio, 1.21; 95% confidence interval, 0.99–1.46). The gestational diabetes mellitus association was specifically among women requiring insulin, whether they were of normal weight (risk ratio, 1.79; 95% confidence interval, 1.06–3.01) or overweight or obese (risk ratio, 1.77; 95% confidence interval, 1.28–2.45). A somewhat stronger association with COVID-19 diagnosis was observed among women with preexisting diabetes mellitus, whether they were of normal weight (risk ratio, 1.93; 95% confidence interval, 1.18–3.17) or overweight or obese (risk ratio, 2.32; 95% confidence interval, 1.82–2.97). When the sample was restricted to those with a real-time polymerase chain reaction test or an antigen test in the week before delivery or during the entire pregnancy,', metadata={'splits_id': '3', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='before delivery or during the entire pregnancy, including missing variables using imputation or controlling for month of enrollment, the observed associations were comparable.', metadata={'splits_id': '4', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus and overweight or obesity were risk factors for COVID-19 diagnosis in pregnancy, and insulin-dependent gestational diabetes mellitus was associated with the disease. Therefore, it is essential that women with these comorbidities are vaccinated.', metadata={'splits_id': '5', 'document_id': 'PMC8686449_abstract.txt'}),\n",
              " Document(page_content='Many studies have explored the relationship between diabetes mellitus (DM) and tuberculosis (TB) demonstrating increased risk of TB among patients with DM and poor prognosis of patients suffering from the association of DM/TB. Owing to a paucity of studies addressing this question, it remains unclear whether patients with DM and TB are more likely than TB patients without DM to be grouped into molecular clusters defined according to the genotype of the infecting Mycobacterium tuberculosis bacillus. That is, whether there is convincing molecular epidemiological evidence for TB transmission among DM patients. Objective: We performed a systematic review and meta-analysis to quantitatively evaluate the propensity for patients with DM and pulmonary TB (PTB) to cluster according to the genotype of the infecting M. tuberculosis bacillus.', metadata={'splits_id': '0', 'document_id': 'PMC5597214_abstract.txt'}),\n",
              " Document(page_content='We conducted a systematic search in MEDLINE and LILACS from 1990 to June, 2016 with the following combinations of key words “tuberculosis AND transmission” OR “tuberculosis diabetes mellitus” OR “Mycobacterium tuberculosis molecular epidemiology” OR “RFLP-IS6110” OR “Spoligotyping” OR “MIRU-VNTR”. Studies were included if they met the following criteria: (i) studies based on populations from defined geographical areas; (ii) use of genotyping by IS6110- restriction fragment length polymorphism (RFLP) analysis and spoligotyping or mycobacterial interspersed repetitive unit-variable number of tandem repeats (MIRU-VNTR) or other amplification methods to identify molecular clustering; (iii) genotyping and analysis of 50 or more cases of PTB; (iv) study duration of 11 months or more; (v) identification of quantitative risk factors for molecular clustering including DM; (vi) > 60% coverage of the study population; and (vii) patients with PTB confirmed bacteriologically. The exclusion', metadata={'splits_id': '1', 'document_id': 'PMC5597214_abstract.txt'}),\n",
              " Document(page_content='PTB confirmed bacteriologically. The exclusion criteria were: (i) Extrapulmonary TB; (ii) TB caused by nontuberculous mycobacteria; (iii) patients with PTB and HIV; (iv) pediatric PTB patients; (v) TB in closed environments (e.g. prisons, elderly homes, etc.); (vi) diabetes insipidus and (vii) outbreak reports. Hartung-Knapp-Sidik-Jonkman method was used to estimate the odds ratio (OR) of the association between DM with molecular clustering of cases with TB. In order to evaluate the degree of heterogeneity a statistical Q test was done. The publication bias was examined with Begg and Egger tests. Review Manager 5.3.5 CMA v.3 and Biostat and Software package R were used.', metadata={'splits_id': '2', 'document_id': 'PMC5597214_abstract.txt'}),\n",
              " Document(page_content='Selection criteria were met by six articles which included 4076 patients with PTB of which 13% had DM. Twenty seven percent of the cases were clustered. The majority of cases (48%) were reported in a study in China with 31% clustering. The highest incidence of TB occurred in two studies from China. The global OR for molecular clustering was 0.84 (IC 95% 0.40–1.72). The heterogeneity between studies was moderate (I2 = 55%, p = 0.05), although there was no publication bias (Beggs test p = 0.353 and Eggers p = 0.429).\\nThere were very few studies meeting our selection criteria. The wide confidence interval indicates that there is not enough evidence to draw conclusions about the association. Clustering of patients with DM in TB transmission chains should be investigated in areas where both diseases are prevalent and focus on specific contexts.', metadata={'splits_id': '3', 'document_id': 'PMC5597214_abstract.txt'}),\n",
              " Document(page_content='Fasting in the Islamic month of Ramadan is obligatory for all sane, healthy adult Muslims. The length of the day varies significantly in temperate regions—typically lasting\\u2009≥\\u200918\\xa0h during peak summer in the UK. The synodic nature of the Islamic calendar means that Ramadan migrates across all four seasons over an approximately\\u200933-year cycle. Despite valid exemptions, there is an intense desire to fast during this month, even among those who are considered to be at high risk, including many individuals with diabetes mellitus. In this review we explore the current scientific and clinical evidence on fasting in patients with diabetes mellitus, focussing on type 2 diabetes mellitus and type 1 diabetes mellitus, with brief reviews on pregnancy, pancreatic diabetes, bariatric surgery, the elderly population and current practice guidelines. We also make recommendations on the management of diabetes patients during the month of Ramadan. Many patients admit to a do-it-yourself approach to', metadata={'splits_id': '0', 'document_id': 'PMC7480213_abstract.txt'}),\n",
              " Document(page_content='patients admit to a do-it-yourself approach to diabetes mellitus management during Ramadan, largely due to an under-appreciation of the risks and implications of the rigors of fasting on their health. Part of the issue may also lie with a healthcare professional’s perceived inability to grasp the religious sensitivities of Muslims in relation to disease management. Thus, the pre-Ramadan assessment is crucial to ensure a safe Ramadan experience. Diabetes patients can be risk-stratified from low, medium to high or very high risk during the pre-Ramadan assessment and counselled accordingly. Those who are assessed to be at high to very high risk are advised not to fast. The current COVID-19 pandemic upgrades those in the high-risk category to very high risk; hence a significant number of diabetes patients may fall under the penumbra of the ‘not to fast’ advisory. We recognize that fasting is a personal choice and if a person chooses to fast despite advice to the contrary, he/she should be', metadata={'splits_id': '1', 'document_id': 'PMC7480213_abstract.txt'}),\n",
              " Document(page_content='despite advice to the contrary, he/she should be adequately supported and monitored closely during Ramadan and for a brief period thereafter. Current advancements in insulin delivery and glucose monitoring technologies are useful adjuncts to strategies for supporting type 1 diabetes patients considered to be high risk as well as ‘high-risk’ type 2 patients manage their diabetes during Ramadan. Although there is a lack of formal trial data, there is sufficient evidence across the different classes of therapeutic hypoglycaemic agents in terms of safety and efficacy to enable informed decision-making and provide a breadth of therapeutic options for the patient and the healthcare professional, even if the professional advice is to abstain. Thus, Ramadan provides an excellent opportunity for patient engagement to discuss important aspects of management, to improve control in the short term during Ramadan and to help the observants understand that the metabolic gains achieved during Ramadan', metadata={'splits_id': '2', 'document_id': 'PMC7480213_abstract.txt'}),\n",
              " Document(page_content='that the metabolic gains achieved during Ramadan are also sustainable in the other months of the year by maintaining a dietary and behavioural discipline. The application of this understanding can potentially prevent long-term complications.', metadata={'splits_id': '3', 'document_id': 'PMC7480213_abstract.txt'}),\n",
              " Document(page_content='The online version of this article (10.1007/s13300-020-00886-y) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '4', 'document_id': 'PMC7480213_abstract.txt'}),\n",
              " Document(page_content='Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin–angiotensin–aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium–glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended.', metadata={'splits_id': '0', 'document_id': 'PMC7664589_abstract.txt'}),\n",
              " Document(page_content='with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.', metadata={'splits_id': '1', 'document_id': 'PMC7664589_abstract.txt'}),\n",
              " Document(page_content='The pathophysiology of coronavirus disease 19 (COVID-19) and diabetes mellitus are interlinked, and diabetes mellitus is associated with severe COVID-19 outcomes. This Review highlights new advances in diabetes mellitus and COVID-19, considering disease mechanisms and clinical management of patients with diabetes mellitus in the ongoing pandemic.\\nUnderlying diabetes mellitus and cardiovascular diseases are considered risk factors for increased coronavirus disease 2019 (COVID-19) disease severity and worse outcomes, including higher mortality.\\nPotential pathogenetic links between COVID-19 and diabetes mellitus include effects on glucose homeostasis, inflammation, altered immune status and activation of the renin–angiotensin–aldosterone system (RAAS).\\nDuring the COVID-19 pandemic, tight control of glucose levels and prevention of diabetes complications might be crucial in patients with diabetes mellitus to keep susceptibility low and to prevent severe courses of COVID-19.', metadata={'splits_id': '2', 'document_id': 'PMC7664589_abstract.txt'}),\n",
              " Document(page_content='Evidence suggests that insulin and dipeptidyl peptidase 4 inhibitors can be used safely in patients with diabetes mellitus and COVID-19; metformin and sodium–glucose cotransporter 2 inhibitors might need to be withdrawn in patients at high risk of severe disease.\\nPharmacological agents under investigation for the treatment of COVID-19 can affect glucose metabolism, particularly in patients with diabetes mellitus; therefore, frequent blood glucose monitoring and personalized adjustment of medications are required.\\nAs COVID-19 lacks definitive treatment so far, patients with diabetes mellitus should follow general preventive rules strictly and monitor glucose levels more frequently, engage in physical activity, eat healthily and control other risk factors.', metadata={'splits_id': '3', 'document_id': 'PMC7664589_abstract.txt'}),\n",
              " Document(page_content='Psychiatry and Family Medicine residents frequently see patients with comorbid mental and physical disorders. Little is known about the difference in knowledge of Psychiatry residents and Family Medicine residents regarding management of common conditions they encounter. This study aimed to assess the knowledge of Psychiatry and Family Medicine residents regarding medical management of schizophrenia, hypertension, diabetes mellitus, and dyslipidemia, as\\xa0the findings could help to refine the training curriculum for residency training.', metadata={'splits_id': '0', 'document_id': 'PMC8061461_abstract.txt'}),\n",
              " Document(page_content='A cross-sectional survey design was used. Psychiatry and Family Medicine residents pursuing their residency in Singapore were recruited from November 2019 to June 2020. The survey questionnaire consisted of questions which assessed the knowledge regarding medical management of schizophrenia, hypertension, diabetes mellitus, and dyslipidemia. Descriptive statistics were used to describe the demographic data; T-tests or Mann-Whitney U tests to compare the differences between groups; and multiple regression analyses to assess the factors associated with Psychiatry residents’ knowledge of hypertension, diabetes mellitus, and dyslipidemia.', metadata={'splits_id': '1', 'document_id': 'PMC8061461_abstract.txt'}),\n",
              " Document(page_content='Fifty-seven out of 70 (81.4%) Psychiatry residents and 58 out of 61 (95.1%) Family Medicine residents participated in the study. The majority of Psychiatry residents encountered patients with hypertension (93.0%), diabetes mellitus (87.7%) and dyslipidemia (91.2%) on a daily to weekly basis. Psychiatry residents had higher scores on questions about schizophrenia versus Family Medicine residents (mean 50.70 versus 43.28, p\\u2009<\\u20090.001). However, Psychiatry residents scored lower on questions about hypertension (mean 33.86 versus 40.98, p\\u2009<\\u20090.001), diabetes mellitus (mean 45.68 versus 49.79, p\\u2009=\\u20090.005) and dyslipidemia (mean 37.04 versus 44.31, p\\u2009<\\u20090.001). Receiving undergraduate medical education locally, compared to receiving it overseas, was associated with better knowledge of hypertension (beta\\u2009=\\u20090.515, p\\u2009=\\u20090.009) and dyslipidemia (beta\\u2009=\\u20090.559, p\\u2009=\\u20090.005); while younger age (26–30 versus >\\u200935 and 31–35 versus >\\u200935) was associated with better knowledge of hypertension (beta\\u2009=\\u20091.361,', metadata={'splits_id': '2', 'document_id': 'PMC8061461_abstract.txt'}),\n",
              " Document(page_content='better knowledge of hypertension (beta\\u2009=\\u20091.361, p\\u2009=\\u20090.002 and beta\\u2009=\\u20091.225, p\\u2009=\\u20090.003). A significant proportion of Psychiatry residents (61.4%) did not agree that the training provided to manage hypertension, diabetes mellitus, and dyslipidemia was adequate. Similarly, majority of Family Medicine residents (62.1%) did not agree that they had adequate training to manage schizophrenia.', metadata={'splits_id': '3', 'document_id': 'PMC8061461_abstract.txt'}),\n",
              " Document(page_content='This study raises the awareness of Psychiatry residents’ sense of discomfort in managing hypertension, diabetes mellitus, or dyslipidemia and conversely Family Medicine residents in management of schizophrenia, which can be further addressed during the training postings within the residency programs. Future studies are needed to look at local (such as training curriculum) and systemic factors (such as practice trends and culture) in order to better align residency selection criteria and training foci with real world practice factors over time.\\nThe online version contains supplementary material available at 10.1186/s12909-021-02658-z.', metadata={'splits_id': '4', 'document_id': 'PMC8061461_abstract.txt'}),\n",
              " Document(page_content='Ethnic minority populations exhibit disproportionately high rates of type 2 diabetes mellitus (T2DM). Electronic health tools have the potential to facilitate the cultural adaptation and tailoring of T2DM education to improve the knowledge and management of diabetes mellitus (DM).\\nThis study aimed (1) to develop an adaptable Interactive Lifestyle Assessment, Counseling, and Education (I-ACE) software to support dietitian-delivered lifestyle counseling among low-socioeconomic status (SES) ethnic minority patients with T2DM and (2) to evaluate its effect on DM-related dietary knowledge and management compared with standard lifestyle advice (SLA) in a randomized controlled trial (RCT).', metadata={'splits_id': '0', 'document_id': 'PMC6913526_abstract.txt'}),\n",
              " Document(page_content='The I-ACE software, developed in consultation with clinical dieticians, incorporates evidence-based dietary and physical activity (PA) recommendations and educational materials. The features and behavioral change techniques include quantitative lifestyle (dietary intake and PA) assessment and simulation, individually tailored education and recommendations, motivational interviewing, and goal setting. For the unblinded pilot RCT, 50 overweight or obese Arab adults (aged 40-62 years) with poorly controlled T2DM were recruited from primary care clinics and randomly assigned to receive 4 in-person, dietician-delivered counseling sessions over 6 months using either (1) the I-ACE tool (experimental arm) or (2) the SLA methods (comparison arm). All outcome assessments were face-to-face. DM-related dietary knowledge (primary outcome) was measured at baseline, 3, 6, and 12 months. Lifestyle and other parameters were measured before, during, and after the intervention. Multiple linear', metadata={'splits_id': '1', 'document_id': 'PMC6913526_abstract.txt'}),\n",
              " Document(page_content='and after the intervention. Multiple linear regression and repeated measures linear mixed models were used to compare the changes in study outcomes and explore time trends in between-group and within-group changes.', metadata={'splits_id': '2', 'document_id': 'PMC6913526_abstract.txt'}),\n",
              " Document(page_content='A total of 25 participants were enrolled in each arm, of whom 24 and 21 completed the final assessment of the primary outcome in the I-ACE and SLA arms, respectively. DM-related lifestyle knowledge increased more rapidly in the I-ACE arm than in the SLA arm (P value for study arm×time interaction=.02). Within the I-ACE arm, the mean (SE) differences in added sugar and dietary fiber intakes from baseline to 12 months were −2.6% (SE 1.0%) of total energy (P=.03) and 2.7 (SE 0.0) g/1000 kcal (P=.003), respectively. The odds of engaging in any leisure PA at 12 months tended to be higher in the I-ACE arm versus SLA arm, but did not reach statistical significance (odds ratio 2.8; 95% CI 0.7-11.6; P=.16). Both arms exhibited significant reductions in HbA1c (P value for change over time <.001).', metadata={'splits_id': '3', 'document_id': 'PMC6913526_abstract.txt'}),\n",
              " Document(page_content='The use of the I-ACE software in a 6-month, 4-session dietician-delivered lifestyle counseling intervention improved the efficiency of lifestyle education, compared with SLA, among low-SES, ethnic minority patients with T2DM. This pilot trial provides justification for conducting a large-scale trial to evaluate its effectiveness and applicability in routine clinical care among ethnically diverse populations.\\nClinicalTrials.gov NCT01858506; https://clinicaltrials.gov/ct2/show/NCT01858506.', metadata={'splits_id': '4', 'document_id': 'PMC6913526_abstract.txt'}),\n",
              " Document(page_content='Very long-term outcomes according to diabetic status of patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) are scant. Both, the durable polymer zotarolimus-eluting stent (DP-ZES), the first DES to gain FDA-approval for specific use in patients with diabetes mellitus, and the polymer-free sirolimus- and probucol-eluting stent (PF-SES), with a unique design that enables effective drug release without the need of a polymer offer the potential to enhance clinical long-term outcomes especially in patients with diabetes mellitus.', metadata={'splits_id': '0', 'document_id': 'PMC8484170_abstract.txt'}),\n",
              " Document(page_content='We investigate 10-year clinical outcomes of the prespecified subgroups of patients with and without diabetes mellitus, randomly assigned to treatment with PF-SES versus DP-ZES in the ISAR-TEST 5 trial. The primary endpoint of interest was major adverse cardiac events (MACE), defined as the composite of all-cause death, any myocardial infarction or any revascularization. Further endpoints of interest were cardiac death, myocardial infarction related to the target vessel and target lesion revascularization as well as the individual components of the primary composite endpoint and the incidence of definite or probable stent thrombosis at 10\\xa0years.', metadata={'splits_id': '1', 'document_id': 'PMC8484170_abstract.txt'}),\n",
              " Document(page_content='This analysis includes a total of 3002 patients randomly assigned to PF-SES (n\\u2009=\\u20092002) or DP-ZES (n\\u2009=\\u20091000). Prevalence of diabetes mellitus was high and comparable, 575 Patients (28.7%) in PF-SES group and 295 patients (29.5%) in DP-ZES group (P\\u2009=\\u20090.66). At 10\\xa0years 53.5% of patients with diabetes mellitus and 68.5% of patients without diabetes mellitus were alive. Regarding major adverse cardiac events, PF-SES as compared to DP-ZES showed comparable event rates in patients with diabetes mellitus (74.8% vs. 79.6%; hazard ratio 0.86; 95% CI 0.73–1.02; P\\u2009=\\u20090.08) and in patients without diabetes (PF-SES 62.5% vs. DP-ZES 62.2%; hazard ratio 0.99; 95% CI 0.88–1.11; P\\u2009=\\u20090.88).\\nAt 10\\xa0years, both new-generation DES show comparable clinical outcome irrespective of diabetic status or polymer strategy. Event rates after PCI in patients with diabetes mellitus are considerable higher than in patients without diabetes mellitus and continue to accrue over time.', metadata={'splits_id': '2', 'document_id': 'PMC8484170_abstract.txt'}),\n",
              " Document(page_content='ClinicalTrials.gov, NCT00598533, Registered 10 January 2008, https://clinicaltrials.gov/ct2/show/NCT00598533?term=NCT00598533\\n Kaplan-Meier estimates of endpoints of interest for patients with vs. without diabetes mellitus treated with PF-SES vs. DP-ZES. Bar graphs: Kaplan-Meier estimates as percentages. PF-SES: polymer-free sirolimus-eluting stent; DP-ZES: durable polymer zotarolimus-eluting stent; DM: diabetes mellitus. Comparison of event rates of individual endpoints in patients with and without diabetes mellitus treated with PF-SES vs. DP-ZES all without statistically significant differences. Comparison of event rates of individual endpoints in overall patients with vs. without diabetes mellitus significantly different (P\\xa0≤\\xa00.01 for all comparisons).\\nThe online version contains supplementary material available at 10.1007/s00392-021-01854-7.', metadata={'splits_id': '3', 'document_id': 'PMC8484170_abstract.txt'}),\n",
              " Document(page_content='Globally, the prevalence of type 1 diabetes mellitus (T1DM) is rising. In 2020, a total of 124,652 Australians had T1DM. Maintaining optimal glycemic control (hemoglobin A1c ≤7.0%, ≤53 mmol/mol) on a standard carbohydrate diet can be a challenge for people living with T1DM. The Diabetes Complications and Control Trial established that macrovascular and microvascular complications could be reduced by improving glycemic control. Recent studies have found that a very low or low carbohydrate diet can improve glycemic control. However, the overall evidence relating to an association between a very low or low carbohydrate diet and glycemic control in people living with T1DM is both limited and mixed. In addition, research has suggested that a reduced quality of life due to anxiety and depression adversely influences glycemic control. Despite a potential link between a very low or low carbohydrate diet and optimal glycemic control, to our knowledge, no research has examined an association', metadata={'splits_id': '0', 'document_id': 'PMC8088871_abstract.txt'}),\n",
              " Document(page_content='no research has examined an association between a low carbohydrate diet, quality of life, and glycemic control, making this study unique in its approach.', metadata={'splits_id': '1', 'document_id': 'PMC8088871_abstract.txt'}),\n",
              " Document(page_content='The study aims to develop a validated diabetes-specific quality of life questionnaire for use in Australian adults with T1DM and to determine if an association exists between a low carbohydrate diet, quality of life, and glycemic control in Australian adults living with T1DM.', metadata={'splits_id': '2', 'document_id': 'PMC8088871_abstract.txt'}),\n",
              " Document(page_content='This cross-sectional study will be conducted in a tertiary hospital outpatient setting and will consist of 3 phases: phase 1, online Australian diabetes-specific quality of life questionnaire development and piloting (25-30 adults with T1DM); phase 2, questionnaire validation (364 adults with T1DM); and phase 3, a 12-week dietary intervention to determine if an association exists between a low carbohydrate diet, quality of life, and glycemic control in adults with T1DM (16-23 adults with T1DM). The validation of the study-developed Australian diabetes-specific quality of life questionnaire, and changes in hemoglobin A1c and quality of life in adults with T1DM while undertaking a low carbohydrate diet over 12 weeks will be the primary outcomes of this study.\\nPhase 1 of the study is currently open for recruitment and has recruited 12 participants to date. It is anticipated that the first results will be submitted for publication in November 2021. Presently, no results are available.', metadata={'splits_id': '3', 'document_id': 'PMC8088871_abstract.txt'}),\n",
              " Document(page_content='This study is the first of its kind in that it will be the first to generate a new validated instrument, which could be used in evidence-based practice and research to understand the quality of life of Australian adults with T1DM. Second, the low carbohydrate dietary intervention outcomes could be used to inform clinicians about an alternative approach to assist T1DM adults in improving their quality of life and glycemic control. Finally, this study could warrant the development of an evidence-based low carbohydrate dietary guideline for adults living with T1DM with the potential to have a profound impact on this population.\\nClinicalTrials.gov NCT04213300; https://clinicaltrials.gov/ct2/show/NCT04213300\\nPRR1-10.2196/25085', metadata={'splits_id': '4', 'document_id': 'PMC8088871_abstract.txt'}),\n",
              " Document(page_content='Evidence suggests that mobile health app use is beneficial for the prevention and management of type 2 diabetes (T2D) and its associated complications; however, population-based research on specific determinants of health app use in people with and without T2D is scarce.\\nThis cross-sectional study aimed to provide population-based evidence on rates and determinants of health app use among adults with and without T2D, thereby covering a prevention perspective and a diabetes management perspective, respectively.', metadata={'splits_id': '0', 'document_id': 'PMC7270854_abstract.txt'}),\n",
              " Document(page_content='The study population included 2327 adults without a known diabetes diagnosis and 1149 adults with known T2D from a nationwide telephone survey in Germany conducted in 2017. Rates of smartphone ownership and health app use were estimated based on weighted sample proportions. Among smartphone owners, determinants of health app use were identified for both groups separately in multivariable logistic regression models. Sociodemographic factors, diabetes-related factors or indicators, psychological and health-related factors, and physician-provided information were selected as potential determinants.', metadata={'splits_id': '1', 'document_id': 'PMC7270854_abstract.txt'}),\n",
              " Document(page_content='Among participants without known diabetes, 74.72% (1690/2327) were smartphone owners. Of those, 49.27% (717/1690) used health apps, most often to improve regular physical activity. Among participants with T2D, 42.26% (481/1149) were smartphone owners. Of those, 41.1% (171/481) used health apps, most commonly to target a healthy diet. Among people without known diabetes, determinants significantly (all P values <.05) associated with an increased likelihood of health app use compared with their reference group were as follows: younger and middle age of 18 to 44 or 45 to 64 years (odds ratios [ORs] 3.89; P<.001 and 1.76; P=.004, respectively), overweight or obesity (ORs 1.58; P<.001 and 2.07; P<.001, respectively), hypertension diagnosis (OR 1.31; P=.045), former or current smoking (ORs 1.51; P=.002 and 1.58; P<.001, respectively), perceiving health as very good (OR 2.21; P<.001), other chronic diseases (OR 1.48; P=.002), and having received health advice from a physician (OR 1.48;', metadata={'splits_id': '2', 'document_id': 'PMC7270854_abstract.txt'}),\n",
              " Document(page_content='received health advice from a physician (OR 1.48; P<.001). A slight or high perceived diabetes risk (ORs 0.78; P=.04 and 0.23; P<.001, respectively) was significantly associated with a decreased likelihood of health app use. Among people with T2D, younger and middle age (18-64 years; OR 1.84; P=.007), female gender (OR 1.61; P=.02), and using a glucose sensor in addition or instead of a glucose meter (OR 2.74; P=.04) were significantly positively associated with health app use.', metadata={'splits_id': '3', 'document_id': 'PMC7270854_abstract.txt'}),\n",
              " Document(page_content='In terms of T2D prevention, age, diabetes-related risk factors, psychological and health-related factors, and medical health advice may inform app development for specific target groups. In addition, health professionals may encourage health app use when giving advice on health behaviors. Concerning T2D management, only a few determinants seem relevant for explaining health app use among people with T2D, indicating a need for more future research on which people with T2D use health apps and why.', metadata={'splits_id': '4', 'document_id': 'PMC7270854_abstract.txt'}),\n",
              " Document(page_content='High levels of psychosocial distress are correlated with worse glycemic control as measured by glycosylated hemoglobin levels (HbA1c). Some interventions specifically targeting diabetes distress have been shown to lead to lower HbA1c values, but the underlying mechanisms mediating this improvement are unknown. In addition, while type 2 diabetes mellitus (T2D) disproportionately affects low-income racial and ethnic minority populations, it is unclear whether interventions targeting distress are differentially effective depending on participants’ baseline characteristics.\\nOur objective was to evaluate the mediators and moderators that would inform interventions for improvements in both glycemic control and diabetes distress.', metadata={'splits_id': '0', 'document_id': 'PMC7834928_abstract.txt'}),\n",
              " Document(page_content='Our target population included 290 Veterans Affairs patients with T2D enrolled in a comparative effectiveness trial of peer support alone versus technology-enhanced peer support with primary and secondary outcomes including HbA1c and diabetes distress at 6 months. Participants in both arms had significant improvements in both HbA1c and diabetes distress at 6 months, so the arms were pooled for all analyses. Goal setting, perceived competence, intrinsic motivation, and decisional conflict were evaluated as possible mediators of improvements in both diabetes distress and HbA1c. Baseline patient characteristics evaluated as potential moderators included age, race, highest level of education attained, employment status, income, health literacy, duration of diabetes, insulin use, baseline HbA1c, diabetes-specific social support, and depression.', metadata={'splits_id': '1', 'document_id': 'PMC7834928_abstract.txt'}),\n",
              " Document(page_content='Among the primarily African American male veterans with T2D, the median age was 63 (SD 10.2) years with a baseline mean HbA1c of 9.1% (SD 1.7%). Improvements in diabetes distress were correlated with improvements in HbA1c in both bivariate and multivariable models adjusted for age, race, health literacy, duration of diabetes, and baseline HbA1c. Improved goal setting and perceived competence were found to mediate both the improvements in diabetes distress and in HbA1c, together accounting for 20% of the effect of diabetes distress on change in HbA1c. Race and insulin use were found to be significant moderators of improvements in diabetes distress and improved HbA1c.', metadata={'splits_id': '2', 'document_id': 'PMC7834928_abstract.txt'}),\n",
              " Document(page_content='Prior studies have demonstrated that some but not all interventions that improve diabetes distress can lead to improved glycemic control. This study found that both improved goal setting and perceived competence over the course of the peer support intervention mediated both improved diabetes distress and improved HbA1c. This suggests that future interventions targeting diabetes distress should also incorporate elements to increase goal setting and perceived competence. The intervention effect of improvements in diabetes distress on glycemic control in peer support may be more pronounced among White and insulin-dependent veterans. Additional research is needed to understand how to better target diabetes distress and glycemic control in other vulnerable populations.', metadata={'splits_id': '3', 'document_id': 'PMC7834928_abstract.txt'}),\n",
              " Document(page_content='Patients with hypothalamic-pituitary disease have the feature of central obesity, insulin resistance, and dyslipidemia, and there is increased prevalence of liver dysfunction consistent with non-alcoholic fatty liver disease (NAFLD) in this population. The causes of hypopituitarism in the reported studies varied and combined pituitary hormone deficiency including central diabetes insipidus is much common in this population. This retrospective cross-sectional study was performed to analyze the clinical characteristics and related factors with NAFLD and cirrhosis in Chinese adult hypopituitary/panhypopituitary patients.\\nTo analyze the clinical characteristics of and related risk factors for NAFLD in Chinese adult hypopituitary patients.', metadata={'splits_id': '0', 'document_id': 'PMC6465940_abstract.txt'}),\n",
              " Document(page_content='Adult Chinese patients with hypopituitarism and/or panhypopituitarism were enrolled at the Pituitary Center of Peking Union Medical College Hospital between August 2012 and April 2018. According to abdominal ultrasonography, these patients were divided into an NAFLD (-) group and an NAFLD (+) group, and the latter was further divided into an NAFLD group and a cirrhotic group. The data, such as patient characteristics, diagnosis, and treatment, were extracted from medical records, and statistical analysis was performed.', metadata={'splits_id': '1', 'document_id': 'PMC6465940_abstract.txt'}),\n",
              " Document(page_content='A total of 36 male and 14 female adult Chinese patients with hypopituitarism were included in this retrospective study; 43 (87.0%) of these patients exhibited growth hormone (GH) deficiency, and 39 (78.3%) had diabetes insipidus. A total of 27 (54.0%) patients were diagnosed with NAFLD, while seven patients were cirrhotic. No significant differences were noted in serum GH or insulin-like growth factor 1 among patients with cirrhosis, subjects with NAFLD, and those without NAFLD. However, plasma osmolality and serum sodium concentration of the cirrhotic patients were 314.9 mOsm/kgH2O and 151.0 mmol/L, respectively, which were significantly higher than those of the NAFLD patients (P = 0.036 and 0.042, respectively). Overweight/obesity and insulin resistance were common metabolic disorders in this population. The body mass index (BMI) and homeostasis model assessment of insulin resistance parameters of the cirrhotic patients were 27.7 kg/m2 and 9.57, respectively, which were', metadata={'splits_id': '2', 'document_id': 'PMC6465940_abstract.txt'}),\n",
              " Document(page_content='27.7 kg/m2 and 9.57, respectively, which were significantly higher than those of the patients without NAFLD (P = 0.011 and 0.044, respectively). A correlation analysis was performed, and fasting insulin concentration was positively associated with plasma osmolality in patients with NAFLD, after adjusting for gender, age, and BMI (r = 0.540, P = 0.046), but no correlation was noted in patients without NAFLD.', metadata={'splits_id': '3', 'document_id': 'PMC6465940_abstract.txt'}),\n",
              " Document(page_content='NAFLD is common in patients with hypopituitarism. Plasma osmolality and serum sodium levels of hypopituitary patients with cirrhosis are higher than those of subjects with NAFLD, and fasting insulin concentration is positively associated with plasma osmolality in patients with NAFLD, which suggests that hyperosmolality might be a contributor to the worsening of NAFLD in hypopituitary patients.', metadata={'splits_id': '4', 'document_id': 'PMC6465940_abstract.txt'}),\n",
              " Document(page_content='Congenital nephrogenic diabetes insipidus (NDI) is a disease characterized by failure of the kidney to concentrate urine in response to vasopressin. Human kindreds with nephrogenic diabetes insipidus have been found to harbor mutations in the vasopressin receptor 2 (Avpr2) gene or the vasopressin-sensitive water channel aquaporin-2 (Aqp2) gene. Development of a treatment is rendered difficult due to the lack of a viable animal model. Through forward genetic screening of ethylnitrosourea-mutagenized mice, we report the identification and characterization of a mouse model of NDI, with an F204V mutation in the Aqp2 gene. Unlike previously attempted murine models of NDI, our mice survive to adulthood and more exactly recapitulate the human disorder. Previous in vitro experiments using renal cell lines suggest recessive Aqp2 mutations result in improper trafficking of the mutant water pore. Using these animals, we have directly proven this hypothesis of improper AQP2 translocation as the', metadata={'splits_id': '0', 'document_id': 'PMC1189073_abstract.txt'}),\n",
              " Document(page_content='hypothesis of improper AQP2 translocation as the molecular defect in nephrogenic diabetes insipidus in the intact organism. Additionally, using a renal cell line we show that the mutated protein, AQP2-F204V, is retained in the endoplasmic reticulum and that this abnormal localization can be rescued by wild-type protein. This novel mouse model allows for further mechanistic studies as well as testing of pharmacological and gene therapies for NDI.', metadata={'splits_id': '1', 'document_id': 'PMC1189073_abstract.txt'}),\n",
              " Document(page_content='Nephrogenic diabetes insipidus (NDI) is a disease marked by excessive urination and thirst. Normally, the hypothalamus senses situations where water is limited and signals to the kidney to increase water reabsorption from urine. The signaling molecule secreted by the hypothalamus is arginine vasopressin (AVP), which binds to a specific protein on the surface of kidney cells, AVP receptor (AVPR2). AVP binding to its receptor on kidney cells begins a series of biochemical events that ultimately results in the insertion of a protein, aquaporin 2 (AQP2), into the outer surface of the kidney cell. As its name suggests, AQP2 facilitates the reuptake of water from the urinary space into the cell, thus concentrating the urine and conserving water. Congenital NDI is caused by mutations in either the water channel, AQP2, or in the receptor, AVPR2. While these mutations have been studied extensively in the lab, work in live animals has been very limited. This report describes the first viable', metadata={'splits_id': '2', 'document_id': 'PMC1189073_abstract.txt'}),\n",
              " Document(page_content='limited. This report describes the first viable mouse model of NDI. Previous models have been attempted by targeted mutation, i.e., genes known to be involved in the disease have been altered in the mouse, a so-called reverse genetic approach. Reverse genetic approaches have so far failed to produce a viable mouse model of NDI. Here the authors take a forward genetic approach in which genes are mutated at random and animals are screened for disease-like properties. As well as proving hypotheses that come from lab studies, this model opens the door to the testing of gene therapy or other therapies for treatment of NDI.', metadata={'splits_id': '3', 'document_id': 'PMC1189073_abstract.txt'}),\n",
              " Document(page_content='The diabetes disease burden in China is heavy, and mobile apps have a great potential for diabetes management. However, there is a lack of investigation of diabetes app use among Chinese diabetes patients and diabetologists. The perspectives and attitudes of diabetes patients and diabetologists regarding diabetes apps are also unclear.\\nOur objectives were to investigate diabetes patients’ and diabetologists’ use, attitudes, and perspectives, as well as patients’ needs, with respect to diabetes apps to provide information regarding the optimal design of diabetes apps and the best strategies to promote their use.', metadata={'splits_id': '0', 'document_id': 'PMC6384538_abstract.txt'}),\n",
              " Document(page_content='Diabetes patients and diabetologists across China were surveyed on the WeChat (Tencent Corp) network using Sojump (Changsha ran Xing InfoTech Ltd) from January 23, 2018, to July 30, 2018. In total, 2 survey links were initially sent to doctors from 46 Latent Autoimmune Diabetes of Adults Study collaborative hospitals in China in 25 major cities and were spread on their WeChat contacts network. We also published the patient survey link on 3 WeChat public accounts and requested diabetes patients to fill out questionnaires. A multivariate regression analysis was used to identify associations of demographic and basic disease information with app usage among adult patients.', metadata={'splits_id': '1', 'document_id': 'PMC6384538_abstract.txt'}),\n",
              " Document(page_content='Overall, 1276 individuals from 30 provincial regions responded to the patient survey; among them, the overall app awareness rate was 29.94% (382/1276) and usage was 15.44% (197/1276). The usage was higher among patients with type 1 diabetes (T1DM) than among patients with type 2 diabetes (T2DM; 108/473, 22.8% vs 79/733, 10.8%; P<.001). The multivariate regression analysis showed that diabetes type, age, education, family income, and location were associated with app use in adult patients (P<.05). The need for and selection of diabetes apps differed slightly between patients with T1DM and patients with T2DM. The reasons why patients discontinued the use of an app included limited time (59/197, 29.9%), complicated operations (50/197, 25.4%), ineffectiveness for glycemic control (48/197, 24.4%), and cost (38/197, 19.3%).', metadata={'splits_id': '2', 'document_id': 'PMC6384538_abstract.txt'}),\n",
              " Document(page_content='Of the 608 responders to the diabetologist survey, 40.5% (246/608) recommended diabetes apps to patients and 25.2% (153/608) used diabetes apps to manage patients. The greatest obstacles to the diabetologists’ use of apps to manage diabetes patients include limited time (280/608, 46.1%), legal issues (129/608, 21.2%), patients’ distrust (108/608, 17.8%), and billing issues (66/608, 10.9%).\\nThe awareness and use of diabetes apps in Chinese people with diabetes and the proportion of diabetologists using diabetes apps to manage patients are low. Designing apps targeting different patient needs and conducting high-quality randomized controlled trials will improve the effectiveness of the apps, provide evidence for patients to choose suitable apps, and be conducive to the promotion of app use.', metadata={'splits_id': '3', 'document_id': 'PMC6384538_abstract.txt'}),\n",
              " Document(page_content='Metastasis to the pituitary gland is extremely rare (∼2% of sellar masses). Clinical, biochemical, and radiologic characteristics of pituitary metastasis are poorly defined and can be difficult to diagnose before surgery. We present an unusual case with pituitary metastasis as the first manifestation of renal cell carcinoma (RCC). A 70-year-old male presented with acute onset of weakness, dizziness, diplopia, and progressively worsening headache. The initial CT head revealed a heterogeneous sellar mass measuring 2.8\\u2009×\\u20091.9\\u2009×\\u20091.7\\u2009cm. A follow-up MRI showed the sellar mass invading the right cavernous sinus. The presumptive diagnosis was a pituitary macroadenoma. Physical examination revealed bilateral 6th cranial nerve palsy and episodes of intermittent binocular horizontal diplopia. Hormonal testing noted possible secondary adrenal insufficiency (AM serum cortisol: 3.3\\u2009mcg/dL, ACTH: 8\\u2009pg/mL), secondary hypothyroidism (TSH: <0.01\\u2009mIU/L, FT4: 0.7\\u2009ng/dL), secondary hypogonadism', metadata={'splits_id': '0', 'document_id': 'PMC7450332_abstract.txt'}),\n",
              " Document(page_content='FT4: 0.7\\u2009ng/dL), secondary hypogonadism (testosterone: 47\\u2009ng/dL, LH: 1.3\\u2009mIU/mL, and FSH: 2.3\\u2009mIU/mL), and elevated serum prolactin (prolactin: 56.8\\u2009ng/ml, normal: 4.0–15.2\\u2009ng/ml). IGF-1 level was normal at 110\\u2009ng/mL (47–192\\u2009ng/mL). The patient was discharged on levothyroxine and hydrocortisone therapy with plans for close surveillance. However, his condition worsened over the next three months, and he was subsequently readmitted with nausea, vomiting, and hypernatremia secondary to diabetes insipidus. Repeat MRI pituitary showed an interval increase in the size of the sellar mass with suprasellar extension and a new mass effect on the optic chiasm. The sellar mass was urgently resected via a trans-sphenoidal approach. The tumor was negative for neuroendocrine markers and pituitary hormone panel, ruling out the diagnosis of pituitary adenoma and triggered workup for metastatic renal cell carcinoma, clear cell type. The diagnosis of renal cell carcinoma was confirmed by the diffuse and', metadata={'splits_id': '1', 'document_id': 'PMC7450332_abstract.txt'}),\n",
              " Document(page_content='cell carcinoma was confirmed by the diffuse and strong staining for renal cell carcinoma markers (Pax-8, RCC-1, and CD10). A follow-up CT scan noted large right renal mass measuring 11\\u2009×\\u200910\\u2009×\\u200911\\u2009cm. The patient underwent a cytoreductive robotic right radical nephrectomy for WHO/ISUP histologic grade II clear cell RCC, stage pT2b pNX pM1. He subsequently received fractionated stereotactic radiotherapy to the pituitary gland. He is presently stable with no radiological evidence of progression or new intracranial disease on subsequent imaging. Pituitary metastasis most commonly occurs from breast, lung, or gastrointestinal tumors but also rarely from renal cell carcinoma. Biochemical findings such as panhypopituitarism, acute clinical signs such as headache, visual symptoms, and diabetes insipidus and interval increase in sellar mass in a short time interval should raise suspicion for sellar metastasis.', metadata={'splits_id': '2', 'document_id': 'PMC7450332_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes mellitus (GDM) is the most common complication during pregnancy and is associated with an increased risk for the development of cardiometabolic diseases. Behavioral interventions can reduce this risk, but current solutions insufficiently address the requirements for such a program. The systematic development of a scalable mobile health (mHealth) promotion program for mothers during the first years post-GDM may contribute to solving this problem.\\nThe aim of this project was to systematically plan and develop a theory- and evidence-based mHealth intervention to change cardiometabolic risk behaviors in women during the first 5 years post-GDM that meets women’s expected standards of commercial health apps.', metadata={'splits_id': '0', 'document_id': 'PMC8150415_abstract.txt'}),\n",
              " Document(page_content='The intervention mapping steps 1 to 4 structured the systematic planning and development of the mHealth program described in this paper. Steps 1 and 2 led to a theory- and evidence-based logic model of change for cardiometabolic health. Based on this model, the prevention program was designed (step 3) and produced (step 4) in cooperation with industrial partners to ensure a high technological standard of the resulting smartphone app for the iPhone (Apple Inc). Step 4 included a user study with women during the first 5 years post-GDM once a beta version of the app (“TRIANGLE”) was available. The user study comprised 2 test rounds of 1 week (n=5) and 4 weeks (n=6), respectively. The tests included validated questionnaires on user acceptance, user logs, and think-alouds with semistructured interviews.', metadata={'splits_id': '1', 'document_id': 'PMC8150415_abstract.txt'}),\n",
              " Document(page_content='The novel TRIANGLE app is among the first self-paced smartphone apps for individual habit change in the 3 lifestyle areas of physical activity, nutrition, and psychosocial well-being. The 3 core features—a challenge system, human coaching, and a library—address 11 behavioral determinants with 39 behavior change methods to support lifestyle changes. Participants in the user study showed a high acceptance, high perceived quality, and high perceived impact of the TRIANGLE app on their health behaviors. Participants tested the app regularly, used it intuitively, and suggested improvements. We then adapted the TRIANGLE app according to the insights from the user study before the full TRIANGLE program production.', metadata={'splits_id': '2', 'document_id': 'PMC8150415_abstract.txt'}),\n",
              " Document(page_content='The intervention mapping approach was feasible to plan and develop an innovative and scalable smartphone solution for women during the first 5 years post-GDM. The resulting TRIANGLE intervention has the potential to support behavior change for cardiometabolic disease prevention. However, the app needs further refinement and testing in clinical trials. Intervention mapping steps 5 (implementation plan) and 6 (evaluation plan) may support the integration of the TRIANGLE intervention into routine care.\\nGerman Clinical Trials Register DRKS00012736; https://www.drks.de/DRKS00012736', metadata={'splits_id': '3', 'document_id': 'PMC8150415_abstract.txt'}),\n",
              " Document(page_content='Longitudinal data on progression, complications, and management of type 2 diabetes mellitus (T2DM) across India are scarce. LANDMARC (CTRI/2017/05/008452), the first pan‐India, longitudinal, prospective, observational study, aims to understand the management and real‐world outcomes of T2DM over 3\\xa0years.\\nAdults (≥25 to ≤60\\xa0years old at T2DM diagnosis; diabetes duration ≥2\\xa0years at enrollment; controlled/uncontrolled on ≥2 anti‐diabetic agents) were enrolled. Baseline characteristics were analyzed using descriptive statistics.', metadata={'splits_id': '0', 'document_id': 'PMC8279635_abstract.txt'}),\n",
              " Document(page_content='Of the 6279 recruited participants, 6236 were eligible for baseline assessment (56.6% [n/N\\xa0=\\xa03528/6236] men; mean\\xa0±\\xa0SD age: 52.1\\xa0±\\xa09.2\\xa0years, diabetes duration: 8.6\\xa0±\\xa05.6\\xa0years). mean\\xa0±\\xa0SD HbA1c, fasting plasma glucose, and postprandial glucose values were 64\\xa0±\\xa017\\xa0mmol/mol (8.1\\xa0±\\xa01.6%), 142.8\\xa0±\\xa050.4\\xa0mg/dl, and 205.7\\xa0±\\xa072.3\\xa0mg/dl, respectively. Only 25.1% (n/N\\xa0=\\xa01122/6236) participants had controlled glycemia (HbA1c\\xa0<\\xa053\\xa0mmol/mol, <7%). Macrovascular and microvascular complications were prevalent in 2.3% (n/N\\xa0=\\xa0145/6236) and 14.5% (n/N\\xa0=\\xa0902/6236) participants, respectively. Among those with complications, non‐fatal myocardial infarction (n/N\\xa0=\\xa074/145, 51.0%) and neuropathy (n/N\\xa0=\\xa0737/902, 81.7%) were the most reported macrovascular and microvascular complication, respectively. Hypertension (n/N\\xa0=\\xa02566/3281, 78.2%) and dyslipidemia (n/N\\xa0=\\xa01635/3281, 49.8%) were the most reported cardiovascular risks. Majority (74.5%; n/N\\xa0=\\xa04643/6236) were taking oral anti‐diabetic drugs (OADs) only,', metadata={'splits_id': '1', 'document_id': 'PMC8279635_abstract.txt'}),\n",
              " Document(page_content='were taking oral anti‐diabetic drugs (OADs) only, while 24.4% (n/N\\xa0=\\xa01522/6236) participants were taking OADs+insulin. Biguanides (n/N\\xa0=\\xa05796/6236, 92.9%) and sulfonylureas (n/N\\xa0=\\xa04757/6236, 76.3%) were the most reported OADs. Basal (n/N\\xa0=\\xa0837/6236, 13.4%) and premix (n/N\\xa0=\\xa0684/6236, 11.0%) insulins were the most reported insulins.', metadata={'splits_id': '2', 'document_id': 'PMC8279635_abstract.txt'}),\n",
              " Document(page_content='Baseline data from LANDMARC help understand the clinical/medical profile of study participants and underscore the extent of suboptimal glycemic control and prevalence of associated complications in a vast majority of Indians with T2DM.\\nPeople with long‐standing diabetes are at an increased risk of diabetes complications and cardiovascular events. In India, progression of diabetes and its complications over a long time has not been studied extensively. The LongitudinAl Nationwide stuDy on Management And Real‐world outComes of diabetes (LANDMARC) study has enrolled 6279 people with type 2 diabetes across India and will prospectively gather data on disease control, treatment, concomitant complications, and risks in these participants over 3years. LANDMARC baseline data represent the real‐world snapshot of a type 2 diabetic profile and underscore poor glycemic control and a considerable burden of complications prevalent in India.', metadata={'splits_id': '3', 'document_id': 'PMC8279635_abstract.txt'}),\n",
              " Document(page_content='Comparing people with Type 2 diabetes mellitus with and without heart failure in terms of metabolic control, therapeutic regimen and comorbidities.\\nThe Prospective Diabetes Registry (DPV) is a longitudinal documentation system for demographics, medical care and outcome in people with diabetes mellitus. It consists of follow‐up data from people with diabetes mellitus who have agreed to be recorded in the registry. Clinical data are submitted by general practitioners, specialists and clinics throughout Germany and Austria. Some 289\\xa0954 people with Type 2 diabetes mellitus (years 2000 to 2015) were analysed using demographic statistics and adjustment for confounders based on linear and logistic regression analysis.', metadata={'splits_id': '0', 'document_id': 'PMC7496405_abstract.txt'}),\n",
              " Document(page_content='People with Type 2 diabetes mellitus (ICD code: E11) and heart failure (ICD code: I50) (N\\xa0=\\xa014\\xa0723) were older, more often women and presented with longer diabetes duration compared with those without heart failure. After adjustment for age, gender and diabetes duration, people with heart failure showed lower HbA1c, higher BMI and more intense insulin therapy. Analysis revealed that people with heart failure were more often treated with insulin, and more frequently received anti‐hypertensives and lipid‐lowering medication. They presented with lower systolic and diastolic BP. People with heart failure more frequently showed a history of comorbidities.\\nHeart failure is common in diabetes mellitus, but the prevalence in the DPV is lower frequent than expected. The reason for improved metabolic control in heart failure may be intensified therapy with insulin, lipid‐lowering medication and anti‐hypertensives in this cohort.', metadata={'splits_id': '1', 'document_id': 'PMC7496405_abstract.txt'}),\n",
              " Document(page_content='Heart failure is a common comorbidity of diabetes mellitus. Prevalence data from intervention studies do not represent real‐world data because the people in studies are often pre‐specified with relation to several underlying diseases. For Germany, data on heart failure prevalence among people with Type 2 diabetes mellitus from large representative cohorts are currently unavailable. Data on diabetes treatment and therapeutic regimens regarding other comorbidities in people with Type 2 diabetes and heart failure are rare.\\nThe Prospective Diabetes Registry (DPV) delivers data from nearly 290\\xa0000 people with Type 2 diabetes in specialized diabetes care and thus represents real‐world data.\\nThe DPV provides data on clinical situation, diabetes treatment and therapeutic regimens regarding other comorbidities in people with Type 2 diabetes and heart failure from all over Germany.', metadata={'splits_id': '2', 'document_id': 'PMC7496405_abstract.txt'}),\n",
              " Document(page_content='The DPV is commonly used to document the real‐world treatment of people with diabetes and either heart failure or other comorbidities. The DPV clearly shows insufficient treatment of dyslipidaemia in people with diabetes and heart failure.', metadata={'splits_id': '3', 'document_id': 'PMC7496405_abstract.txt'}),\n",
              " Document(page_content='Multipotent mesenchymal stem/stromal cells (MSC) including adipose-derived stromal cells (ADSC) have been successfully applied for cardiovascular diseases treatment. Their regenerative potential is considered due to the multipotency, paracrine activity and immunologic privilege. However, therapeutic efficacy of autologous MSC for myocardial ischemia therapy is modest. We analyzed if ADSC properties are attenuated in patients with chronic diseases such as coronary artery disease (CAD) and diabetes mellitus type 2 (T2DM).', metadata={'splits_id': '0', 'document_id': 'PMC4268805_abstract.txt'}),\n",
              " Document(page_content='ADSC were isolated from subcutaneous fat tissue of patients without established cardiovascular diseases and metabolic disorders (control group, n\\u2009=\\u200919), patients with CAD only (n\\u2009=\\u200932) and patients with CAD and T2DM (n\\u2009=\\u200928). ADSC phenotype (flow cytometry) was CD90+/CD73+/CD105+/CD45−/CD31− and they were capable of adipogenic and osteogenic differentiation. ADSC morphology and immunophenotype were similar for all patients, but ADSC from patients with CAD and T2DM had higher proliferation activity and shorter telomeres compared to control patients.', metadata={'splits_id': '1', 'document_id': 'PMC4268805_abstract.txt'}),\n",
              " Document(page_content='ADSC conditioned media stimulated capillary-like tubes formation by endothelial cells (EA.hy926), but this effect significantly decreased for patients with CAD (p\\u2009=\\u20090.03) and with CAD\\u2009+\\u2009T2DM (p\\u2009=\\u20090.017) compared to the control group. Surprisingly we revealed significantly higher secretion of some pro-angiogenic factors (ELISA) by ADSC: vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) for patients with CAD and HGF and placental growth factor (PlGF) for patients with CAD\\u2009+\\u2009T2DM. Among angiogenesis inhibitors such as thrombospondin-1, endostatin and plasminogen activator inhibitor-1 (PAI-1) level of PAI-1 in ADSC conditioned media was significantly higher for patients with CAD and CAD\\u2009+\\u2009T2DM compared to the control group (p\\u2009<\\u20090.01). Inhibition of PAI-1 in ADSC conditioned media by neutralizing antibodies partially restored ADSC angiogenic activity (p\\u2009=\\u20090.017).', metadata={'splits_id': '2', 'document_id': 'PMC4268805_abstract.txt'}),\n",
              " Document(page_content='ADSC angiogenic activity is significantly declined in patients with CAD and T2DM, which could restrict the effectiveness of autologous ADSC cell therapy in these cohorts of patients. This impairment might be due to the disturbance in coordinated network of pro- and anti-angiogenic growth factors secreted by ADSC. Changes in ADSC secretome differ between patients with CAD and T2DM and further investigation are necessary to reveal the MSC-involved mechanisms of cardiovascular and metabolic diseases and develop novel approaches to their correction using the methods of regenerative medicine.\\nThe online version of this article (doi:10.1186/s12967-014-0337-4) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC4268805_abstract.txt'}),\n",
              " Document(page_content='The 20–70% participation of diabetes patients in lifestyle interventions (LSI) worldwide seems to be rather sub-optimal, in spite of all intents of such interventions to delay further progress of the disease. Positive effects through LSI are expected in particular for patients who suffer less from diabetes-related limitations or other chronic diseases. Seeing that diabetes prevalence and with it mortality are increasing, LSI have become an inherent part of diabetes treatment standards. Various qualitative studies have been carried out to identify participation barriers for LSI. However, these have not resulted in more detailed knowledge about the relative importance of factors with an inhibiting impact on participation. Since it cannot be assumed that all of the influencing factors have equivalent values, it is necessary to investigate their individual importance with regard to a positive or negative decision about participating. There are no systematic reviews on patient preferences', metadata={'splits_id': '0', 'document_id': 'PMC6264623_abstract.txt'}),\n",
              " Document(page_content='are no systematic reviews on patient preferences for LSI programs in diabetes prevention. As a result, the main objectives of this systematic review are to (i) identify existing patient preference elicitation studies related to LSI for diabetic patients, (ii) summarize the methods applied and findings, and (iii) appraise the reporting and methodological quality of such studies.', metadata={'splits_id': '1', 'document_id': 'PMC6264623_abstract.txt'}),\n",
              " Document(page_content='We will perform systematic literature searches to identify suitable studies from 14 electronic databases. Retrieved study records will be included based on predefined eligibility criteria as defined in this protocol. We will run abstract and full-text screenings and then extract data from all selected studies by filling in a predefined data extraction spreadsheet. We will undertake a descriptive, narrative synthesis of findings to address the study objectives, since no pooling for quantified preferences is for methodological reasons implementable. We will pay special attention to aspects of methodological quality of preference elicitation by applying established evaluation criteria of the ISPOR and some own developed criteria for different elicitation techniques. All critical stages within the screening, data extraction, and synthesis processes will be conducted by two pairs of authors. This protocol adheres to PRISMA and PRISMA-P standards.', metadata={'splits_id': '2', 'document_id': 'PMC6264623_abstract.txt'}),\n",
              " Document(page_content='The proposed systematic review will provide an overview of the methods used and current practice in the elicitation and quantification of patients’ preferences for diabetes prevention lifestyle interventions. Furthermore, the methodological quality of the identified studies will be appraised as well.\\nPROSPERO CRD42018086988\\nThe online version of this article (10.1186/s13643-018-0884-5) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6264623_abstract.txt'}),\n",
              " Document(page_content='Wolfram Syndrome (WFS) is known to involve diabetes mellitus, diabetes insipidus, optic nerve atrophy, vision loss, hearing impairment, motor abnormalities, and neurodegeneration, but has been less clearly linked to cognitive, sleep, and psychiatric abnormalities. We sought to determine whether these abnormalities are present in children, adolescents, and young adults with WFS compared to age- and gender-matched individuals with and without type 1 diabetes using standardized measures.', metadata={'splits_id': '0', 'document_id': 'PMC4450481_abstract.txt'}),\n",
              " Document(page_content='Individuals with genetically-confirmed WFS (n\\u2009=\\u200919, ages 7–27) were compared to age- and gender- equivalent groups of individuals with type 1 diabetes (T1DM; n\\u2009=\\u200925), and non-diabetic healthy controls (HC: n\\u2009=\\u200925). Cognitive performance across multiple domains (verbal intelligence, spatial reasoning, memory, attention, smell identification) was assessed using standardized tests. Standardized self- and parent-report questionnaires on psychiatric symptoms and sleep disturbances were acquired from all groups and an unstructured psychiatric interview was performed within only the WFS group.', metadata={'splits_id': '1', 'document_id': 'PMC4450481_abstract.txt'}),\n",
              " Document(page_content='The three groups were similar demographically (age, gender, ethnicity, parental IQ). WFS and T1DM had similar duration of diabetes but T1DM had higher HbA1C levels than WFS and as expected both groups had higher levels than HC. The WFS group was impaired on smell identification and reported sleep quality, but was not impaired in any other cognitive or self-reported psychiatric domain. In fact, the WFS group performed better than the other two groups on selected memory and attention tasks. However, based upon a clinical evaluation of only WFS patients, we found that psychiatric and behavioral problems were present and consisted primarily of anxiety and hypersomnolence.', metadata={'splits_id': '2', 'document_id': 'PMC4450481_abstract.txt'}),\n",
              " Document(page_content='This study found that cognitive performance and psychological health were relatively preserved WFS patients, while smell and sleep abnormalities manifested in many of the WFS patients. These findings contradict past case and retrospective reports indicating significant cognitive and psychiatric impairment in WFS. While many of these patients were diagnosed with anxiety and hypersomnolence, self-reported measures of psychiatric symptoms indicated that the symptoms were not of grave concern to the patients. It may be that cognitive and psychiatric issues become more prominent later in life and/or in later stages of the disease, but this requires standardized assessment and larger samples to determine. In the relatively early stages of WFS, smell and sleep-related symptoms may be useful biomarkers of disease and should be monitored longitudinally to determine if they are good markers of progression as well.\\nCurrent Clinicaltrials.gov Trial NCT02455414.', metadata={'splits_id': '3', 'document_id': 'PMC4450481_abstract.txt'}),\n",
              " Document(page_content='Supplemental Digital Content is available in the text.\\nPatients with established coronary artery disease or peripheral artery disease often have diabetes mellitus. These patients are at high risk of future vascular events.\\nIn a prespecified analysis of the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies), we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus without diabetes mellitus in preventing major vascular events. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included all-cause mortality and all major vascular events (cardiovascular death, myocardial infarction, stroke, or major adverse limb events, including amputation). The primary safety end point was a modification of the International Society on Thrombosis and Haemostasis criteria for major bleeding.', metadata={'splits_id': '0', 'document_id': 'PMC7314494_abstract.txt'}),\n",
              " Document(page_content='There were 10\\u2009341 patients with diabetes mellitus and 17\\u2009054 without diabetes mellitus in the overall trial. A consistent and similar relative risk reduction was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and without (n=11\\u2009356) diabetes mellitus for the primary efficacy end point (hazard ratio, 0.74, P=0.002; and hazard ratio, 0.77, P=0.005, respectively, Pinteraction=0.77) and all-cause mortality (hazard ratio, 0.81, P=0.05; and hazard ratio, 0.84, P=0.09, respectively; Pinteraction=0.82). However, although the absolute risk reductions appeared numerically larger in patients with versus without diabetes mellitus, both subgroups derived similar benefit (2.3% versus 1.4% for the primary efficacy end point at 3 years, Gail-Simon qualitative Pinteraction<0.0001; 1.9% versus 0.6% for all-cause mortality, Pinteraction=0.02; 2.7% versus 1.7% for major vascular events, Pinteraction<0.0001). Because the bleeding', metadata={'splits_id': '1', 'document_id': 'PMC7314494_abstract.txt'}),\n",
              " Document(page_content='Pinteraction<0.0001). Because the bleeding hazards were similar among patients with and without diabetes mellitus, the prespecified net benefit for rivaroxaban appeared particularly favorable in the patients with diabetes mellitus (2.7% versus 1.0%; Gail-Simon qualitative Pinteraction=0.001).', metadata={'splits_id': '2', 'document_id': 'PMC7314494_abstract.txt'}),\n",
              " Document(page_content='In stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a similar relative degree of benefit on coronary, cerebrovascular, and peripheral end points in patients with and without diabetes mellitus. Given their higher baseline risk, the absolute benefits appeared larger in those with diabetes mellitus, including a 3-fold greater reduction in all-cause mortality.\\nURL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.', metadata={'splits_id': '3', 'document_id': 'PMC7314494_abstract.txt'}),\n",
              " Document(page_content='This study introduced a web-based educational intervention for Australian women with gestational diabetes mellitus (GDM). The aim was to improve knowledge on healthy diet and lifestyle in GDM. Evaluation of the intervention explored women’s knowledge and understanding of GDM, healthy diet, healthy food, and healthy lifestyle, after using the web-based program compared to women receiving standard clinic-based GDM education.', metadata={'splits_id': '0', 'document_id': 'PMC4974775_abstract.txt'}),\n",
              " Document(page_content='A total of 116 women, aged 18–45 years old, newly diagnosed with GDM, participated (Intervention (n)\\u2009=\\u200956 and control (n)\\u2009=\\u200960). Women were randomly allocated to the intervention or control groups and both groups attended a standard GDM education class. Group 1(Intervention) additionally used an online touch screen/computer program. All women completed a questionnaire following the computer program and/or the education class. All questions evaluating levels of knowledge had more than one correct answer and scores were graded from 0 to 1, with each correct component receiving a score, eg. 0.25 per each correct answer in a 4 answer question. Chi-square test was performed to compare the two groups regarding knowledge of GDM.', metadata={'splits_id': '1', 'document_id': 'PMC4974775_abstract.txt'}),\n",
              " Document(page_content='Findings indicated that the majority of women in the intervention group reported correct answers for “types of carbohydrate foods” for pregnant women with GDM, compared to the control group (62.5\\xa0% vs 58.3\\xa0%, respectively). Most women in both groups had an excellent understanding of “fruits and vegetables” (98.2\\xa0% vs 98.3\\xa0%), and the majority of women in the intervention group understood that they should exercise daily for 30\\xa0min, compared to the control group (92.9\\xa0% vs 91.7\\xa0%). Both groups had a good understanding across all categories, however, the majority of women in the intervention group scored all correct answers (score\\u2009=\\u20091) in term of foetal effects (17.9\\xa0% vs 13.3\\xa0%, respectively), maternal predictors (5.4\\xa0% vs 5\\xa0%), care requirements (39.3\\xa0% vs 23.3\\xa0%), GDM perceptions (48.2\\xa0% vs 46.7\\xa0%) and GDM treatment (67.9\\xa0% vs 61.7\\xa0%), compared to women in the control group.', metadata={'splits_id': '2', 'document_id': 'PMC4974775_abstract.txt'}),\n",
              " Document(page_content='The study suggested that both approaches, standard education and standard education plus web-based program, resulted in excellent knowledge scores, but not statistically significant difference between groups. Multiple and immediate access to the web-based education program at home may prove useful as a source of reference for women with GDM. Future study comparing results pre and post intervention is needed.\\nACTRN12615000697583; Date registered: 03/07/2015; Retrospectively registered.\\nThe online version of this article (doi:10.1186/s12884-016-0996-7) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC4974775_abstract.txt'}),\n",
              " Document(page_content='The placebo response in patients with diabetes mellitus is very common. A systematic evaluation needs to be updated with the current evidence about the placebo response in diabetes mellitus and the associated factors in clinical trials of anti-diabetic medicine.\\nLiterature research was conducted in Medline, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov for studies published between the date of inception and June 2019. Randomized placebo-controlled trials conducted in type 1and type 2 diabetes mellitus (T1DM/T2DM) were included. Random-effects model and meta-regression analysis were accordingly used. This meta-analysis was registered in PROSPERO as CRD42014009373.', metadata={'splits_id': '0', 'document_id': 'PMC7667845_abstract.txt'}),\n",
              " Document(page_content='Significantly weight elevation (effect size (ES)\\u2009=\\u20090.33\\u2009kg, 95% CI, 0.03 to 0.61\\u2009kg) was observed in patients with placebo treatments in T1DM subgroup while significantly HbA1c reduction (ES\\u2009=\\u2009−\\u20090.12%, 95% CI, −\\u20090.16 to −\\u20090.07%) and weight reduction (ES\\u2009=\\u2009−\\u20090.40\\u2009kg, 95% CI, −\\u20090.50 to −\\u20090.29\\u2009kg) were observed in patients with placebo treatments in T2DM subgroup. Greater HbA1c reduction was observed in patients with injectable placebo treatments (ES\\u2009=\\u2009−\\u20090.22%, 95% CI, −\\u20090.32 to −\\u20090.11%) versus oral types (ES\\u2009=\\u2009−\\u20090.09%, 95% CI, −\\u20090.14 to −\\u20090.04%) in T2DM (P\\u2009=\\u20090.03). Older age (β\\u2009=\\u2009−\\u20090.01, 95% CI, −\\u20090.02 to −\\u20090.01, P\\u2009<\\u20090.01) and longer diabetes duration (β\\u2009=\\u2009−\\u20090.02, 95% CI, −\\u20090.03 to −\\u20090.21\\u2009×\\u200910−2, P\\u2009=\\u20090.03) was significantly associated with more HbA1c reduction by placebo in T1DM. However, younger age (β\\u2009=\\u20090.02, 95% CI, 0.01 to 0.03, P\\u2009=\\u20090.01), lower male percentage (β\\u2009=\\u20090.01, 95% CI, 0.22\\u2009×\\u200910−2, 0.01, P\\u2009<\\u20090.01), higher baseline BMI (β\\u2009=\\u2009−\\u20090.02, 95% CI, −\\u20090.04 to −\\u20090.26\\u2009×\\u200910−2,', metadata={'splits_id': '1', 'document_id': 'PMC7667845_abstract.txt'}),\n",
              " Document(page_content='BMI (β\\u2009=\\u2009−\\u20090.02, 95% CI, −\\u20090.04 to −\\u20090.26\\u2009×\\u200910−2, P\\u2009=\\u20090.02), and higher baseline HbA1c (β\\u2009=\\u2009−\\u20090.09, 95% CI, −\\u20090.16 to −\\u20090.01, P\\u2009=\\u20090.02) were significantly associated with more HbA1c reduction by placebo in T2DM. Shorter diabetes duration (β\\u2009=\\u20090.06, 95% CI, 0.06 to 0.10, P\\u2009<\\u20090.01) was significantly associated with more weight reduction by placebo in T2DM. However, the associations between baseline BMI, baseline HbA1c, and placebo response were insignificant after the adjusted analyses.', metadata={'splits_id': '2', 'document_id': 'PMC7667845_abstract.txt'}),\n",
              " Document(page_content='The placebo response in diabetes mellitus was systematically outlined. Age, sex, disease severity (indirectly reflected by baseline BMI and baseline HbA1c), and disease\\xa0duration were associated with placebo response in diabetes mellitus. The association between baseline BMI, baseline HbA1c, and placebo response may be the result of regression to the mean.', metadata={'splits_id': '3', 'document_id': 'PMC7667845_abstract.txt'}),\n",
              " Document(page_content='Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat patients with many advanced solid tumor and hematological malignancies to improve their prognosis. Case reports of their endocrine immune-related adverse events [irAEs]) are increasingly published as more real-world patients with these malignancies are treated with these drugs. They alert physicians of a drug’s AEs (which may change during a drug’s life cycle) and contribute to post-marketing safety surveillance. Using a modified framework of Arksey and O’Malley, we conducted a scoping review of the spectrum and characteristics of ICI-induced endocrinopathies case reports before and after ICIs are marketed.', metadata={'splits_id': '0', 'document_id': 'PMC6343255_abstract.txt'}),\n",
              " Document(page_content='In July 2017, we searched, without date and language restrictions, 4 citation databases for ICI-induced endocrinopathies. We also hand-searched articles’ references, contents of relevant journals, and ran supplemental searches to capture recent reports through January 2018. For this study, a case should have information on type of cancer, type of ICI, clinical presentation, biochemical tests, treatment plus temporal association of ICI initiation with endocrinopathies. Two endocrinologists independently extracted the data which were then summarized and categorized.', metadata={'splits_id': '1', 'document_id': 'PMC6343255_abstract.txt'}),\n",
              " Document(page_content='One hundred seventy nine articles reported 451 cases of ICI-induced endocrinopathies - 222 hypopituitarism, 152 thyroid disorders, 66 diabetes mellitus, 6 primary adrenal insufficiencies, 1 ACTH-dependent Cushing’s syndrome, 1 hypoparathyroidism and 3 diabetes insipidus cases. Their clinical presentations reflect hormone excess or deficiency. Some were asymptomatic and others life-threatening. One or more endocrine glands could be affected. Polyglandular endocrinopathies could present simultaneously or in sequence. Many occur within 5\\u2009months of therapy initiation; a few occurred after ICI was stopped. Mostly irreversible, they required long-term hormone replacement. High dose steroids were used when non-endocrine AEs coexisted or as therapy in adrenal insufficiency. There was variability of information in the case reports but all met the study criteria to make a diagnosis.', metadata={'splits_id': '2', 'document_id': 'PMC6343255_abstract.txt'}),\n",
              " Document(page_content='The spectrum of ICI-induced endocrinopathies is wide (5 glands affected) and their presentation varied (12 endocrinopathies). Clinical reasoning integrating clinical, biochemical and treatment information is needed to properly diagnose and manage them. Physicians should be vigilant for their occurrence and be able to diagnose, investigate and manage them appropriately at onset and follow-up.\\nThe online version of this article (10.1186/s40842-018-0073-4) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6343255_abstract.txt'}),\n",
              " Document(page_content='There is limited evidence on whether screening for type 2 diabetes mellitus affects health outcomes. A recent systematic review of randomised clinical trials found only one trial that met their inclusion criteria; therefore, current guidelines for screening interventions for type 2 diabetes mellitus are based on expert opinions and best practice rather than synthesised evidence. This systematic review seeks to collate evidence from non-randomised studies to investigate the effect of screening for adults with type 2 diabetes on outcomes including diabetes-related morbidity, mortality (all-cause and diabetes-related) and harms.', metadata={'splits_id': '0', 'document_id': 'PMC7359237_abstract.txt'}),\n",
              " Document(page_content='This systematic review will follow Effective Practice and Organisation of Care (EPOC) guidelines for the synthesis of non-randomised studies. We will search PubMed/MEDLINE, Scopus, Web of Science, CINAHL, Academic Search Premier and Health Source Nursing Academic (from inception onwards). We will include non-randomised trials, controlled before-after studies, interrupted time-series studies, repeated measures studies and concurrently controlled prospective cohort studies. The primary outcome will be diabetes-related morbidity (microvascular complications of diabetic retinopathy, nephropathy or neuropathy or macrovascular complications of non-fatal myocardial infarction, peripheral arterial disease or non-fatal stroke). The secondary outcomes will be mortality (all-cause and diabetes-related) and harms of screening strategies to patients (including psychological harms or adverse events following treatments) or to health care system (including resource allocation for false-positives or', metadata={'splits_id': '1', 'document_id': 'PMC7359237_abstract.txt'}),\n",
              " Document(page_content='resource allocation for false-positives or overdiagnosis). Two reviewers will independently screen all citations and full-text articles. Data will be abstracted by one reviewer and checked by a second. The risk of bias of individual studies will be appraised using the ROBINS-I tool. GRADE will be used to determine the quality of the scientific evidence. If feasible, we will conduct random effects meta-analysis where appropriate. If necessary, analyses will be conducted to explore the potential sources of heterogeneity (e.g. age, sex, socio-economic status, rural versus urban or low-middle income versus high-income country). We will disseminate the findings via publications and through relevant networks.', metadata={'splits_id': '2', 'document_id': 'PMC7359237_abstract.txt'}),\n",
              " Document(page_content='The protocol outlines the methods for systematically reviewing and synthesising evidence of screening strategies for type 2 diabetes mellitus and their effect on health outcomes associated with the disease. The potential impact of this systematic review is improved evidence-informed decision-making for policies and practice for screening of type-2 diabetes.\\nPROSPERO CRD42020147439', metadata={'splits_id': '3', 'document_id': 'PMC7359237_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes mellitus (GDM) is glucose intolerance first recognised during pregnancy. Both modalities and thresholds of the GDM diagnostic test, the Oral Glucose Tolerance Test (OGTT), have varied widely over time and among countries. Additionally, OGTT limitations include inconsistency, poor patient tolerability, and questionable diagnostic reliability. Many biological parameters have been reported to be modified by GDM and could potentially be used as diagnostic indicators. This study aimed\\xa0to 1) systematically explore biomarkers reported in the literature as differentiating GDM from healthy pregnancies\\xa02) screen those indicators assessed against OGTT to propose OGTT alternatives.', metadata={'splits_id': '0', 'document_id': 'PMC8504031_abstract.txt'}),\n",
              " Document(page_content='A systematic review of GDM\\xa0diagnostic indicators was performed according to PRISMA guidelines (PROSPERO registration\\xa0CRD42020145499).\\xa0Inclusion criteria were\\xa0full-text, comprehensible English-language articles published January 2009-January 2021, where a biomarker (from blood, ultrasound, amniotic fluid, placenta) was compared between GDM and normal glucose tolerance (NGT) women from the second trimester onward to immediately postpartum. GDM diagnostic method had to be clearly specified, and the number of patients per study higher than 30 in total or 15 per group. Results were synthesised by biomarkers.', metadata={'splits_id': '1', 'document_id': 'PMC8504031_abstract.txt'}),\n",
              " Document(page_content='Of 13,133 studies identified in initial screening, 174 studies (135,801 participants) were included. One hundred and twenty-nine studies described blood analytes, one amniotic fluid analytes, 27 ultrasound features, 17 post-natal features. Among the biomarkers evaluated in exploratory studies, Adiponectin, AFABP, Betatrophin, CRP, Cystatin-C, Delta-Neutrophil Index, GGT, TNF-A were those demonstrating statistically and clinically significant differences in substantial cohorts of patients (>\\u2009500). Regarding biomarkers assessed versus OGTT (i.e. potential OGTT alternatives) most promising were Leptin\\u2009>\\u200948.5 ng/ml, Ficolin3/adiponectin ratio\\u2009≥\\u20091.06, Chemerin/FABP\\u2009>\\u20090.71, and Ultrasound Gestational Diabetes Score\\u2009>\\u20094. These all demonstrated sensitivity and specificity\\u2009>\\u200980% in adequate sample sizes (>\\u2009/\\u2009=\\u2009100).', metadata={'splits_id': '2', 'document_id': 'PMC8504031_abstract.txt'}),\n",
              " Document(page_content='Numerous biomarkers may differentiate GDM from normoglycaemic pregnancy.\\xa0Given the limitations of the OGTT and the lack of a gold standard for GDM diagnosis, advanced phase studies are needed to triangulate the most promising biomarkers. Further studies are also recommended to assess the sensitivity and specificity of promising biomarkers not yet assessed against OGTT.\\nPROSPERO registration number CRD42020145499.\\nThe online version contains supplementary material available at 10.1186/s40842-021-00126-7.', metadata={'splits_id': '3', 'document_id': 'PMC8504031_abstract.txt'}),\n",
              " Document(page_content='Disorders of water and sodium balance can occur after brain injury. Prolonged polyuria resulting from central diabetes insipidus and cerebral salt wasting complicated by gradient washout and a type of secondary nephrogenic diabetes insipidus, however, has not been described previously, to the best of our knowledge. We report an unusual case of an infant with glioblastoma who, after tumor resection, was treated for concurrent central diabetes insipidus and cerebral salt wasting complicated by secondary nephrogenic diabetes insipidus.', metadata={'splits_id': '0', 'document_id': 'PMC7547417_abstract.txt'}),\n",
              " Document(page_content='A 5-month-old Hispanic girl was found to have a large, hemorrhagic, suprasellar glioblastoma causing obstructive hydrocephalus. Prior to mass resection, she developed central diabetes insipidus. Postoperatively, she continued to have central diabetes insipidus and concurrent cerebral salt wasting soon after. She was managed with a vasopressin infusion, sodium supplementation, fludrocortisone, and urine output replacements. Despite resolution of her other major medical issues, she remained in the pediatric intensive care unit for continual and aggressive management of water and sodium derangements. Starting on postoperative day 18, her polyuria began increasing dramatically and did not abate with increasing vasopressin. Nephrology was consulted. Her blood urea nitrogen was undetectable during this time, and it was thought that she may have developed a depletion of inner medullary urea and osmotic gradient: a “gradient washout.” Supplemental dietary protein was added to her enteral', metadata={'splits_id': '1', 'document_id': 'PMC7547417_abstract.txt'}),\n",
              " Document(page_content='dietary protein was added to her enteral nutrition, and her fluid intake was decreased. Within 4 days, her blood urea nitrogen increased, and her vasopressin and fluid replacement requirements significantly decreased. She was transitioned soon thereafter to subcutaneous desmopressin and transferred out of the pediatric intensive care unit.', metadata={'splits_id': '2', 'document_id': 'PMC7547417_abstract.txt'}),\n",
              " Document(page_content='Gradient washout has not been widely reported in humans, although it has been observed in the mammalian kidneys after prolonged polyuria. Although not a problem with aquaporin protein expression or production, gradient washout causes a different type of secondary nephrogenic diabetes insipidus because the absence of a medullary gradient impairs water reabsorption. We report a case of an infant who developed complex water and sodium imbalances after brain injury. Prolonged polyuria resulting from both water and solute diuresis with low enteral protein intake was thought to cause a urea gradient washout and secondary nephrogenic diabetes insipidus. The restriction of fluid replacements and supplementation of enteral protein appeared adequate to restore the renal osmotic gradient and efficacy of vasopressin.', metadata={'splits_id': '3', 'document_id': 'PMC7547417_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus is emerging as an epidemic worldwide, and the incidence and prevalence of diabetes have drastically changed in China over the past 30 years, but data on its mortality rate are scarce. This study aimed to analyze the time trends of mortality rates among patients with diabetes in the rural and urban population in China between 1987 and 2019.\\nThe research data come from China’s annual report on national health statistics and the Chinese Health Statistics Yearbook. Age-standardized mortality rates were calculated by using the direct method based on the World Standard Population from the WHO. Joinpoint regression analysis was employed to estimate the annual percent change and average annual percentage changes of mortality rates of diabetes mellitus.', metadata={'splits_id': '0', 'document_id': 'PMC8801697_abstract.txt'}),\n",
              " Document(page_content='An overall trend for increment in diabetes mortality was observed. The crude mortality rates and age-standardized mortality rates of diabetes for urban and rural residents in China showed a significant increasing trend between 1987 and 2019. Mortality due to diabetes in urban areas has been higher than in rural areas for 30 years. However, due to the rapid increase of rural diabetes mortality in the past decade, the gap between the two gradually narrowed. The age-standardized mortality rates of diabetes increased by about 38.5% in urban areas and 254.9% in rural areas over the whole study period. In addition, the age-standardized mortality rate of females with diabetes was higher than that of males, but this pattern began to change in urban areas in 2012. Finally, the age-standardized mortality rates in the elderly population in China are higher with a faster growth rate, especially in rural areas.', metadata={'splits_id': '1', 'document_id': 'PMC8801697_abstract.txt'}),\n",
              " Document(page_content='The mortality rate of diabetes is on the rise in China. The rapid growth of the mortality rate of diabetes in rural areas leads to the reduction of the urban–rural gap. Male mortality rates in urban areas have surpassed those of women. At the same time, the mortality rate of diabetes showed obvious elder-group orientation. As China’s population ages, the burden of death and disability caused by diabetes and its complications will continue to increase. These results indicate that diabetes has become a significant public health problem in China. Such an effect increases the demand for strategies aimed at the prevention and treatment of diabetes mellitus. In addition to the prevention and intervention of diabetes in high-risk groups, it is also necessary to establish diabetes screening networks to identify patients with mild symptoms. Early detection and timely intervention can effectively reduce the incidence and mortality of diabetes.', metadata={'splits_id': '2', 'document_id': 'PMC8801697_abstract.txt'}),\n",
              " Document(page_content='The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has rapidly involved the entire world and exposed the pressing need for collaboration between public health and other stakeholders from the clinical, scientific, regulatory, pharmaceutical, and medical device and technology communities. To discuss how to best protect people with diabetes from serious outcomes from COVID-19, Diabetes Technology Society, in collaboration with Sansum Diabetes Research Institute, hosted the “International COVID-19 and Diabetes Virtual Summit” on August 26-27, 2020. This unique, unprecedented real-time conference brought together physicians, scientists, government officials, regulatory experts, industry representatives, and people with diabetes from six continents to review and analyze relationships between COVID-19 and diabetes. Over 800 attendees logged in. The summit consisted of five sessions: (I) Keynotes, (II) Preparedness,', metadata={'splits_id': '0', 'document_id': 'PMC7925443_abstract.txt'}),\n",
              " Document(page_content='five sessions: (I) Keynotes, (II) Preparedness, (III) Response, (IV) Recovery, and (V) Surveillance; eight parts: (A) Background, (B) Resilience, (C) Outpatient Care, (D) Inpatient Care, (E) Resources, (F) High-Risk Groups, (G) Regulation, and (H) The Future; and 24 sections: (1) Historic Pandemics and Impact on Society, (2) Pathophysiology/Risk Factors for COVID-19, (3) Social Determinants of COVID-19, (4) Preparing for the Future, (5) Medications and Vaccines, (6) Psychology of Patients and Caregivers, (7) Outpatient Treatment of Diabetes Mellitus and Non-Pharmacologic Intervention, (8) Technology and Telehealth for Diabetes Outpatients, (9) Technology for Inpatients, (10) Management of Diabetes Inpatients with COVID-19, (11) Ethics, (12) Accuracy of Diagnostic Tests, (13) Children, (14) Pregnancy, (15) Economics of Care for COVID-19, (16) Role of Industry, (17) Protection of Healthcare Workers, (18) People with Diabetes, (19) International Responses to COVID-19, (20) Government', metadata={'splits_id': '1', 'document_id': 'PMC7925443_abstract.txt'}),\n",
              " Document(page_content='Responses to COVID-19, (20) Government Policy, (21) Regulation of Tests and Treatments, (22) Digital Health Technology, (23) Big Data Statistics, and 24) Patient Surveillance and Privacy. The two keynote speeches were entitled (1) COVID-19 and Diabetes—Meeting the Challenge and (2) Knowledge Gaps and Research Opportunities for Diabetes and COVID-19. While there was an emphasis on diabetes and its interactions with COVID-19, the panelists also discussed the COVID-19 pandemic in general. The meeting generated many novel ideas for collaboration between experts in medicine, science, government, and industry to develop new technologies and disease treatment paradigms to fight this global pandemic.', metadata={'splits_id': '2', 'document_id': 'PMC7925443_abstract.txt'}),\n",
              " Document(page_content='Sleep duration is a risk factor for incident diabetes mellitus and CHD. The primary aim of the present study was to investigate, in sex-specific analyses, the role of incident diabetes as the possible biological mechanism for the reported association between short/long sleep duration and incident CHD. Considering that diabetes is a major risk factor for CHD, we hypothesised that any association with sleep duration would not hold for cases of incident CHD occurring before incident diabetes (‘non-diabetes CHD’) but would hold true for cases of incident CHD following incident diabetes (‘diabetes-CHD’).', metadata={'splits_id': '0', 'document_id': 'PMC6448951_abstract.txt'}),\n",
              " Document(page_content='A total of 6966 men and 9378 women aged 45–73\\xa0years from the Malmö Diet Cancer Study, a population-based, prospective cohort, who had answered questions on habitual sleep duration and did not have a history of prevalent diabetes or CHD were included in the analyses. Incident cases of diabetes and CHD were identified using national registers. Sex-specific Cox proportional hazards regression models were stratified by BMI and adjusted for known covariates of diabetes and CHD.', metadata={'splits_id': '1', 'document_id': 'PMC6448951_abstract.txt'}),\n",
              " Document(page_content='Mean follow-up times for incident diabetes (n\\xa0=\\xa01137/1016 [men/women]), incident CHD (n\\xa0=\\xa01170/578), non-diabetes CHD (n\\xa0=\\xa01016/501) and diabetes-CHD (n\\xa0=\\xa0154/77) were 14.2–15.2\\xa0years for men, and 15.8–16.5\\xa0years for women. In men, short sleep duration (<\\xa06\\xa0h) was associated with incident diabetes (HR 1.35, 95% CI 1.01, 1.80), CHD (HR 1.41, 95% CI 1.06, 1.89) and diabetes-CHD (HR 2.34, 95% CI 1.20, 4.55). Short sleep duration was not associated with incident non-diabetes CHD (HR 1.35, 95% CI 0.98, 1.87). Long sleep duration (≥\\xa09\\xa0h) was associated with incident diabetes (HR 1.37, 95% CI 1.03, 1.83), CHD (HR 1.33, 95% CI 1.01, 1.75) and diabetes-CHD (HR 2.10, 95% CI 1.11, 4.00). Long sleep duration was not associated with incident non-diabetes CHD (HR 1.33, 95% CI 0.98, 1.80). In women, short sleep duration was associated with incident diabetes (HR 1.53, 95% CI 1.16, 2.01), CHD (HR 1.46, 95% CI 1.03, 2.07) and diabetes-CHD (HR 2.88, 95% CI 1.37, 6.08). Short sleep duration was not', metadata={'splits_id': '2', 'document_id': 'PMC6448951_abstract.txt'}),\n",
              " Document(page_content='95% CI 1.37, 6.08). Short sleep duration was not associated with incident non-diabetes CHD (HR 1.29, 95% CI 0.86, 1.93).', metadata={'splits_id': '3', 'document_id': 'PMC6448951_abstract.txt'}),\n",
              " Document(page_content='The associations between sleep duration and incident CHD directly reflect the associations between sleep duration and incident diabetes. Incident diabetes may thus be the explanatory mechanism for the association between short and long sleep duration and incident CHD.\\nThe online version of this article (10.1007/s00125-017-4464-3) contains peer-reviewed but unedited supplementary material, which is available to authorised users.', metadata={'splits_id': '4', 'document_id': 'PMC6448951_abstract.txt'}),\n",
              " Document(page_content='Diabetic patients, during the course of the disease, are most likely to experience depressive symptoms that might ultimately lead to suicidal ideation or suicide. The size of literature in diabetes depression/suicide is a good indicator of national and international efforts to address psychological co-morbidities associated with diabetes mellitus (DM). Therefore, the objective of this study was to give a comprehensive analysis, both quantitative and qualitative, of scientific literature in diabetes depression/suicide.\\nSciVerse Scopus was used to retrieve relevant literature up to 2016.', metadata={'splits_id': '0', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='In total, 1664 journal documents were retrieved with an average of 26.9 citations per article and an h-index of 98. Publications started in 1949 but showed a steep and noticeable increase after 2001. Retrieved articles were published in 641 different journals with Diabetes Care journal being the top productive one with a total of 130 (7.8%) articles. Researchers from 83 different countries participated in retrieved publications. Researchers from the United States of America participated in publishing 685 articles. There was a strong and positive correlation between research output and Gross Domestic Product (r\\u2009=\\u20090.083; p\\u2009<\\u20090.001) but not with prevalence or mortality caused by DM. Researchers from 4870 different institutions/organizations participated in publishing retrieved articles. Publications from the University of Washington, Seattle, USA had the highest h-index (38), while “VA medical centers” had the highest number of publications (75; 4.5%). In total, 5715 authors appeared in', metadata={'splits_id': '1', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='(75; 4.5%). In total, 5715 authors appeared in retrieved articles giving an average of 3.4 authors per article. Top cited articles focused on prevalence, impact of depression on glycemic control, and potential risk of diabetic complications. The total number of publications in depression/suicide in diabetic patients was lesser than that in cardiac (1938) or in cancer (1828) patients. However, publications in diabetes depression/suicide exceeded those in cardiac and cancer in the last 2\\xa0years of the study period.', metadata={'splits_id': '2', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='The current study showed a noticeable growth of publications indicative of the importance of this topic. Research focusing on the psychiatric component of diabetes mellitus needs to be strengthened and encouraged. At the practical level, screening for depression/suicide among patients attending primary healthcare clinics is needed to optimize health and quality of life of diabetic patients.\\nThe online version of this article (10.1186/s12991-018-0214-2) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='With the rise in pre-mature mortality rate from non-communicable disease (NCD), there is a need for evidence-based interventions. We evaluated existing systematic reviews on effectiveness of integration of healthcare services, in particular with focus on delivery of care designed to improve health and process outcomes in people with multi-morbidity, where at least one of the conditions was diabetes or hypertension.', metadata={'splits_id': '0', 'document_id': 'PMC6011271_abstract.txt'}),\n",
              " Document(page_content='We searched MEDLINE, EMBASE, Cochrane Library, and Health Evidence to November 8, 2016 and consulted experts. One review author screened titles, abstracts and two review authors independently screened short listed full-texts and selected reviews for inclusion. We considered systematic reviews evaluating integration of care, compared to usual care, for people with multi-morbidity. One review author extracted data and another author verified it. Two review authors independently evaluated risk of bias using ROBIS and AMSTAR. Inter-rater reliability was analysed for ROBIS and AMSTAR using Cohen’s kappa and percent agreement. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was used to assess reporting.', metadata={'splits_id': '1', 'document_id': 'PMC6011271_abstract.txt'}),\n",
              " Document(page_content='We identified five systematic reviews on integration of care. Four reviews focused on comorbid diabetes and depression and two covered hypertension and comorbidities of cardiovascular disease, depression, or diabetes. Interventions were poorly described. The health outcomes evaluated included risk of all-cause mortality, measures of depression, cholesterol levels, HbA1c levels, effect of depression on HbA1c levels, symptom improvement, systolic blood pressure, and hypertension control. Process outcomes included access and utilisation of healthcare services, costs, and quality of care. Overall, three reviews had a low and medium risk of bias according to ROBIS and AMSTAR respectively, while two reviews had high risk of bias as judged by both ROBIS and AMSTAR. Findings have demonstrated that collaborative care in general resulted in better health and process outcomes when compared to usual care for both depression and diabetes and hypertension and diabetes.', metadata={'splits_id': '2', 'document_id': 'PMC6011271_abstract.txt'}),\n",
              " Document(page_content='Several knowledge gaps were identified on integration of care for comorbidities with diabetes and/or hypertension: limited research on this topic for hypertension, limited reviews that included primary studies based in low-middle income countries, and limited reviews on collaborative care for communicable and NCDs.\\nThe online version of this article (10.1186/s12913-018-3290-8) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6011271_abstract.txt'}),\n",
              " Document(page_content='Diagnosis of monogenic as well as atypical forms of diabetes mellitus has important clinical implications for their specific diagnosis, prognosis, and targeted treatment. Single gene mutations that affect beta-cell function represent 1–2% of all cases of diabetes. However, phenotypic heterogeneity and lack of family history of diabetes can limit the diagnosis of monogenic forms of diabetes. Next-generation sequencing technologies provide an excellent opportunity to screen large numbers of individuals with a diagnosis of diabetes for mutations in disease-associated genes.', metadata={'splits_id': '0', 'document_id': 'PMC5717832_abstract.txt'}),\n",
              " Document(page_content='We utilized a targeted sequencing approach using the Illumina HiSeq to perform a case-control sequencing study of 22 monogenic diabetes genes in 4016 individuals with type 2 diabetes (including 1346 individuals diagnosed before the age of 40 years) and 2872 controls. We analyzed protein-coding variants identified from the sequence data and compared the frequencies of pathogenic variants (protein-truncating variants and missense variants) between the cases and controls.', metadata={'splits_id': '1', 'document_id': 'PMC5717832_abstract.txt'}),\n",
              " Document(page_content='A total of 40 individuals with diabetes (1.8% of early onset sub-group and 0.6% of adult onset sub-group) were carriers of known pathogenic missense variants in the GCK, HNF1A, HNF4A, ABCC8, and INS genes. In addition, heterozygous protein truncating mutations were detected in the GCK, HNF1A, and HNF1B genes in seven individuals with diabetes. Rare missense mutations in the GCK gene were significantly over-represented in individuals with diabetes (0.5% carrier frequency) compared to controls (0.035%). One individual with early onset diabetes was homozygous for a rare pathogenic missense variant in the WFS1 gene but did not have the additional phenotypes associated with Wolfram syndrome.', metadata={'splits_id': '2', 'document_id': 'PMC5717832_abstract.txt'}),\n",
              " Document(page_content='Targeted sequencing of genes linked with monogenic diabetes can identify disease-relevant mutations in individuals diagnosed with type 2 diabetes not suspected of having monogenic forms of the disease. Our data suggests that GCK-MODY frequently masquerades as classical type 2 diabetes. The results confirm that MODY is under-diagnosed, particularly in individuals presenting with early onset diabetes and clinically labeled as type 2 diabetes; thus, sequencing of all monogenic diabetes genes should be routinely considered in such individuals. Genetic information can provide a specific diagnosis, inform disease prognosis and may help to better stratify treatment plans.\\nThe online version of this article (doi:10.1186/s12916-017-0977-3) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC5717832_abstract.txt'}),\n",
              " Document(page_content='Although important achievements have been done in type 2 diabetes mellitus (T2D) treatment and glycemic control, new strategies may take advantage of non-pharmacological approaches and of other potential determinants of health (e.g., socioeconomic status, education, diabetes knowledge, physical activity, and self-care behavior). However, the relationships between these factors are not totally clear and have not been studied in the context of large urban settings. This study aimed to explore the relationship between these determinants of glycemic control (GC) in a low-income urban population from Mexico City, focused in exploring potential the mediation of self-care behaviors in the association between diabetes knowledge and GC.', metadata={'splits_id': '0', 'document_id': 'PMC7449009_abstract.txt'}),\n",
              " Document(page_content='A multicenter cross-sectional study was conducted in patients with type 2 diabetes (T2D) from 28 primary care outpatient centers located in Mexico City. Using multivariable-adjusted models, we determined the associations between diabetes knowledge, self-care behaviors, and GC. The mediation analyses to determine the pathways on glycemic control were done using linear regression models, where the significance of indirect effects was calculated with bootstrapping.', metadata={'splits_id': '1', 'document_id': 'PMC7449009_abstract.txt'}),\n",
              " Document(page_content='The population (N\\u2009=\\u2009513) had a mean age of 53.8\\u2009years (standard deviation: 11.3\\u2009yrs.), and 65.9% were women. Both socioeconomic status and level of education were directly associated with diabetes knowledge. Using multivariable-adjusted linear models, we found that diabetes knowledge was associated with GC (β: -0.102, 95% Confidence Interval [95% CI] -0.189, −\\u20090.014). Diabetes knowledge was also independently associated with self-care behavior (for physical activity: β: 0.181, 95% CI 0.088, 0.273), and self-care behavior was associated with GC (for physical activity: β: -0.112, 95% CI -0.194, −\\u20090.029). The association between diabetes knowledge and GC was not observed after adjustment for self-care behaviors, especially physical activity (β: -0.084, 95% CI -0.182, 0.014, p-value: 0.062). Finally, the mediation models showed that the effect of diabetes knowledge on GC was 17% independently mediated by physical activity (p-value: 0.049).', metadata={'splits_id': '2', 'document_id': 'PMC7449009_abstract.txt'}),\n",
              " Document(page_content='Socioeconomic and educational gradients influence diabetes knowledge among primary care patients with type 2 diabetes. Self-care activities, particularly physical activity, mediated the effect of diabetes knowledge on GC. Our results indicate that diabetes knowledge should be reinforced in low-income T2D patients, with an emphasis on the benefits physical activity has on improving GC.', metadata={'splits_id': '3', 'document_id': 'PMC7449009_abstract.txt'}),\n",
              " Document(page_content='Pancreatic cancer is one of the cancers with the highest mortality rate which is most often attributed to late diagnosis. The identification of risk factors is therefore important. While gestational diabetes also shares mechanisms of action with diabetes mellitus, several studies have provided hypotheses that could explain the pathophysiology of the link between diabetes mellitus and risk of pancreatic cancer. Accordingly, the aim of our study was to determine the risk of developing pancreatic cancer in women with a history of gestational diabetes from a quasi-exhaustive national medico-administrative database for deliveries in France. We included 1,368,755 women in our study. We showed that gestational diabetes was significantly associated with a greater risk of pancreatic cancer, regardless of subsequent type 2 diabetes. Our results suggest a better follow-up of patients after a gestational diabetes in order to identify high-risk profiles of developing more serious conditions, such', metadata={'splits_id': '0', 'document_id': 'PMC7829937_abstract.txt'}),\n",
              " Document(page_content='of developing more serious conditions, such as pancreatic cancer.', metadata={'splits_id': '1', 'document_id': 'PMC7829937_abstract.txt'}),\n",
              " Document(page_content='The aim of this large retrospective cohort study was to use a quasi-exhaustive national medico-administrative database of deliveries in France to determine the risk of developing pancreatic cancer (PC) in women with a history of gestational diabetes mellitus (GDM). This nationwide population-based study included women aged 14–55 who gave birth between 1st January 2008 and 31 December 2009. The women were followed-up epidemiologically for eight years. Survival analyses using Cox regression models, adjusted for age, subsequent type 2 diabetes, and tobacco consumption, were performed on the time to occurrence of hospitalization for PC. The onset of GDM, tobacco consumption and subsequent type 2 diabetes were considered as time-dependent variables. Among 1,352,560 women included, 95,314 had a history of GDM (7.05%) and 126 women were hospitalized for PC (0.01%). Over the eight years of follow-up, GDM was significantly associated with a higher risk of hospitalization with PC in the first', metadata={'splits_id': '2', 'document_id': 'PMC7829937_abstract.txt'}),\n",
              " Document(page_content='risk of hospitalization with PC in the first Cox regression model adjusted for age and subsequent type 2 diabetes (HR = 1.81 95% CI [1.06–3.10]). The second Cox regression model adjusted for the same covariates, plus tobacco consumption, showed that GDM was still significantly associated with a higher risk of hospitalization for PC with nearly the same estimated risk (HR = 1.77 95% CI [1.03–3.03]). Gestational diabetes was significantly associated with a greater risk of hospital admission for pancreatic cancer within eight years, regardless of subsequent type 2 diabetes.', metadata={'splits_id': '3', 'document_id': 'PMC7829937_abstract.txt'}),\n",
              " Document(page_content='To study the epidemiology, genetic landscape and causes of childhood diabetes mellitus in the State of Qatar.\\nAll patients (aged 0–18\\u2009years) with diabetes mellitus underwent biochemical, immunological and genetic testing. American Diabetes Association guidelines were used to classify types of diabetes mellitus. The incidence and prevalence of all the different types of diabetes mellitus were calculated.', metadata={'splits_id': '0', 'document_id': 'PMC8668069_abstract.txt'}),\n",
              " Document(page_content='Total number of children with diabetes mellitus was 1,325 (type\\u20091 n\\u2009=\\u20091,096, ≥1 antibody; type\\u20092 n\\u2009=\\u2009104, type\\u20091B n\\u2009=\\u200953; maturity onset diabetes of the young n\\u2009=\\u200920; monogenic autoimmune n\\u2009=\\u20094; neonatal diabetes mellitus n\\u2009=\\u200910;, syndromic diabetes mellitus n\\u2009=\\u200923; and double diabetes mellitus n\\u2009=\\u200915). The incidence and prevalence of type\\u20091 diabetes were 38.05 and 249.73 per 100,000, respectively, and for type\\u20092 were 2.51 and 23.7 per 100,000, respectively. The incidence of neonatal diabetes mellitus was 34.4 per 1,000,000 live births, and in indigenous Qataris the incidence was 43.6 per 1,000,000 live births. The prevalence of type\\u20091 diabetes and type\\u20092 diabetes in Qatari children was double compared with other nationalities. The prevalence of maturity onset diabetes of the young in Qatar was 4.56 per 100,000.', metadata={'splits_id': '1', 'document_id': 'PMC8668069_abstract.txt'}),\n",
              " Document(page_content='This is the first prospective and comprehensive study to document the epidemiology and genetic landscape of childhood diabetes mellitus in this region. Qatar has the fourth highest incidence of type\\u20091 diabetes mellitus, with the incidence and prevalence being higher in Qatari compared with non‐Qatari. The prevalence of type\\u20092 diabetes mellitus is also higher in Qatar than in Western countries. The incidence of neonatal diabetes mellitus is the second highest in the world. GCK is the most common form of maturity onset diabetes of the young, and a large number of patients have type\\u20091B diabetes mellitus.', metadata={'splits_id': '2', 'document_id': 'PMC8668069_abstract.txt'}),\n",
              " Document(page_content='This is the first comprehensive, prospective study from the Middle East North Africa region to systematically study the causes of diabetes in every child in the State of Qatar. The State of Qatar has the fourth highest incidence of type\\u20091 diabetes in the world. The incidence of type\\u20092 diabetes is much higher in Qatar than in Western countries. Both type\\u20091 and type\\u20092 diabetes are more common in the Qatari population than the non‐Qatari population. Mutations in GCK were the most common cause of maturity onset diabetes of the young, and mutations in the PTF1A and INS genes were the most common cause of neonatal diabetes in this population.', metadata={'splits_id': '3', 'document_id': 'PMC8668069_abstract.txt'}),\n",
              " Document(page_content='In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM.\\nMEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria.', metadata={'splits_id': '0', 'document_id': 'PMC7245758_abstract.txt'}),\n",
              " Document(page_content='In non-pregnant adults, the recommended HbA1c target is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1c is 6.5–7.5%. When HbA1c is 7.5–9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1c remains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction (<\\u200940%) and glomerular filtration rate (eGFR)\\u2009>\\u200930\\xa0mL/min/1.73\\xa0m2, metformin plus an SGLT-2i is recommended to reduce', metadata={'splits_id': '1', 'document_id': 'PMC7245758_abstract.txt'}),\n",
              " Document(page_content='plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30–60\\xa0mL/min/1.73\\xa0m2 or eGFR 30–90\\xa0mL/min/1.73\\xa0m2 with albuminuria\\u2009>\\u200930\\xa0mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM.', metadata={'splits_id': '2', 'document_id': 'PMC7245758_abstract.txt'}),\n",
              " Document(page_content='Despite mounting evidence of the positive relationship between diabetes mellitus (DM) and heart failure (HF), the entire context of the magnitude of risk for HF in relation to DM remains insufficiently understood. The principal reason is because new‐onset HF (HF occurring in participants without a history of HF) and recurrent HF (HF re‐occurring in patients with a history of HF) are not discriminated. This meta‐analysis aims to comprehensively and separately assess the risk of new‐onset and recurrent HF depending on the presence or absence of DM. We systematically searched cohort studies that examined the relationship between DM and new‐onset or recurrent HF using EMBASE and MEDLINE (from 1 Jan 1950 to 28 Jul 2019). The risk ratio (RR) for HF in individuals with DM compared with those without DM was pooled with a random‐effects model. Seventy‐four and 38 eligible studies presented data on RRs for new‐onset and recurrent HF, respectively. For new‐onset HF, the pooled RR [95% confidence', metadata={'splits_id': '0', 'document_id': 'PMC7524078_abstract.txt'}),\n",
              " Document(page_content='For new‐onset HF, the pooled RR [95% confidence interval (CI)] of 69 studies that examined HF as a whole [i.e. combining HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF)] was 2.14 (1.96–2.34). The large between‐study heterogeneity (I 2\\xa0=\\xa099.7%, P\\xa0<\\xa00.001) was significantly explained by mean age [pooled RR (95% CI) 2.60 (2.38–2.84) for mean age\\xa0<\\xa060\\xa0years vs. pooled RR (95% CI) 1.95 (1.79–2.13) for mean age\\xa0≥\\xa060\\xa0years] (P\\xa0<\\xa00.001). Pooled RRs (95% CI) of seven and eight studies, respectively, that separately examined HFpEF and HFrEF risk were 2.22 (2.02–2.43) for HFpEF and 2.73 (2.71–2.75) for HFrEF. The risk magnitudes between HFpEF and HFrEF were not significantly different in studies that examined both HFpEF and HFrEF risks (P\\xa0=\\xa00.86). For recurrent HF, pooled RR (95% CI) of the 38 studies was 1.39 (1.33–1.45). The large between‐study heterogeneity (I 2\\xa0=\\xa080.1%, P\\xa0<\\xa00.001) was significantly explained by the proportion of men [pooled RR (95%', metadata={'splits_id': '1', 'document_id': 'PMC7524078_abstract.txt'}),\n",
              " Document(page_content='by the proportion of men [pooled RR (95% CI) 1.53 (1.40–1.68) for < 65% men vs. 1.32 (1.25–1.39) for ≥65% men (P\\xa0=\\xa00.01)] or the large pooled RR for studies of only participants with HFpEF [pooled RR (95% CI), 1.73 (1.32–2.26) (P\\xa0=\\xa00.002)]. Results indicate that DM is a significant risk factor for both new‐onset and recurrent HF. It is suggested that the risk magnitude is large for new‐onset HF especially in young populations and for recurrent HF especially in women or individuals with HFpEF. DM is associated with future HFpEF and HFrEF to the same extent.', metadata={'splits_id': '2', 'document_id': 'PMC7524078_abstract.txt'}),\n",
              " Document(page_content='There has been an appreciable increase in the number of people in Africa with metabolic syndrome and Type 2 diabetes (T2DM) in recent years as a result of a number of factors. Factors include lifestyle changes, urbanisation, and the growing consumption of processed foods coupled with increasing levels of obesity. Currently there are 19 million adults in Africa with diabetes, mainly T2DM (95%), estimated to grow to 47 million people by 2045 unless controlled. This has a considerable impact on morbidity, mortality and costs in the region. There are a number of issues to address to reduce the impact of T2DM including improving detection rates and current access to services alongside addressing issues of adherence to prescribed medicines. There are also high rates of co-morbidities with infectious diseases such as HIV and tuberculosis in patients in Africa with T2DM that require attention.', metadata={'splits_id': '0', 'document_id': 'PMC7098994_abstract.txt'}),\n",
              " Document(page_content='Document ongoing activities across Africa to improve the care of patients with T2DM especially around issues of identification, access, and adherence to changing lifestyles and prescribed medicines. In addition, discussing potential ways forward to improve the care of patients with T2DM based on ongoing activities and experiences including addressing key issues associated with co-morbidities with infectious diseases.\\nContextualise the findings from a wide range of publications including internet based publications of national approaches coupled with input from senior level government, academic and other professionals from across Africa to provide future guidance.', metadata={'splits_id': '1', 'document_id': 'PMC7098994_abstract.txt'}),\n",
              " Document(page_content='A number of African countries are actively instigating programmes to improve the care of patients with T2DM starting with improved diagnosis. This recognises the growing burden of non-communicable diseases across Africa, which has been neglected in the past. Planned activities include programmes to improve detection rates and address key issues with diet and lifestyle changes, alongside improving monitoring of care and activities to enhance adherence to prescribed medicines. In addition, addressing potential complexities involving diabetes patients with infectious disease co-morbidities. It is too early to fully assess the impact of such activities,\\nThere are a number of ongoing activities across Africa to improve the management of patients with diabetes including co-morbidities. However, more needs to be done considering the high and growing burden of T2DM in Africa. Ongoing research will help further benefit resource allocation and subsequent care.', metadata={'splits_id': '2', 'document_id': 'PMC7098994_abstract.txt'}),\n",
              " Document(page_content='Gestational Diabetes Mellitus (GDM) is associated with future cardio-metabolic risks for the mother and her child. In addition, one-third of women with recent GDM develop postpartum depression. Given these adverse impacts of GDM on the health of the mother and her offspring, it is important to intervene on modifiable factors, such as diet, physical activity, and psychosocial well-being. This integrative review therefore explored evidence on how these modifiable factors interact in women with GDM and their offspring, and how effective combined interventions are on reducing adverse impacts of GDM.', metadata={'splits_id': '0', 'document_id': 'PMC6367798_abstract.txt'}),\n",
              " Document(page_content='A comprehensive search strategy included carefully selected terms that corresponded to the domains of interest (diet, physical activity and psychosocial well-being). The databases searched for articles published between 1980 and February 2018 were: CINAHL, PsycINFO, Embase, Pubmed and Cochrane. Studies that were included in this review were either observational or intervention studies that included at least two domains of interest. Articles had to at least report data on maternal outcomes of women with GDM.', metadata={'splits_id': '1', 'document_id': 'PMC6367798_abstract.txt'}),\n",
              " Document(page_content='The search strategies identified 14′419 citations after excluding duplicates. After screening titles and then abstracts, 114 articles were selected for detailed evaluation of their full text, and 16 were included in this review: two observational and 14 intervention studies. Results from observational studies showed that psychosocial well-being (social support and self-efficacy) were positively associated with physical activity and dietary choice. Intervention studies always included diet and physical activity interventions, although none integrated psychosocial well-being in the intervention. These lifestyle interventions mostly led to increased physical activity, improved diet and lower stress perception. Many of these lifestyle interventions also reduced BMI and postpartum diabetes status, improved metabolic outcomes and reduced the risk of preterm deliveries and low birth weight.', metadata={'splits_id': '2', 'document_id': 'PMC6367798_abstract.txt'}),\n",
              " Document(page_content='This integrative review showed that psychosocial well-being interacted with diet as well as with physical activity in women with GDM. We recommend that future studies consider integrating psychosocial well-being in their intervention, as observational studies demonstrated that social support and self-efficacy helped with adopting a healthy lifestyle following GDM diagnosis.\\nThe online version of this article (10.1186/s12884-019-2185-y) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6367798_abstract.txt'}),\n",
              " Document(page_content='Prevalence studies usually depend on self-report of disease status in survey data or administrative data collections and may over- or under-estimate disease prevalence. The establishment of a linked data collection provided an opportunity to explore the accuracy and completeness of capture of information about diabetes in survey and administrative data collections.', metadata={'splits_id': '0', 'document_id': 'PMC3893423_abstract.txt'}),\n",
              " Document(page_content='Baseline questionnaire data at recruitment to the 45 and Up Study was obtained for 266,848 adults aged 45 years and over sampled from New South Wales, Australia in 2006–2009, and linked to administrative data about hospitalisation from the Admitted Patient Data Collection (APDC) for 2000–2009, claims for medical services (MBS) and pharmaceuticals (PBS) from Medicare Australia data for 2004–2009. Diabetes status was determined from response to a question ‘Has a doctor EVER told you that you have diabetes’ (n\\u2009=\\u200923,981) and augmented by examination of free text fields about diagnosis (n\\u2009=\\u2009119) or use of insulin (n\\u2009=\\u200958). These data were used to identify the sub-group with type 1 diabetes. We explored the agreement between self-report of diabetes, identification of diabetes diagnostic codes in APDC data, claims for glycosylated haemoglobin (HbA1c) in MBS data, and claims for dispensed medication (oral hyperglycaemic agents and insulin) in PBS data.', metadata={'splits_id': '1', 'document_id': 'PMC3893423_abstract.txt'}),\n",
              " Document(page_content='Most participants with diabetes were identified in APDC data if admitted to hospital (79.3%), in MBS data with at least one claim for HbA1c testing (84.7%; 73.4% if 2 tests claimed) or in PBS data through claim for diabetes medication (71.4%). Using these alternate data collections as an imperfect ‘gold standard’ we calculated sensitivities of 83.7% for APDC, 63.9% (80.5% for two tests) for MBS, and 96.6% for PBS data and specificities of 97.7%, 98.4% and 97.1% respectively. The lower sensitivity for HbA1c may reflect the use of this test to screen for diabetes suggesting that it is less useful in identifying people with diabetes without additional information. Kappa values were 0.80, 0.70 and 0.80 for APDC, MBS and PBS respectively reflecting the large population sample under consideration. Compared to APDC, there was poor agreement about identifying type 1 diabetes status.', metadata={'splits_id': '2', 'document_id': 'PMC3893423_abstract.txt'}),\n",
              " Document(page_content='Self-report of diagnosis augmented with free text data indicating diabetes as a chronic condition and/or use of insulin among medications used was able to identify participants with diabetes with high sensitivity and specificity compared to available administrative data collections.', metadata={'splits_id': '3', 'document_id': 'PMC3893423_abstract.txt'}),\n",
              " Document(page_content='The Thai Type\\xa01 Diabetes and Diabetes Diagnosed Before Age 30 Years Registry, Care and Network was established in 2014 and involved 31 hospitals. The objective of the registry was to evaluate glycemic control and complications of patients with type\\xa01 diabetes.\\nPatients’ demographics, clinical data, frequencies of daily self‐monitoring of blood glucose (SMBG), glycemic control and complications were collected.', metadata={'splits_id': '0', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='Among the 1,907 type\\xa01 diabetes patients, the mean age was 21.2\\xa0±\\xa011.3\\xa0years. The mean glycated hemoglobin level was 9.35\\xa0±\\xa02.41%, with significant variations among age groups (P\\xa0<\\xa00.001). Conventional insulin treatment and intensive insulin treatment were used in 43 and 57% of patients, respectively. Mean glycated hemoglobin levels were significantly higher in patients treated with conventional insulin treatment compared to those treated with intensive insulin treatment (9.63\\xa0±\\xa02.34 vs 9.17\\xa0±\\xa02.46%, P\\xa0=\\xa00.002). Compared to the conventional insulin treatment group, significantly more patients in the intensive insulin treatment group achieved good glycemic control (P\\xa0<\\xa00.001), and fewer had diabetic retinopathy (P\\xa0=\\xa00.031). The prevalence of microvascular complications increased significantly with age (P\\xa0<\\xa00.001). Multivariate analysis showed good glycemic control to be associated with age 25 to <45\\xa0years, intensive insulin treatment with SMBG three or more times daily and diabetes', metadata={'splits_id': '1', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='with SMBG three or more times daily and diabetes duration of 1 to <5\\xa0years.', metadata={'splits_id': '2', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='Most Thai type\\xa01 diabetes patients were not meeting the recommended glycemic target. As a result of this study, the national program to improve the quality of diabetes treatment and education has been implemented, and the results are ongoing.', metadata={'splits_id': '3', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='This study reflects a nationwide snapshot of the management and outcomes of 1,907 patients with type\\xa01 diabetes in Thailand. A total of 43% of patients were found to be receiving conventional insulin treatment, and 57% were receiving intensive insulin treatment. Most of the Thai type\\xa01 diabetes patients that we enrolled in this study were not meeting their recommended glycemic target. Good glycemic control was achieved by just 13% of patients receiving conventional insulin treatment, and by just 19% of patients receiving intensive insulin treatment. Multivariate analysis showed good glycemic control to be significantly associated with the 25 to <45\\xa0years age group, intensive insulin therapy with self‐monitoring of blood glucose three or more times daily and duration of disease of 1 to <5 years.', metadata={'splits_id': '4', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='Supplemental Digital Content is available in the text.\\nRecent clinical trials of new glucose-lowering treatments have drawn attention to the importance of hospitalization for heart failure as a complication of diabetes mellitus. However, the epidemiology is not well described, particularly for type 1 diabetes mellitus. We examined the incidence and case-fatality of heart failure hospitalizations in the entire population aged ≥30 years resident in Scotland during 2004 to 2013.\\nDate and type of diabetes mellitus diagnosis were linked to heart failure hospitalizations and deaths using the national Scottish registers. Incidence rates and case-fatality were estimated in regression models (quasi-Poisson and logistic regression respectively). All estimates are adjusted for age, sex, socioeconomic status, and calendar-year.', metadata={'splits_id': '0', 'document_id': 'PMC6287897_abstract.txt'}),\n",
              " Document(page_content='Over the 10-year period of the study, among 3.25 million people there were 91, 429, 22 959, and 1313 incident heart failure events among those without diabetes mellitus, with type 2, and type 1 diabetes mellitus, respectively. The crude incidence rates of heart failure hospitalization were therefore 2.4, 12.4, and 5.6 per 1000 person-years for these 3 groups. Heart failure hospitalization incidence was higher in people with diabetes mellitus, regardless of type, than in people without. Relative differences were smallest for older men, in whom the difference was nonetheless large (men aged 80, rate ratio 1.78; 95% CI, 1.45–2.19). Rates declined similarly, by 0.2% per calendar-year, in people with type 2 diabetes mellitus and without diabetes mellitus. Rates fell faster, however, in those with type 1 diabetes mellitus (2.2% per calendar-year, rate ratio for type 1/calendar-year interaction 0.978; 95% CI, 0.959–0.998).', metadata={'splits_id': '1', 'document_id': 'PMC6287897_abstract.txt'}),\n",
              " Document(page_content='Thirty-day case-fatality was similar among people with type 2 diabetes mellitus and without diabetes mellitus, but was higher in type 1 diabetes mellitus for men (odds ratio, 0.96; 95% CI, 0.95–0.96) and women (odds ratio, 0.98; 95% CI, 0.97–0.98). Case-fatality declined over time for all groups (3.3% per calendar-year, odds ratio per calendar-year 0.967; 95% CI, 0.961–0.973).\\nDespite falling incidence, particularly in type 1 diabetes mellitus, heart failure remains ≈2-fold higher than in people without diabetes mellitus, with higher case-fatality in those with type 1 diabetes mellitus. These findings support the view that heart failure is an under-recognized and important complication in diabetes mellitus, particularly for type 1 disease.', metadata={'splits_id': '2', 'document_id': 'PMC6287897_abstract.txt'}),\n",
              " Document(page_content=\"To provide an estimate of the effect of interventions on comorbid depressive disorder (MDD) or subthreshold depression in type 1 and type 2 diabetes.\\nSystematic review and meta‐analysis. We searched PubMed, PsycINFO, Embase, and the Cochrane Library for randomized controlled trials evaluating the outcome of depression treatments in diabetes and comorbid MDD or subthreshold symptoms published before August 2019 compared to care as usual (CAU), placebo, waiting list (WL), or active comparator treatment as in a comparative effectiveness trial (CET). Primary outcomes were depressive symptom severity and glycemic control. Cohen's d is reported.\", metadata={'splits_id': '0', 'document_id': 'PMC7882189_abstract.txt'}),\n",
              " Document(page_content='Forty‐three randomized controlled trials (RCTs) were selected, and 32 RCTs comprising 3,543 patients were included in the meta‐analysis. Our meta‐analysis showed that, compared to CAU, placebo or WL, all interventions showed a significant effect on combined outcome 0,485 (95% CI 0.360; 0.609). All interventions showed a significant effect on depression. Pharmacological treatment, group therapy, psychotherapy, and collaborative care had a significant effect on glycemic control. High baseline depression score was associated with a greater reduction in HbA1c and depressive outcome. High baseline HbA1c was associated with a greater reduction in HbA1c.', metadata={'splits_id': '1', 'document_id': 'PMC7882189_abstract.txt'}),\n",
              " Document(page_content='All treatments are effective for comorbid depression in type 1 diabetes and type 2 diabetes. Over the last decade, new interventions with large effect sizes have been introduced, such as group‐based therapy, online treatment, and exercise. Although all interventions were effective for depression, not all treatments were effective for glycemic control. Effective interventions in comorbid depressive disorder may not be as effective in comorbid subthreshold depression. Baseline depression and HbA1c scores modify the treatment effect. Based on the findings, we provide guidance for treatment depending on patient profile and desired outcome, and discuss possible avenues for further research.', metadata={'splits_id': '2', 'document_id': 'PMC7882189_abstract.txt'}),\n",
              " Document(page_content='This systematic review and meta‐analysis exploring psychotherapeutic, pharmacologic, and other interventions shows beneficial treatment effects for comorbid depression in type 1 and type 2 diabetes mellitus with moderate‐to‐large effect sizes for most intervention types. Although all interventions were effective for depression, not all treatments were effective for glycemic control. Effective interventions in comorbid depressive disorder may not be as effective in comorbid subthreshold depression.', metadata={'splits_id': '3', 'document_id': 'PMC7882189_abstract.txt'}),\n",
              " Document(page_content='To evaluate the association between incidence of any kidney cancer and type 2 diabetes mellitus.', metadata={'splits_id': '0', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='A random sample of 1,000,000 subjects covered by the National Health Insurance was recruited. A total of 998728 people (115655 diabetes and 883073 non-diabetes) without kidney cancer at recruitment were followed from 2003 to 2005. The cumulative incidence of kidney cancer from 2003 to 2005 in diabetic patients and non-diabetic people in all ages and in age <40, 40–64, 65–74 and ≥75 years were calculated in the diabetic patients and the non-diabetic people, respectively. Logistic regression was used to estimate the odds ratios comparing diabetic patients to non-diabetic people in the respective age groups. Multivariable-adjusted odds ratios for kidney cancer with regards to diabetes status and diabetes duration (as a continuous variable or categorized into subgroups of non-diabetes, diabetes duration <1 year, 1–2.9 years, 3–4.9 years and ≥5 years) were estimated after multivariable adjustment. The multivariable-adjusted odds ratios for all baseline variables were also estimated for', metadata={'splits_id': '1', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='all baseline variables were also estimated for diabetic patients and non-diabetic people, respectively.', metadata={'splits_id': '2', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='The 3-year cumulative incidence of kidney cancer in the diabetic patients and the non-diabetic people was 166.9 and 33.1 per 100,000 person-years, respectively. The incidence increased with regards to increasing age in both the diabetic patients and the non-diabetic people, but a higher risk of kidney cancer for the diabetic patients compared to the non-diabetic people was consistently observed in different age groups. After multivariable adjustment, the odds ratio for diabetic patients versus non-diabetic people was 1.7 (95% confidence interval: 1.3–2.1, P<0.01). While compared to the non-diabetic people, the odds ratio (95% confidence interval) for diabetes duration <1, 1–2.9 years, 3–4.9 years and ≥5 years was 1.5 (0.8–2.7), 1.6 (1.0–2.4), 1.6 (1.1–2.4) and 1.7 (1.3–2.3), respectively (P-trend <0.01). Analyses conducted in the diabetic patients and the non-diabetic people, respectively, consistently showed age, nephropathy and end-stage renal disease as significant risk factors of', metadata={'splits_id': '3', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='renal disease as significant risk factors of kidney cancer. Additionally, living in metropolitan Taipei region might also be associated with a higher risk of kidney cancer in the non-diabetic people, indicating a potential link between kidney cancer and some factors related to urbanization.', metadata={'splits_id': '4', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='Patients with type 2 diabetes mellitus have a significantly higher risk of kidney cancer.', metadata={'splits_id': '5', 'document_id': 'PMC4641625_abstract.txt'}),\n",
              " Document(page_content='Physical activity has been inconsistently associated with risk of gestational diabetes mellitus in epidemiological studies, and questions remain about the strength and shape of the dose–response relationship between the two. We therefore conducted a systematic review and meta-analysis of cohort studies and randomized trials\\xa0on physical activity and gestational diabetes mellitus. PubMed, Embase and Ovid databases were searched for cohort studies, and randomized controlled trials of physical activity and risk of gestational diabetes mellitus, up to August 5th 2015. Summary relative risks (RRs) were estimated using a random effects model. Twenty-five studies (26 publications) were included. For total physical activity the summary RR for high versus low activity was 0.62 (95\\xa0% CI 0.41–0.94, I2\\xa0=\\xa00\\xa0%, n\\xa0=\\xa04) before pregnancy, and 0.66 (95\\xa0% CI 0.36–1.21, I2\\xa0=\\xa00\\xa0%, n\\xa0=\\xa03) during pregnancy. For leisure-time physical activity the respective summary RRs for high versus low activity was 0.78', metadata={'splits_id': '0', 'document_id': 'PMC5065594_abstract.txt'}),\n",
              " Document(page_content='summary RRs for high versus low activity was 0.78 (95\\xa0% CI 0.61–1.00, I2\\xa0=\\xa047\\xa0%, n\\xa0=\\xa08) before pregnancy, and it was 0.80 (95\\xa0% CI 0.64–1.00, I2\\xa0=\\xa017\\xa0%, n\\xa0=\\xa017) during pregnancy. The summary RR for pre-pregnancy activity was 0.70 (95\\xa0% CI 0.49–1.01, I2\\xa0=\\xa072.6\\xa0%, n\\xa0=\\xa03) per increment of 5\\xa0h/week and for activity during pregnancy was 0.98 (95\\xa0% CI 0.87–1.09, I2\\xa0=\\xa00\\xa0%, n\\xa0=\\xa03) per 5\\xa0h/week. There was evidence of a nonlinear association between physical activity before pregnancy and the risk of gestational diabetes mellitus, pnonlinearity\\xa0=\\xa00.005, with a slightly steeper association at lower levels of activity although further reductions in risk were observed up to 10\\xa0h/week. There was also evidence of nonlinearity for physical activity in early pregnancy, pnonlinearity\\xa0=\\xa00.008, with no further reduction in risk above 8\\xa0h/week.\\xa0There was some indication of inverse associations between walking (before and during pregnancy) and vigorous activity (before pregnancy) and the risk of gestational', metadata={'splits_id': '1', 'document_id': 'PMC5065594_abstract.txt'}),\n",
              " Document(page_content='(before pregnancy) and the risk of gestational diabetes mellitus. This meta-analysis suggests that there is a significant inverse association between physical activity before pregnancy and in early pregnancy and the risk of gestational diabetes mellitus. Further studies are needed to clarify the association between\\xa0specific types\\xa0and intensities of activity and gestational diabetes mellitus.', metadata={'splits_id': '2', 'document_id': 'PMC5065594_abstract.txt'}),\n",
              " Document(page_content='The online version of this article (doi:10.1007/s10654-016-0176-0) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC5065594_abstract.txt'}),\n",
              " Document(page_content='Immune checkpoint inhibitors are the mainstay of treatment for advanced melanoma, and their use is being increasingly implicated in the development of autoimmune endocrinopathies. We present a case of a 52-year-old man with metastatic melanoma on combination nivolumab and ipilumimab therapy who developed concurrent hypophysitis, type 1 diabetes mellitus (T1DM) and diabetes insipidus. He presented prior to third cycle of combination treatment with a headache, myalgias and fatigue. Biochemistry and MRI pituitary confirmed anterior pituitary dysfunction with a TSH: 0.02\\u2009mU/L (0.5–5.5\\u2009mU/L), fT4: 5.2\\u2009pmol/L (11–22\\u2009pmol/L), fT3: 4.0\\u2009pmol/L (3.2–6.4\\u2009pmol/L), cortisol (12:00\\u2009h): <9\\u2009nmol/L (74–286\\u2009nmol/L), FSH: 0.7\\u2009IU/L (1.5–9.7\\u2009IU/L), LH: <0.1\\u2009IU/L (1.8–9.2\\u2009IU/L), PRL: 1\\u2009mIU/L (90–400\\u2009mIU/L), SHBG: 34\\u2009nmol/L (19–764\\u2009nmol/L) and total testosterone: <0.4\\u2009nmol/L (9.9–27.8\\u2009nmol/L). High-dose dexamethasone (8\\u2009mg) was administered followed by hydrocortisone, thyroxine and topical testosterone', metadata={'splits_id': '0', 'document_id': 'PMC5830856_abstract.txt'}),\n",
              " Document(page_content='thyroxine and topical testosterone replacement. Two weeks post administration of the third cycle, he became unwell with lethargy, weight loss and nocturia. Central diabetes insipidus was diagnosed on the basis of symptoms and sodium of 149\\u2009mmol/L (135–145\\u2009mmol/L). Desmopressin nasal spray was instituted with symptom resolution and normalization of serum sodium. Three weeks later, he presented again polyuric and polydipsic. His capillary glucose was 20.8\\u2009mmol/L (ketones of 2.4\\u2009mmol), low C-peptide 0.05\\u2009nmol/L (0.4–1.5\\u2009nmol/L) and HbA1c of 7.7%. T1DM was suspected, and he was commenced on an insulin infusion with rapid symptom resolution. Insulin antibodies glutamic acid decarboxylase (GAD), insulin antibody-2 (IA-2) and zinc transporter-8 (ZnT8) were negative. A follow-up MRI pituitary revealed findings consistent with recovering autoimmune hypophysitis. Immunotherapy was discontinued based on the extent of these autoimmune endocrinopathies.', metadata={'splits_id': '1', 'document_id': 'PMC5830856_abstract.txt'}),\n",
              " Document(page_content='The most effective regime for treatment of metastatic melanoma is combination immunotherapy with nivolumab and ipilumimab, and this therapy is associated with a high incidence of autoimmune endocrinopathies.\\nGiven the high prevalence of immune-related adverse events, the threshold for functional testing should be low.\\nTraditional antibody testing may not be reliable to identify early-onset endocrinopathy.\\nRoutine screening pathways have yet to be adequately validated through clinical trials.', metadata={'splits_id': '2', 'document_id': 'PMC5830856_abstract.txt'}),\n",
              " Document(page_content='Although increased reactive oxygen species (ROS) generation is a major mechanism leading to cardiac remodeling in diabetes mellitus, research into the effects of anti‐oxidation on diabetic cardiac remodeling remains scarce and controversial. Glucagon‐like peptide‐1 (GLP‐1) shows potential anti‐oxidative effects besides lowering blood glucose. The objective of this research was to investigate the effects of GLP‐1 on cardiac remodeling and the molecular mechanism involved in diabetes mellitus.\\nStreptozotocin‐induced diabetic rats received exenatide treatment for 3\\xa0months. Cardiac function, cardiac weight index and myocardial interstitial fibrosis were measured. Cardiomyocytes were cultured in high‐glucose medium with GLP‐1 treatment. The ROS production, apoptosis and the levels of mammalian target of rapamycin complex\\xa01/p70 ribosomal protein S6 kinase protein expression in cardiomyocytes were analyzed.', metadata={'splits_id': '0', 'document_id': 'PMC6944832_abstract.txt'}),\n",
              " Document(page_content='Experimental diabetes mellitus showed impaired cardiac diastolic function, increased brain natriuretic peptide expression and increased interstitial collagen deposition in the myocardium, which were ameliorated by exenatide treatment. Exenatide reduced myocardial ROS production and apoptosis in diabetes mellitus. Also, high glucose‐induced ROS generation and apoptosis in cardiomyocytes were inhibited by GLP‐1, as well as the levels of mammalian target of rapamycin complex\\xa01/p70 ribosomal protein S6 kinase phosphorylation. Furthermore, GLP‐1 treatment upregulated adenosine monophosphate‐activated protein kinase activity in high‐glucose‐induced cardiomyocyte.', metadata={'splits_id': '1', 'document_id': 'PMC6944832_abstract.txt'}),\n",
              " Document(page_content='Glucagon‐like peptide‐1 protects the cardiomyocytes from oxidative stress and apoptosis in diabetes mellitus, which might contribute to the improvement of cardiac remodeling. The cardiac protection of GLP‐1 might be dependent on inhibition of mammalian target of rapamycin complex\\xa01/p70 ribosomal protein S6 kinase, through an adenosine monophosphate‐activated protein kinase‐mediated pathway.\\nGlucagon‐like peptide‐1 protects cardiomyocytes against oxidative stress, apoptosis and the resultant myocardial fibrosis in diabetes mellitus, which might contribute to the improvement of cardiac remodeling. The protective effects of glucagon‐like peptide‐1 are dependent on downstream inhibition of mammalian target of rapamycin complex\\xa01/p70 ribosomal protein S6 kinase, through an adenosine monophosphate‐activated protein kinase‐mediated pathway.', metadata={'splits_id': '2', 'document_id': 'PMC6944832_abstract.txt'}),\n",
              " Document(page_content='The global prevalence of diabetes mellitus (DM) has been increasing over recent decades. In Germany, the prevalence for DM type 1 and type 2 in adults is estimated at about 7.7%. Hence, diabetes has to be classified as a serious public health concern. Being diagnosed with DM and facing possible sequelae might have a negative impact on patients’ mental and physical well-being. However, diabetes not only affects patients themselves, but also their close relatives. To improve the quality of life for patients and relatives alike, the German Association of Diabetes Nurses and Education experts (VDBD) elaborated the first education program tailor-made for relatives of diabetes patients. This article describes the concept and design of the trial evaluating the efficacy of this education program called “DiaLife—Living Together with Diabetes”.', metadata={'splits_id': '0', 'document_id': 'PMC6704511_abstract.txt'}),\n",
              " Document(page_content='This evaluation study is a cluster randomized controlled trial, in which the study centers will be randomly assigned either to the intervention group or the control group. Study centers will recruit relatives of and patients with DM type 1 and type 2. Members of the intervention group will participate in the education program DiaLife, whereas participants randomized in the control group will act as waiting-list controls. The study will assess the efficacy of DiaLife by comparing diabetes-related knowledge between the intervention and control groups as the primary outcome for participants. As the primary outcome in patients, the Hba1c value will be assessed. In addition, diabetes-related distress, family interaction, and other secondary endpoints will be considered as secondary outcomes. Long-term efficacy will be assessed 6 and 12\\u2009months after intervention. Hierarchical regression models will be used to analyze effects over time.', metadata={'splits_id': '1', 'document_id': 'PMC6704511_abstract.txt'}),\n",
              " Document(page_content='While there is scientific evidence for the efficacy of education programs addressed to (diabetes) patients, there is a research gap with regard to intervention studies evaluating the efficacy of education programs designed for patients’ relatives. The study results will provide information on the efficacy of the DiaLife education program. In addition, factors that might hinder a successful implementation of an education program for relatives will be identified.\\nGerman Clinical Trials Register, DRKS00015157. Registered on 24 August 2018.\\nThe online version of this article (10.1186/s13063-019-3600-4) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '2', 'document_id': 'PMC6704511_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes mellitus (GDM) is associated with several maternal complications in pregnancy, including preeclampsia, preterm labor, need for induction of labor, and cesarean delivery as well as increased long-term risks of type 2 diabetes, metabolic syndrome, and cardiovascular disease. Intrauterine exposure to GDM raises the risk for complications in offspring as well, including stillbirth, macrosomia, and birth trauma, and long-term risk of metabolic disease. One of the strongest risk factors for GDM is the occurrence of GDM in a prior pregnancy. Preliminary data from epidemiologic and bariatric surgery studies suggest that reducing body weight before pregnancy can prevent the development of GDM, but no adequately powered trial has tested the effects of a maternal lifestyle intervention before pregnancy to reduce body weight and prevent GDM recurrence.', metadata={'splits_id': '0', 'document_id': 'PMC8024941_abstract.txt'}),\n",
              " Document(page_content='The principal aim of the Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional is to determine whether a lifestyle intervention to reduce body weight before pregnancy can reduce GDM recurrence. This two-site trial targets recruitment of 252 women with overweight and obesity who have previous histories of GDM and who plan to have another pregnancy in the next 1–3\\u2009years. Women are randomized within site to a comprehensive pre-pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception or an educational control group. Participants are assessed preconceptionally (at study entry, after 4\\u2009months, and at brief quarterly visits until conception), during pregnancy (at 26\\u2009weeks’ gestation), and at 6\\u2009weeks postpartum. The primary outcome is GDM recurrence, and secondary outcomes include fasting glucose, biomarkers of cardiometabolic disease, prenatal and perinatal complications, and changes over time in weight, diet, physical activity, and', metadata={'splits_id': '1', 'document_id': 'PMC8024941_abstract.txt'}),\n",
              " Document(page_content='over time in weight, diet, physical activity, and psychosocial measures.', metadata={'splits_id': '2', 'document_id': 'PMC8024941_abstract.txt'}),\n",
              " Document(page_content='The Gestational Diabetes Prevention /Prevención de la Diabetes Gestacional is the first randomized controlled trial to evaluate the effects of a lifestyle intervention delivered before pregnancy to prevent GDM recurrence. If found effective, the proposed lifestyle intervention could lay the groundwork for shifting current treatment practices towards the interconception period and provide evidence-based preconception counseling to optimize reproductive outcomes and prevent GDM and associated health risks.\\nClinicalTrials.gov NCT02763150. Registered on May 5, 2016', metadata={'splits_id': '3', 'document_id': 'PMC8024941_abstract.txt'}),\n",
              " Document(page_content='Patients diagnosed with diabetes mellitus (DM) who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) belong to the most vulnerable patient subgroups. Emerging data has shown increased risks of severe infections, increased in ICU admissions, longer durations of admission, and increased mortality among coronavirus disease 2019 (COVID-19) patients with diabetes. We performed a subgroup analysis comparing the outcomes of patients diagnosed with DM (n\\u2009=\\u20092191) versus patients without DM (n\\u2009=\\u20098690) on our data from our study based on a nationwide, comparative, retrospective, cohort study among adult, hospitalized COVID-19 patients involving 37 hospital sites from around the Philippines. We determined distribution differences between two independent samples using Mann–Whitney U and t tests. Data on the time to onset of mortality, respiratory failure, intensive care unit (ICU) admission were used to build Kaplan–Meier curves and to compute for hazard ratios (HR).', metadata={'splits_id': '0', 'document_id': 'PMC8709842_abstract.txt'}),\n",
              " Document(page_content='curves and to compute for hazard ratios (HR). The odds ratios (OR) for longer ventilator dependence, longer ICU stay, and longer hospital stays were computed via multivariate logistic regression. Adjusted hazard ratios (aHR) and ORs (aOR) with 95% CI were calculated. We included a total of 10,881 patients with confirmed COVID-19 infection (2191 have DM while 8690 did not have DM). The median age of the DM cohort was 61, with a female to male ratio of 1:1.25 and more than 50% of the DM population were above 60\\xa0years old. The aOR for mortality was significantly higher among those in the DM group by 1.46 (95% CI 1.28–1.68; p\\u2009<\\u20090.001) as compared to the non-DM group. Similarly, the aOR for respiratory failure was also significantly higher among those in the DM group by 1.67 (95% CI 1.46–1.90). The aOR for developing severe COVID-19 at nadir was significantly higher among those in the DM group by 1.85 (95% CI 1.65–2.07; p\\u2009<\\u20090.001). The aOR for ICU admission was significantly higher among', metadata={'splits_id': '1', 'document_id': 'PMC8709842_abstract.txt'}),\n",
              " Document(page_content='for ICU admission was significantly higher among those in the DM group by 1.80 (95% CI 1.59–2.05) than those in the non-DM group. DM patients had significantly longer duration of ventilator dependence (aOR 1.33, 95% CI 1.08–1.64; p\\u2009=\\u20090.008) and longer hospital admission (aOR 1.13, 95% CI 1.01–1.26; p\\u2009=\\u20090.027). The presence of DM among COVID-19 patients significantly increased the risk of mortality, respiratory failure, duration of ventilator dependence, severe/critical COVID-19, ICU admission, and length of hospital stay.', metadata={'splits_id': '2', 'document_id': 'PMC8709842_abstract.txt'}),\n",
              " Document(page_content='We present a case of central diabetes insipidus (DI) secondary to neurosarcoidosis. The path to final diagnosis was challenging. Along with reporting the case, we review the available medical literature relating to neurosarcoidosis and central diabetes insipidus\\xa0in this case report. Patient is a 56-year-old female with notable history of rheumatoid arthritis, anxiety, asthma, hypertension, spinal stenosis, and seizures of unknown etiology who presented to the emergency department for worsening headache for one week. She also endorsed decreased vision, photophobia, nausea, vomiting, gait abnormality, polyuria, and polydipsia over the past three months. Physical exam and neurological exam were unremarkable. Labs on presentation were notable for hypernatremia, increased serum osmolality and urine output of 5 L/day. Given her persistent headache and history of seizure, she underwent a CT head without contrast which showed a posterior suprasellar soft tissue fullness measuring 6 mm in the', metadata={'splits_id': '0', 'document_id': 'PMC7682679_abstract.txt'}),\n",
              " Document(page_content='soft tissue fullness measuring 6 mm in the hypothalamic region.\\xa0She then had additional imaging studies of the brain including MRI brain w/wo contrast and MRI pituitary w/wo contrast. MRI of the brain showed enlarged optic chiasm with increased T2 signal involving the proximal optic nerves and bilateral optic tracts, no brain parenchymal lesions to suggest multiple sclerosis. MRI of the pituitary w/wo contrast showed suprasellar mass arising from either the hypothalamus or less likely the chiasm which was concerning for high-grade glioma initially. Lumbar puncture was done that showed lymphocytic pleocytosis. Patient underwent right supraorbital craniotomy for biopsy of the suprasellar lesion. Surgical pathology showed noncaseating granulomatous inflammation most consistent with neuro-sarcoidosis. The diagnosis of neurosarcoidosis was made and patient was started on high dose steroids. Although central DI can be seen as a post-op complication, in our case, based on the', metadata={'splits_id': '1', 'document_id': 'PMC7682679_abstract.txt'}),\n",
              " Document(page_content='a post-op complication, in our case, based on the clinical\\xa0presentation, labs\\xa0and imaging, there was concern of central DI on initial presentation. Patient was started on desmopressin 50 mg twice a day which resulted in marked improvement in urine output, serum sodium, and osmolality.\\xa0Although it is rare to have nervous system involvement of sarcoidosis, symptoms of central diabetes insipidus could represent the first clinical manifestations of neurosarcoidosis. Proper treatment should be initiated in a timely fashion to avoid complications such as hydrocephalus.', metadata={'splits_id': '2', 'document_id': 'PMC7682679_abstract.txt'}),\n",
              " Document(page_content='Wolfram syndrome is a rare genetic disease characterized by insulin-dependent diabetes, optic nerve atrophy, sensorineural hearing loss and neurodegeneration. Although olfactory dysfunction, a classical clinical marker of neurodegenerative processes, has been reported in Wolfram syndrome, its use as a clinical marker in Wolfram is limited due to data scarcity. In addition, it is unknown whether Wolfram syndrome affects the sense of taste.', metadata={'splits_id': '0', 'document_id': 'PMC7036249_abstract.txt'}),\n",
              " Document(page_content='Smell and taste perception were assessed in participants with Wolfram syndrome (n\\u2009=\\u200940) who were 15.1\\u2009±\\u20096.0\\u2009years of age (range: 5.1–28.7\\u2009years) and two sex- and age-matched control groups: one group with type 1 diabetes mellitus (T1D; n\\u2009=\\u200925) and a healthy control group (HC; n\\u2009=\\u200929). Smell sensitivity was assessed by measuring n-butanol detection thresholds and smell identification by using the University of Pennsylvania Smell Identification Test (UPSIT). Taste function was assessed using NIH Toolbox, which includes the assessment of sucrose (sweet) taste preference, and perceived intensity of sucrose, sodium chloride (salty), and quinine hydrochloride (bitter) both in the tip of the tongue (regional test) and the whole mouth.', metadata={'splits_id': '1', 'document_id': 'PMC7036249_abstract.txt'}),\n",
              " Document(page_content='Smell sensitivity was not significantly different among groups; however, smell identification was impaired in Wolfram syndrome, as reflected by significantly lower UPSIT scores in Wolfram syndrome compared to HC and T1D (P\\u2009<\\u20090.001). Compared to participants in the control groups, participants with Wolfram syndrome had a blunted perception of sweetness and saltiness when taste stimuli were applied regionally (P\\u2009<\\u20090.05), but differences in perceived intensity were no longer significant among groups when taste stimuli were tasted with the whole mouth. Groups preferred similar sucrose concentrations.', metadata={'splits_id': '2', 'document_id': 'PMC7036249_abstract.txt'}),\n",
              " Document(page_content='Wolfram syndrome was associated with olfactory dysfunction. However, the olfactory dysfunction was qualitative (related to smell identification) and not secondary to olfactory insensitivity or diabetes, suggesting is arising from dysfunction in central olfactory brain regions. In contrast to olfaction, and despite decreased perception of taste intensity in the anterior tongue, the sense of taste was overall well-conserved in individuals with Wolfram syndrome. Future longitudinal studies of taste and smell perception in Wolfram syndrome will be important to determine the use of the chemical senses as clinical markers of disease progression.', metadata={'splits_id': '3', 'document_id': 'PMC7036249_abstract.txt'}),\n",
              " Document(page_content='Diabetes self-management education (DSME) can be delivered in many forms. Group based DSME is widespread due to being a cheaper method and the added advantages of having patient meet and discuss with each other. assess effects of group-based DSME compared to routine treatment on clinical, lifestyle and psychosocial outcomes in type-2 diabetes patients.\\nA systematic review with meta-analysis. Computerised bibliographic database were searched up to January 2008 for randomised controlled trials evaluating group-based DSME for adult type-2 diabetics versus routine treatment where the intervention had at least one session and =/>6\\u2009months follow-up. At least two reviewers independently extracted data and assessed study quality.', metadata={'splits_id': '0', 'document_id': 'PMC3418213_abstract.txt'}),\n",
              " Document(page_content='In total 21 studies (26 publications, 2833 participants) were included. Of all the participants 4 out of 10 were male, baseline age was 60\\u2009years, BMI 31.6, HbA1c 8.23%, diabetes duration 8\\u2009years and 82% used medication. For the main clinical outcomes, HbA1c was significantly reduced at 6\\u2009months (0.44% points; P\\u2009=\\u20090.0006, 13 studies, 1883 participants), 12\\u2009months (0.46% points; P\\u2009=\\u20090.001, 11 studies, 1503 participants) and 2\\u2009years (0.87% points; P\\u2009<\\u20090.00001, 3 studies, 397 participants) and fasting blood glucose levels were also significantly reduced at 12\\u2009months (1.26\\u2009mmol/l; P\\u2009<\\u20090.00001, 5 studies, 690 participants) but not at 6\\u2009months. For the main lifestyle outcomes, diabetes knowledge was improved significantly at 6\\u2009months (SMD 0.83; P\\u2009=\\u20090.00001, 6 studies, 768 participants), 12\\u2009months (SMD 0.85; P\\u2009<\\u20090.00001, 5 studies, 955 participants) and 2\\u2009years (SMD 1.59; P\\u2009=\\u20090.03, 2 studies, 355 participants) and self-management skills also improved significantly at 6\\u2009months (SMD 0.55;', metadata={'splits_id': '1', 'document_id': 'PMC3418213_abstract.txt'}),\n",
              " Document(page_content='improved significantly at 6\\u2009months (SMD 0.55; P\\u2009=\\u20090.01, 4 studies, 534 participants). For the main psychosocial outcomes, there were significant improvement for empowerment/self-efficacy (SMD 0.28, P\\u2009=\\u20090.01, 2 studies, 326 participants) after 6\\u2009months. For quality of life no conclusion could be drawn due to high heterogeneity. For the secondary outcomes there were significant improvements in patient satisfaction and body weight at 12\\u2009months for the intervention group. There were no differences between the groups in mortality rate, body mass index, blood pressure and lipid profile.', metadata={'splits_id': '2', 'document_id': 'PMC3418213_abstract.txt'}),\n",
              " Document(page_content='Group-based DSME in people with type 2 diabetes results in improvements in clinical, lifestyle and psychosocial outcomes.', metadata={'splits_id': '3', 'document_id': 'PMC3418213_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus is a complex disease that affects many organ systems, leading to concerns about deteriorating population health status and ever-increasing healthcare expenditure. Many people with diabetes do not achieve optimal glycaemic control and other metabolic indices, leading to a heightened risk of developing complications. Adequate knowledge of diabetes complications is a prerequisite for risk-factor reduction and prevention of the consequences of the disease. Therefore, this study aimed to evaluate the knowledge of chronic complications of diabetes among persons living with type 2 diabetes mellitus in northern Ghana.', metadata={'splits_id': '0', 'document_id': 'PMC7592765_abstract.txt'}),\n",
              " Document(page_content='A descriptive cross-sectional study was conducted among 320 patients with type 2 diabetes mellitus in northern Ghana. The consecutive sampling technique was employed to recruit participants from September to November 2018. Data analysis was performed using IBM statistical package for social science version 23. Descriptive statistics such as frequencies and percentages were used. Both bivariate and multivariate logistic regression analysis were employed to determine associations between knowledge of diabetes complications and demographic/clinical characteristics of participants, at 95% confidence interval with statistical significance at P<0.05.', metadata={'splits_id': '1', 'document_id': 'PMC7592765_abstract.txt'}),\n",
              " Document(page_content='The majority of participants (54.1%) had inadequate knowledge and 45.9% had adequate knowledge of diabetes complications. The factors associated with inadequate level of knowledge were female gender [AOR = 0.29 (95%CI: 0.14–0.56), p<0.001], older age [AOR = 0.45 (95%CI:0.20–0.99), p = 0.049], primary education [AOR = 0.13 (95%CI: 0.03–0.51), p = 0.004], no formal education [AOR = 0.16 (95%CI: 0.05–0.50), p = 0.002], rural dwellers [AOR = 0.50 (95%CI: 0.27–0.95), p = 0.033] and unknown family history diabetes [AOR = 0.38 (95%CI: 0.17–0.82), p = 0.014].', metadata={'splits_id': '2', 'document_id': 'PMC7592765_abstract.txt'}),\n",
              " Document(page_content='More than half of the studied population had inadequate knowledge of diabetes complications. Female gender, rural dwellers, and low education level were factors positively associated with inadequate knowledge of diabetes complications. A multisectoral approach is needed, where the government of Ghana together with other sectors of the economy such as the health, education and local government sectors work collaboratively in the development of locally tailored diabetes education programmes to promote healthy self-care behaviours relevant for the prevention of diabetes and its complications.', metadata={'splits_id': '3', 'document_id': 'PMC7592765_abstract.txt'}),\n",
              " Document(page_content='We report a disease-causing mutation in the β-cell–enriched MAFA transcription factor. Strikingly, the missense p.Ser64Phe MAFA mutation was associated with either of two distinct phenotypes, multiple insulin-producing neuroendocrine tumors of the pancreas—a condition known as insulinomatosis—or diabetes mellitus, recapitulating the physiological properties of MAFA both as an oncogene and as a key islet β-cell transcription factor. The implication of MAFA in these human phenotypes will provide insights into how this transcription factor regulates human β-cell activity as well as into the mechanisms of Maf-induced tumorigenesis.', metadata={'splits_id': '0', 'document_id': 'PMC5798333_abstract.txt'}),\n",
              " Document(page_content='The β-cell–enriched MAFA transcription factor plays a central role in regulating glucose-stimulated insulin secretion while also demonstrating oncogenic transformation potential in vitro. No disease-causing MAFA variants have been previously described. We investigated a large pedigree with autosomal dominant inheritance of diabetes mellitus or insulinomatosis, an adult-onset condition of recurrent hyperinsulinemic hypoglycemia caused by multiple insulin-secreting neuroendocrine tumors of the pancreas. Using exome sequencing, we identified a missense MAFA mutation (p.Ser64Phe, c.191C>T) segregating with both phenotypes of insulinomatosis and diabetes. This mutation was also found in a second unrelated family with the same clinical phenotype, while no germline or somatic MAFA mutations were identified in nine patients with sporadic insulinomatosis. In the two families, insulinomatosis presented more frequently in females (eight females/two males) and diabetes more often in males (12', metadata={'splits_id': '1', 'document_id': 'PMC5798333_abstract.txt'}),\n",
              " Document(page_content='males) and diabetes more often in males (12 males/four females). Four patients from the index family, including two homozygotes, had a history of congenital cataract and/or glaucoma. The p.Ser64Phe mutation was found to impair phosphorylation within the transactivation domain of MAFA and profoundly increased MAFA protein stability under both high and low glucose concentrations in β-cell lines. In addition, the transactivation potential of p.Ser64Phe MAFA in β-cell lines was enhanced compared with wild-type MAFA. In summary, the p.Ser64Phe missense MAFA mutation leads to familial insulinomatosis or diabetes by impacting MAFA protein stability and transactivation ability. The human phenotypes associated with the p.Ser64Phe MAFA missense mutation reflect both the oncogenic capacity of MAFA and its key role in islet β-cell activity.', metadata={'splits_id': '2', 'document_id': 'PMC5798333_abstract.txt'}),\n",
              " Document(page_content='High N-terminal pro-brain-type natriuretic peptide levels have been associated with a lower risk of type 2 diabetes mellitus (T2D). However, less is known about other cardiac stress biomarkers in this context. Here we evaluated the association of mid-regional pro-atrial natriuretic peptide (MR-proANP), C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM) with incident T2D and changes in glucose metabolism.', metadata={'splits_id': '0', 'document_id': 'PMC7566143_abstract.txt'}),\n",
              " Document(page_content='We performed a prospective cohort study using data from the population-based KORA F4/FF4 study. 1773 participants (52.3% women) with MR-proANP measurements and 960 (52.7% women) with copeptin, CT-proET-1 and MR-proADM measurements were included. We examined associations of circulating plasma levels of MR-proANP, copeptin, CT-proET-1 and MR-proADM with incident T2D, the\\xa0combined endpoint of\\xa0incident prediabetes/T2D and with fasting and 2\\xa0h-glucose, fasting insulin, HOMA-IR, HOMA-B and HbA1c at follow-up. Logistic and linear regression models adjusted for age, sex, waist circumference, height, hypertension, total/HDL cholesterol ratio, triglycerides, smoking, physical activity and parental history of diabetes were used to compute effect estimates.', metadata={'splits_id': '1', 'document_id': 'PMC7566143_abstract.txt'}),\n",
              " Document(page_content='During a median follow-up time of 6.4\\xa0years (25th and 75th percentiles: 6.0 and 6.6, respectively), 119 out of the 1773 participants and 72 out of the 960 participants developed T2D. MR-proANP was inversely associated with incident T2D (odds ratio [95% confidence interval]: 0.75 [0.58; 0.96] per 1-SD increase of log MR-proANP). Copeptin was positively associated with incident prediabetes/T2D (1.29 [1.02; 1.63] per 1-SD increase of log copeptin). Elevated levels of CT-proET-1 were associated with increased HOMA-B at follow-up, while elevated MR-proADM levels were associated with increased fasting insulin, HOMA-IR and HOMA-B at follow-up. These associations were independent of previously described diabetes risk factors.', metadata={'splits_id': '2', 'document_id': 'PMC7566143_abstract.txt'}),\n",
              " Document(page_content='High plasma concentrations of MR-proANP contributed to a lower risk of incident T2D, whereas high plasma concentrations of copeptin were associated with an increased risk of incident prediabetes/T2D. Furthermore, high plasma concentrations of CT-proET-1 and MR-proADM were associated with increased insulin resistance. Our study provides evidence that biomarkers implicated in cardiac stress are associated with incident T2D and changes in glucose metabolism.', metadata={'splits_id': '3', 'document_id': 'PMC7566143_abstract.txt'}),\n",
              " Document(page_content='Type 1 diabetes mellitus is believed to result from destruction of the insulin-producing β-cells in pancreatic islets that is mediated by autoimmune mechanisms. The classic view is that autoreactive T cells mistakenly destroy healthy (‘innocent’) β-cells. We propose an alternative view in which the β-cell is the key contributor to the disease. By their nature and function, β-cells are prone to biosynthetic stress with limited measures for self-defence. β-Cell stress provokes an immune attack that has considerable negative effects on the source of a vital hormone. This view would explain why immunotherapy at best delays progression of type 1 diabetes mellitus and points to opportunities to use therapies that revitalize β-cells, in combination with immune intervention strategies, to reverse the disease. We present the case that dysfunction occurs in both the immune system and β-cells, which provokes further dysfunction, and present the evidence leading to the consensus that islet', metadata={'splits_id': '0', 'document_id': 'PMC7722981_abstract.txt'}),\n",
              " Document(page_content='the evidence leading to the consensus that islet autoimmunity is an essential component in the pathogenesis of type 1 diabetes mellitus. Next, we build the case for the β-cell as the trigger of an autoimmune response, supported by analogies in cancer and antitumour immunity. Finally, we synthesize a model (‘connecting the dots’) in which both β-cell stress and islet autoimmunity can be harnessed as targets for intervention strategies.', metadata={'splits_id': '1', 'document_id': 'PMC7722981_abstract.txt'}),\n",
              " Document(page_content='This Review examines the evidence that β-cells are active participants in the dialogue with the immune system during the development of type 1 diabetes mellitus. The authors suggest that therapies targeting β-cell health, vitality and function might prove essential, in combination with immunotherapy, to change the course of events leading to β-cell destruction.\\nAutoreactive T cells are part of the normal T cell repertoire.\\nβ-Cells are poorly equipped to survive an inflammatory milieu and participate in their own destruction.\\nMetabolic activity drives β-cell dysfunction and destruction.\\nInflammation triggers profound metabolic, epigenetic and autoantigenic changes, which expose β-cells to the immune system.\\nThe immune response to distressed β-cells might be one with ‘good intentions’, as infected tissues or tumours provoke the immune system in similar ways.', metadata={'splits_id': '2', 'document_id': 'PMC7722981_abstract.txt'}),\n",
              " Document(page_content='Immunotherapy might be insufficient to cure type 1 diabetes mellitus; β-cell therapy might contribute to reducing β-cell immunogenicity and islet autoimmunity.', metadata={'splits_id': '3', 'document_id': 'PMC7722981_abstract.txt'}),\n",
              " Document(page_content='Primary care clinicians will see a higher incidence of type 2 diabetes in adult patients, and the diagnosis and management of an initial presentation of type 1 diabetes can pose challenges to clinicians who see it less frequently. Symptoms of hyperglycemia and risk of ketoacidosis may be missed. Further, endocrine autoimmune disease can run together in patients and families.', metadata={'splits_id': '0', 'document_id': 'PMC5706424_abstract.txt'}),\n",
              " Document(page_content='A 49-year-old Caucasian female with history of pituitary adenoma and Graves’ disease with history of thyroid ablation presented in the outpatient setting due to hand tingling of her right middle finger that was worse in the mornings and improved throughout the day. She also complained of excessive thirst, finding herself drinking more water than usual and waking up in the night to urinate. There was no dysuria or haematuria, and no other neurologic symptoms. She did report feeling hungry. She had no family history of diabetes, normal body mass index of 21.7, and reported taking her thyroid replacement medication every day. The differential diagnosis for her thirst included dehydration, psychogenic polydipsia, diabetes mellitus, diabetes insipidus, and anxiety. The patient had normal vital signs and was well appearing; labs were ordered for her on her way home from clinic with no medications. Labs revealed a random blood glucose level of 249\\xa0mg/dL, normal renal function, a normal B12', metadata={'splits_id': '1', 'document_id': 'PMC5706424_abstract.txt'}),\n",
              " Document(page_content='of 249\\xa0mg/dL, normal renal function, a normal B12 of 996\\xa0pg/mL, and an elevated thyroid stimulating hormone level of 25.67 u[iU]/mL. On follow up with her primary care provider 5 days later, additional labs were drawn showing A1C of 11.5%, 1+ ketonuria, a negative Acetest, and a normal basic metabolic panel, except for a fasting glucose of 248\\xa0mg/dL, and Free T3 of 2.42\\xa0pg/mL, and Free T4 of 1.7\\xa0ng/dL. Islet cell antibodies and glutamic acid decarboxylase antibodies were both positive, consistent with type 1 diabetes. She was started on insulin and improved.', metadata={'splits_id': '2', 'document_id': 'PMC5706424_abstract.txt'}),\n",
              " Document(page_content='Given the patient’s age, this is a less common presentation of type 1 diabetes mellitus, as a part of polyglandular autoimmune syndrome type IIIa. It serves as a reminder that clinicians should remember that patients with one autoimmune disease (in this case, h/o Graves’ disease) are at higher risk for diabetes and other endocrine autoimmune diseases and should be screened appropriately. Clinicians should keep latent type 1 diabetes in the differential in adulthood to ensure proper and timely treatment.', metadata={'splits_id': '3', 'document_id': 'PMC5706424_abstract.txt'}),\n",
              " Document(page_content='To investigate whether the association of severe mental illness with Type 2 diabetes varies by ethnicity and age.\\nWe conducted a cross‐sectional analysis of data from an ethnically diverse sample of 588 408 individuals aged ≥18 years, registered to 98% of general practices (primary care) in London, UK. The outcome of interest was prevalent Type 2 diabetes.', metadata={'splits_id': '0', 'document_id': 'PMC5484374_abstract.txt'}),\n",
              " Document(page_content='Relative to people without severe mental illness, the relative risk of Type 2 diabetes in people with severe mental illness was greatest in the youngest age groups. In the white British group the relative risks were 9.99 (95% CI 5.34, 18.69) in those aged 18–34 years, 2.89 (95% CI 2.43, 3.45) in those aged 35–54 years and 1.16 (95% CI 1.04, 1.30) in those aged ≥55 years, with similar trends across all ethnic minority groups. Additional adjustment for anti‐psychotic prescriptions only marginally attenuated the associations. Assessment of estimated prevalence of Type 2 diabetes in severe mental illness by ethnicity (absolute measures of effect) indicated that the association between severe mental illness and Type 2 diabetes was more marked in ethnic minorities than in the white British group with severe mental illness, especially for Indian, Pakistani and Bangladeshi individuals with severe mental illness.', metadata={'splits_id': '1', 'document_id': 'PMC5484374_abstract.txt'}),\n",
              " Document(page_content='The relative risk of Type 2 diabetes is elevated in younger populations. Most associations persisted despite adjustment for anti‐psychotic prescriptions. Ethnic minority groups had a higher prevalence of Type 2 diabetes in the presence of severe mental illness. Future research and policy, particularly with respect to screening and clinical care for Type 2 diabetes in populations with severe mental illness, should take these findings into account.\\nThere is limited evidence of the association of severe mental illness with Type 2 diabetes mellitus in ethnic minorities.', metadata={'splits_id': '2', 'document_id': 'PMC5484374_abstract.txt'}),\n",
              " Document(page_content='Using data from >500 000 people, we established that: (1) risk of Type 2 diabetes was increased up to 10‐fold in people with severe mental illness compared with groups without severe mental illness, irrespective of ethnicity, and was greatest in the youngest age groups; (2) prevalence of Type 2 diabetes was highest in Bangladeshi people with severe mental illness but was also high in all other South Asian, black African and black Caribbean groups; and (3) most associations persisted despite adjustment for anti‐psychotic prescriptions.', metadata={'splits_id': '3', 'document_id': 'PMC5484374_abstract.txt'}),\n",
              " Document(page_content='The aim of this study was to examine ethnicity‐specific associations between type\\xa02 diabetes mellitus and the risk of a cardiovascular disease (CVD) event as well as risk of specific CVD phenotypes in England.\\nWe obtained data from the Clinical Practice Research Datalink for adults with and without type\\xa02 diabetes mellitus diagnosed 2000–2006. The outcome was the first CVD event during 2007–2017 and the following components: aortic aneurysm, cerebrovascular accidents, heart failure, myocardial infarction, peripheral vascular disease and other CVD‐related conditions. Flexible parametric survival models were used to estimate ethnicity‐specific adjusted hazard ratios.', metadata={'splits_id': '0', 'document_id': 'PMC8264396_abstract.txt'}),\n",
              " Document(page_content='A total of 734,543 people with and without type\\xa02 diabetes mellitus (29,847; 4.1%) were included; most were of white ethnicity (93.0% with and 92.3% without type\\xa02 diabetes mellitus) followed by South Asian (3.2 and 4.6%). During a median follow‐up period of 11.0\\xa0years, 67,218 events occurred (6,156 in individuals with type\\xa02 diabetes mellitus). Type\\xa02 diabetes mellitus was associated with a small increase in CVD events (adjusted hazard ratio 1.06, 95% confidence interval 1.02–1.09) in individuals of white ethnicity; whereas the adjusted hazard ratios were considerably higher in individuals of South Asian ethnicity (1.28, 95% confidence interval 1.09–1.51), primarily due to an increased risk of myocardial infarction (1.53, 95% confidence interval 1.08–2.18).', metadata={'splits_id': '1', 'document_id': 'PMC8264396_abstract.txt'}),\n",
              " Document(page_content='Despite universal access to healthcare, there are large disparities in CVD outcomes in people with and without type\\xa02 diabetes mellitus. Other non‐traditional risk factors might play a role in the higher CVD risk associated with type\\xa02 diabetes mellitus in individuals of South Asian ethnicity.\\nDespite universal access to healthcare, there are large ethnic disparities in cardiovascular disease outcomes in people with and without type\\xa02 diabetes mellitus. Type\\xa02 diabetes mellitus was associated with a small increase in cardiovascular disease events (adjusted hazard ratio 1.06, 95% confidence interval 1.02–1.09) in individuals of white ethnicity; whereas the adjusted hazard ratio was considerably higher in individuals of South Asian ethnicity (1.28, 95% confidence interval 1.09–1.51), primarily due to an increased risk of myocardial infarction (adjusted hazard ratio 1.53, 95% confidence interval 1.08–2.18).', metadata={'splits_id': '2', 'document_id': 'PMC8264396_abstract.txt'}),\n",
              " Document(page_content='Atypical presentations of diabetes mellitus (DM) have been reported in non-European ethnic populations under various names. It is unclear whether those names are used for the same or different clinical phenotypes. Unclear terminology may lead to inappropriate treatment and an underestimation of the burden caused by atypical diabetes phenotypes overlapping with classic types of diabetes. This review aimed to describe the terms used for atypical forms of diabetes and to investigate whether the terms are used for similar or different phenotypes.', metadata={'splits_id': '0', 'document_id': 'PMC6818125_abstract.txt'}),\n",
              " Document(page_content='PubMed and Scopus were searched for relevant publications in French or English available before 15 September 2015 using the terms: ”Atypical diabetes”, “Malnutrition Related Diabetes Mellitus (MRDM)”, “Fibro-calculus pancreatic diabetes (FCPD)”, Protein deficient Pancreatic Diabetes (PDPD)”, “African diabetes”, “Ketosis prone-type 2 diabetes”, “tropical diabetes”, “Flatbush diabetes”, “J-type diabetes”. Titles, abstracts screening and quality assessment were performed by two independent authors. Observational studies addressing atypical diabetes in humans aged 14 years and above were included. One author extracted data from selected articles.', metadata={'splits_id': '1', 'document_id': 'PMC6818125_abstract.txt'}),\n",
              " Document(page_content='22 articles among 350 identified articles were retained for data extraction. Two atypical diabetes phenotypes were identified, each of them with a variety of names but similar definitions. One phenotype occurred in very thin people less than 30 years of age, typically from poor socio-economic backgrounds and requires insulin for life. It differs from type 1 diabetes in the tolerance of high blood glucose without ketosis in the absence of exogenous insulin. The second phenotype resembles type1 diabetes as it presents with ketosis at onset but responds well, as type2 diabetes, to oral hypoglycemic drugs after initial stabilization with insulin. It occurs in individuals who are usually over 30 years of age, with normal or overweight and absence of auto antibodies mainly found in type 1 diabetes.', metadata={'splits_id': '2', 'document_id': 'PMC6818125_abstract.txt'}),\n",
              " Document(page_content='The scarce existing literature used various terms for similar diabetes phenotypes. Agreement on nomenclature for the various forms of diabetes using the above reported characteristics are needed in populations where atypical forms of diabetes exist as well as better characterization of phenotypes and genotypes to inform evidence based treatment.', metadata={'splits_id': '3', 'document_id': 'PMC6818125_abstract.txt'}),\n",
              " Document(page_content='Background: Decompensated diabetes is associated with a higher prevalence and severity of periodontitis and poorer response to periodontal therapy. It is conceivable that periodontal therapy may cause systemic and local complications in this type of patients. The aim of the present study was to identify and describe the best available evidence for the treatment of periodontitis in decompensated diabetics.', metadata={'splits_id': '0', 'document_id': 'PMC8757839_abstract.txt'}),\n",
              " Document(page_content='Material and methods: An expert committee including participants from different areas gathered to discuss and develop a treatment guideline under the guidance of the Cochrane Associate Center, Faculty of Dentistry, University of Chile. In total, four research questions were prepared. The questions prepared related to decompensated diabetic patients (glycated hemoglobin >8) were, (1) Does the exposure to periodontal treatment increase the risk of infectious or systemic complications? (2) Does the antibiotic treatment or prophylaxis, compared to not giving it, reduce infectious complications? (3) Does the exposure to periodontal treatment, compared to no treatment, reduce the glycated hemoglobin levels (HbA1c)? Last question was related to diabetic patients, (4) Does the exposure to a higher level of HbA1c, compared to stable levels, increase the risk of infectious complications? Based on these questions, a search strategy was developed using MEDLINE and EPISTEMONIKOS. Only systematic', metadata={'splits_id': '1', 'document_id': 'PMC8757839_abstract.txt'}),\n",
              " Document(page_content='using MEDLINE and EPISTEMONIKOS. Only systematic reviews were considered.', metadata={'splits_id': '2', 'document_id': 'PMC8757839_abstract.txt'}),\n",
              " Document(page_content='Results: For question 1, the search yielded 12 records in EPISTEMONIKOS and 23 in MEDLINE. None of these studies addressed the question. For question 2, the search yielded 58 records in EPISTEMONIKOS and 11 in MEDLINE. None of these studies addressed the question. For question 3, the search yielded 16 records in EPISTEMONIKOS and 11 in MEDLINE. Thirteen addressed the question. For question 4, the search yielded 7 records in EPISTEMONIKOS and 9 in MEDLINE. One addressed the question.\\nConclusions: In decompensated diabetic patients, there is lack of scientific information about risk of infectious or systemic complications as a result of periodontal treatment and about the impact of antibiotic treatment or prophylaxis on reduction if infectious complications. A defined HbA1c threshold for dental and periodontal treatment in diabetic patients has yet to be determined. Finally, periodontal treatment does have an impact on HbA1c levels.', metadata={'splits_id': '3', 'document_id': 'PMC8757839_abstract.txt'}),\n",
              " Document(page_content='Introduction: Gestational diabetes (GDM), defined as hyperglycemia with onset or initial recognition during pregnancy, has a rising prevalence paralleling the rise in type 2 diabetes (T2DM) and obesity. GDM is associated with short-term and long-term consequences for both mother and child. Therefore, it is crucial we efficiently identify all cases and initiate early treatment, reducing fetal exposure to hyperglycemia and reducing GDM-related adverse pregnancy outcomes. For this reason, GDM screening is recommended as part of routine pregnancy care. The current screening method, the oral glucose tolerance test (OGTT), is a lengthy, cumbersome and inconvenient test with poor reproducibility. Newer biomarkers that do not necessitate a fasting sample are needed for the prompt diagnosis of GDM. The aim of this scoping review is to highlight and describe emerging protein biomarkers that fulfill these requirements for the diagnosis of GDM. Materials and Methods: This scoping review was', metadata={'splits_id': '0', 'document_id': 'PMC8038821_abstract.txt'}),\n",
              " Document(page_content='Materials and Methods: This scoping review was conducted according to preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines for scoping reviews using Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing & Allied Health Literature (CINAHL), PubMed, Embase and Web of Science with a double screening and extraction process. The search included all articles published in the literature to July 2020. Results: Of the 3519 original database citations identified, 385 were eligible for full-text review. Of these, 332 (86.2%) were included in the scoping review providing a total of 589 biomarkers studied in relation to GDM diagnosis. Given the high number of biomarkers identified, three post hoc criteria were introduced to reduce the items set for discussion: we chose only protein biomarkers with at least five citations in the articles identified by our search and published in the years 2017–2020. When applied, these criteria', metadata={'splits_id': '1', 'document_id': 'PMC8038821_abstract.txt'}),\n",
              " Document(page_content='the years 2017–2020. When applied, these criteria identified a total of 15 biomarkers, which went forward for review and discussion. Conclusions: This review details protein biomarkers that have been studied to find a suitable test for GDM diagnosis with the potential to replace the OGTT used in current GDM screening protocols. Ongoing research efforts will continue to identify more accurate and practical biomarkers to take GDM screening and diagnosis into the 21st century.', metadata={'splits_id': '2', 'document_id': 'PMC8038821_abstract.txt'}),\n",
              " Document(page_content='Population surveys of Type 2 diabetes mellitus and obesity conducted in Samoa over three decades have used varying methodologies and definitions. This study standardizes measures, and trends of Type 2 diabetes mellitus and obesity for 1978–2013 are projected to 2020 for adults aged 25–64 years.\\nUnit records from eight surveys (n = 12 516) were adjusted to the previous census for Division of residence, sex and age to improve national representativeness. Type 2 diabetes mellitus is defined as a fasting plasma glucose ≥ 7.0 mmol/l and/or on medication. Obesity is defined as BMI ≥ 30 kg/m2. Random effects meta‐regression was employed to assess time trends following logit transformation. Poisson regression from strata was used to assess the effects of mean BMI changes on Type 2 diabetes mellitus period trends.', metadata={'splits_id': '0', 'document_id': 'PMC5411261_abstract.txt'}),\n",
              " Document(page_content='Over 1978–2013, Type 2 diabetes mellitus prevalence increased from 1.2% to 19.6% in men (2.3% per 5 years), and from 2.2% to 19.5% in women (2.2% per 5 years). Obesity prevalence increased from 27.7% to 53.1% in men (3.6% per 5 years) and from 44.4% to 76.7% (4.5% per 5 years) in women. Type 2 diabetes mellitus and obesity prevalences increased in all age groups. From period trends, Type 2 diabetes mellitus prevalence in 2020 is projected to be 26% in men and women. Projected obesity prevalence is projected to be 59% in men and 81% in women. Type 2 diabetes mellitus period trends attributable to BMI increase are estimated as 31% (men) and 16% (women), after adjusting for age.', metadata={'splits_id': '1', 'document_id': 'PMC5411261_abstract.txt'}),\n",
              " Document(page_content='This is the first study to produce trends of Type 2 diabetes mellitus and obesity in Samoa based on standardized data from population surveys. Type 2 diabetes mellitus is equally prevalent in both sexes, and obesity is widespread. Type 2 diabetes mellitus prevalence in Samoa is likely to continue to increase in the near future.\\nThis is the first study to standardize previously conducted, disparate population‐based measures of Type 2 diabetes mellitus and obesity from unit records of empirical surveys to produce period trends in Samoa.\\nPrevalences of Type 2 diabetes mellitus and obesity have increased over 35 years (1978–2013), and are projected to continue to increase in the near future.\\nThe increase in Type 2 diabetes mellitus is partially attributed to the rise in obesity and effective interventions to reduce obesity are urgently required.', metadata={'splits_id': '2', 'document_id': 'PMC5411261_abstract.txt'}),\n",
              " Document(page_content='Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycaemia in infancy that leads to unfavourable neurological outcome if not treated adequately. In patients with severe diffuse CHI it remains under discussion whether pancreatic surgery should be performed or intensive medical treatment with the acceptance of recurrent episodes of mild hypoglycaemia is justified. Near-total pancreatectomy is associated with high rates of insulin-dependent diabetes mellitus and exocrine pancreatic insufficiency. Little is known about the management and long-term glycaemic control of CHI patients with diabetes after pancreatic surgery. We searched the German/Austrian DPV database and compared the course of 42 CHI patients with diabetes to that of patients with type 1 diabetes mellitus (T1DM). Study groups were compared at diabetes onset and after a follow-up period of 6.1 [3.3–9.7] (median [interquartile range]) years.', metadata={'splits_id': '0', 'document_id': 'PMC6304089_abstract.txt'}),\n",
              " Document(page_content='The majority of CHI patients with diabetes were treated with insulin (85.2% [70.9–99.5] at diabetes onset, and 90.5% [81.2–99.7] at follow-up). However, compared to patients with T1DM, significantly more patients in the CHI group with diabetes were treated with conventional insulin therapy (47.8% vs. 24.4%, p\\u2009=\\u20090.03 at diabetes onset, and 21.1% vs. 6.4% at follow-up, p\\u2009=\\u20090.003), and only a small number of CHI patients were treated with insulin pumps. Daily insulin dose was significantly lower in CHI patients with diabetes than in patients with T1DM, both at diabetes onset (0.3 [0.2–0.5] vs. 0.6\\u2009IE/kg/d [0.4–0.8], p\\u2009=\\u20090.003) and follow-up (0.8 [0.4–1.0] vs. 0.9 [0.7–1.0] IE/kg/d, p\\u2009=\\u20090.02), while daily carbohydrate intake was comparable in both groups. Within the first treatment year, HbA1c levels were significantly lower in CHI patients with diabetes (6.2% [5.5–7.9] vs. 7.2% [6.5–8.2], p\\u2009=\\u20090.003), but increased to a level comparable to that of T1DM patients at follow-up.', metadata={'splits_id': '1', 'document_id': 'PMC6304089_abstract.txt'}),\n",
              " Document(page_content='comparable to that of T1DM patients at follow-up. Interestingly, in CHI patients, the risk of severe hypoglycaemia tends to be higher only at diabetes onset (14.8% vs. 5.8%, p\\u2009=\\u20090.1).', metadata={'splits_id': '2', 'document_id': 'PMC6304089_abstract.txt'}),\n",
              " Document(page_content='In surgically treated CHI patients insulin treatment needs to be intensified in order to achieve good glycaemic control. Our data furthermore emphasize the need for improved medical treatment options for patients with diazoxide- and/or octreotide-unresponsive CHI.', metadata={'splits_id': '3', 'document_id': 'PMC6304089_abstract.txt'}),\n",
              " Document(page_content='Patients with diabetes mellitus have an increased risk of fractures; however, the underlying mechanism is largely unknown. We aimed to investigate whether the risk of major osteoporotic fractures in diabetes patients differs between subjects initiated with alendronate and denosumab, respectively.', metadata={'splits_id': '0', 'document_id': 'PMC8825412_abstract.txt'}),\n",
              " Document(page_content='We conducted a retrospective nationwide cohort study through access to all discharge diagnoses (ICD-10 system) from the National Danish Patient Registry along with all redeemed drug prescriptions (ATC classification system) from the Health Service Prescription Registry. We identified all subjects with a diabetes diagnosis between 2000 and 2018 and collected data on the first new prescription of anti-osteoporotic treatment between 2011 and 2018. Exposure was defined as either alendronate or denosumab treatment initiated after diabetes diagnosis. Outcome information was collected by identification of all major osteoporotic fracture (MOF) diagnoses, i.e., hip, spine, forearm, and humerus, from exposure until 2018 or censoring by emigration or death. The risk of fracture was calculated as hazard ratios (HR) using multiply adjusted Cox proportional models with death as a competing risk.', metadata={'splits_id': '1', 'document_id': 'PMC8825412_abstract.txt'}),\n",
              " Document(page_content='We included 8,745 subjects initiated with either alendronate (n = 8,255) or denosumab (n = 490). The cohort consisted of subjects with a mean age of 73.62 (SD ± 9.27) years, primarily females (69%) and suffering mainly from type 2 diabetes (98.22%) with a median diabetes duration at baseline of 5.45 years (IQR 2.41–9.19). Those in the denosumab group were older (mean 75.60 [SD ± 9.72] versus 73.51 [SD ± 9.23] years), had a higher proportion of women (81% versus 68%, RR 1.18 [95% CI 1.13–1.24], and were more comorbid (mean CCI 2.68 [95% CI 2.47–2.88] versus 1.98 [95% CI 1.93–2.02]) compared to alendronate initiators. In addition, denosumab users had a higher prevalence of previous fractures (64% versus 46%, RR 1.38 [95% CI 1.28–1.48]). The\\xa0adjusted HR for any MOF after treatment initiation with denosumab was 0.89 (95% CI 0.78–1.02) compared to initiation with alendronate.', metadata={'splits_id': '2', 'document_id': 'PMC8825412_abstract.txt'}),\n",
              " Document(page_content='The risk of incident MOF among subjects with diabetes was similar between those initially treated with alendronate and denosumab. These findings indicate that the two treatment strategies are equally effective in preventing osteoporotic fractures in subjects with diabetes.', metadata={'splits_id': '3', 'document_id': 'PMC8825412_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus and hypertension are risk factors for cardiovascular disease, which is the most common cause of death in the world. People with intellectual disability (ID) have been reported to have high rates of both these disorders. The aim of this study was to describe and compare prevalence ratios of diabetes mellitus and hypertension between older adults with ID and their age peers in the general population, and to describe and compare treatment patterns in these two groups.', metadata={'splits_id': '0', 'document_id': 'PMC5701367_abstract.txt'}),\n",
              " Document(page_content='This is a Swedish register-based study, in which we established a cohort of people aged 55+ years and who had received support for those with ID in 2012\\xa0(n\\u2009=\\u20097936). We also established a same-sized referent cohort from the general population matched by sex and year of birth. Information on diagnoses of diabetes mellitus and hypertension, and prescription of drugs for these disorders, were collected from national registers for the period 2006–2012. The two cohorts were compared using generalized linear models (GLM).', metadata={'splits_id': '1', 'document_id': 'PMC5701367_abstract.txt'}),\n",
              " Document(page_content='People with ID were 20% more likely than the general population to have a diagnosis of diabetes mellitus, and 26% more likely to have prescription of drugs for diabetes mellitus. People in the general population were 81% more likely to have a diagnosis of hypertension, and 9% more likely to have a prescription of drugs for hypertension. Among those with diabetes, ID was associated with higher occurrence of prescription of insulin combination drugs and sulfonylureas, but lower occurrence of prescription of dipeptidyl peptidase (DPP) 4-inhibitors and exenatide/liraglutide. Among those with hypertension, ID was associated with higher occurrence of prescription of diuretics, but lower occurrence of prescription of calcium channel blockers and angiotensin II antagonists.', metadata={'splits_id': '2', 'document_id': 'PMC5701367_abstract.txt'}),\n",
              " Document(page_content='Treatment regimens among people with ID tended to include older types of medication compared with what was prescribed in the general population. To ensure that this is medically appropriate and not due to failure to update the treatment regimen, it is important to investigate if the people with ID and diabetes mellitus or hypertension are subjected to the same regular drug reviews that are recommended for older adults in general.\\nThe online version of this article (10.1186/s12877-017-0658-2) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC5701367_abstract.txt'}),\n",
              " Document(page_content='Improving detection of depression in people with diabetes is recommended. However, little is known about how different health systems compare in depression detection. We estimated and compared the (1) prevalence of depression detection in people with and without diabetes, and (2) association between diabetes and undiagnosed depression across three health systems.\\nCross-sectional analysis of three nationally representative studies: The Irish Longitudinal Study on Ageing, the English Longitudinal Study on Ageing and the Health and Retirement Study.\\nCommunity-dwelling adults in Ireland, England and the USA.\\nAdults aged ≥50 years.', metadata={'splits_id': '0', 'document_id': 'PMC8515475_abstract.txt'}),\n",
              " Document(page_content='Adults aged ≥50 years.\\nThe primary outcome was depression diagnosis. The secondary outcome was any depression. Any depression was defined by the presence of self-reported doctor-diagnosed depression or current depression symptoms on the Centre for Epidemiological Studies-Depression scale. Depression diagnosis was categorised as: undiagnosed, symptomatic and diagnosed, and asymptomatic and diagnosed. We estimated age-standardised prevalence of depression diagnosis by country and diabetes status. Anyone who self-reported having ever received a doctor diagnosis of diabetes was classified as having diabetes. Among respondents with depression, we estimated the association between diabetes and undiagnosed depression by country using multivariable logistic regression.', metadata={'splits_id': '1', 'document_id': 'PMC8515475_abstract.txt'}),\n",
              " Document(page_content='The prevalence of depression (diagnosed and undiagnosed) was higher in people with diabetes in each country with absolute rates varying by country; undiagnosed prevalence (Ireland: diabetes 10.1% (95% CI 7.5% to 12.8%) vs no diabetes 7.5% (95% CI 6.8% to 8.2%), England: diabetes 19.3% (95% CI 16.5% to 22.2%) vs no diabetes 11.8% (95% CI 11.0% to 12.6%), USA: diabetes 7.4% (95% CI 6.4% to 8.4%) vs no diabetes 6.1% (95% CI 5.7% to 6.6%)). In the fully adjusted model, there was no clear pattern of association between diabetes status and undiagnosed depression; Ireland: OR=0.82 (95% CI 0.5 to 1.3), England: OR=1.47 (95% CI 1.0 to 2.1), USA: OR=0.80 (95% CI 0.7 to 1.0).\\nAlthough undiagnosed depression was more prevalent among people with diabetes, the relationship between diabetes and undiagnosed depression differed by country. Targeted efforts are needed to improve depression detection among community-dwelling older adults, particularly those with diabetes.', metadata={'splits_id': '2', 'document_id': 'PMC8515475_abstract.txt'}),\n",
              " Document(page_content='Type 2 diabetes mellitus (T2DM) has become a world-wide epidemic. This chronic metabolic disease has a major impact on life expectancy and on quality of life. The burden of this disease includes a number of co-morbidities. However, estimates of prevalence, incidence and associated diseases as well as the current temporal development and regional differences are largely missing for South Western Germany.\\nLifetime diagnosis-based prevalence, incidence and presence of concomitant co-morbidities were examined between the years 2007 and 2010 in the claims data set of all insured persons of the AOK Baden-Wuerttemberg, a large statutory health insurance. The analysis was based on the respective WHO-ICD-10 codes. Data were standardized for age and sex on the residential population of about 10 million inhabitants of South Western Germany.', metadata={'splits_id': '0', 'document_id': 'PMC4559219_abstract.txt'}),\n",
              " Document(page_content='The total study cohort involved approximately 3.5 million persons each year. The standardized diagnosis-based prevalence (SDP) of T2DM rose from 6.6\\xa0%, 7.4\\xa0%, 8.0\\xa0%, up to 8.6\\xa0% in the years 2007 to 2010. Yearly SDP was between 14.0\\xa0% and 18.9\\xa0% at an age range of 60 to 64\\xa0years and between 26.7\\xa0% and 31.8\\xa0% at an age of 75\\xa0years or older. In the year 2010 the regional distributions of standardized diagnosis-based prevalence were between 7.6\\xa0% and 11.6\\xa0%, respectively. Incidence rates were 8.3 in 2008, 7.8 in 2009, and 8.7 in 2010 (all rates per 1000). The excess disease risk (odds ratio) of T2DM was for adiposity 2.8 to 3.0, hypertension 2.4 to 3.7, coronary heart disease 1.8 to 1.9, stroke 1.7 to 1.8, renal insufficiency 2.8 to 3.4, and retinopathy 2.8 to 2.9 in the years 2007 to 2010. These co-morbidities appeared several years earlier compared to the non-diabetic population.', metadata={'splits_id': '1', 'document_id': 'PMC4559219_abstract.txt'}),\n",
              " Document(page_content='T2DM is common and increasing in South Western Germany. In particular a quarter of the population in higher ages was afflicted by T2DM. Interestingly a region-specific pattern was observed as well as an increase in numbers during earlier years in life. Our data underline the need for diabetes awareness programmes including early diagnosis measures as well as structured and timely health surveys for major diseases such as T2DM and its concomitant co-morbidities.\\nThe online version of this article (doi:10.1186/s12889-015-2188-1) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '2', 'document_id': 'PMC4559219_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus is a common co-existing disease in the critically ill. Diabetes mellitus may reduce the risk of acute respiratory distress syndrome (ARDS), but data from previous studies are conflicting. The objective of this study was to evaluate associations between pre-existing diabetes mellitus and ARDS in critically ill patients with acute hypoxemic respiratory failure (AHRF).', metadata={'splits_id': '0', 'document_id': 'PMC6203969_abstract.txt'}),\n",
              " Document(page_content='An ancillary analysis of a global, multi-centre prospective observational study (LUNG SAFE) was undertaken. LUNG SAFE evaluated all patients admitted to an intensive care unit (ICU) over a 4-week period, that required mechanical ventilation and met AHRF criteria. Patients who had their AHRF fully explained by cardiac failure were excluded. Important clinical characteristics were included in a stepwise selection approach (forward and backward selection combined with a significance level of 0.05) to identify a set of independent variables associated with having ARDS at any time, developing ARDS (defined as ARDS occurring after day 2 from meeting AHRF criteria) and with hospital mortality. Furthermore, propensity score analysis was undertaken to account for the differences in baseline characteristics between patients with and without diabetes mellitus, and the association between diabetes mellitus and outcomes of interest was assessed on matched samples.', metadata={'splits_id': '1', 'document_id': 'PMC6203969_abstract.txt'}),\n",
              " Document(page_content='Of the 4107 patients with AHRF included in this study, 3022 (73.6%) patients fulfilled ARDS criteria at admission or developed ARDS during their ICU stay. Diabetes mellitus was a pre-existing co-morbidity in 913 patients (22.2% of patients with AHRF). In multivariable analysis, there was no association between diabetes mellitus and having ARDS (OR 0.93 (0.78–1.11); p\\u2009=\\u20090.39), developing ARDS late (OR 0.79 (0.54–1.15); p\\u2009=\\u20090.22), or hospital mortality in patients with ARDS (1.15 (0.93–1.42); p\\u2009=\\u20090.19). In a matched sample of patients, there was no association between diabetes mellitus and outcomes of interest.\\nIn a large, global observational study of patients with AHRF, no association was found between diabetes mellitus and having ARDS, developing ARDS, or outcomes from ARDS.\\nNCT02010073. Registered on 12 December 2013.\\nThe online version of this article (10.1186/s13054-018-2158-y) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '2', 'document_id': 'PMC6203969_abstract.txt'}),\n",
              " Document(page_content='To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.\\nSystematic review and meta-analysis.\\nMedline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.\\nObservational studies investigating progression to T2DM. Inclusion criteria were postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.', metadata={'splits_id': '0', 'document_id': 'PMC7218708_abstract.txt'}),\n",
              " Document(page_content='This meta-analysis of 20 studies assessed a total of 1\\u2009332\\u2009373 individuals (67\\u2009956 women with GDM and 1\\u2009264\\u2009417 controls). Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I2 statistic. The pooled relative risk for the incidence of T2DM between participants with GDM and controls was estimated. Reasons for heterogeneity between studies were investigated by prespecified subgroup and meta-regression analyses. Publication bias was assessed by funnel plots and, overall, studies were deemed to have a low risk of bias (P=0.58 and P=0.90). The overall relative risk for T2DM was almost 10 times higher in women with previous GDM than in healthy controls (9.51, 95% confidence interval 7.14 to 12.67, P<0.001). In populations of women with previous GDM, the cumulative incidence of T2DM was 16.46% (95% confidence interval 16.16% to 16.77%) in women of mixed ethnicity, 15.58% (13.30% to 17.86%) in a predominantly non-white population, and 9.91%', metadata={'splits_id': '1', 'document_id': 'PMC7218708_abstract.txt'}),\n",
              " Document(page_content='a predominantly non-white population, and 9.91% (9.39% to 10.42%) in a white population. These differences were not statistically significant between subgroups (white v mixed populations, P=0.26; white v non-white populations, P=0.54). Meta-regression analyses showed that the study effect size was not significantly associated with mean study age, body mass index, publication year, and length of follow-up.', metadata={'splits_id': '2', 'document_id': 'PMC7218708_abstract.txt'}),\n",
              " Document(page_content='Women with a history of GDM appear to have a nearly 10-fold higher risk of developing T2DM than those with a normoglycaemic pregnancy. The magnitude of this risk highlights the importance of intervening to prevent the onset of T2DM, particularly in the early years after pregnancy.\\nPROSPERO CRD42019123079.', metadata={'splits_id': '3', 'document_id': 'PMC7218708_abstract.txt'}),\n",
              " Document(page_content='Over the past few decades, the prevalence of Diabetes Mellitus (DM) has risen rapidly in Iran and other low and middle-income countries. We investigated the prevalence of DM, pre-diabetes, undiagnosed and uncontrolled diabetes and its relationship with some associated socioeconomic factors in the Yazd Greater Area in Iran.\\nYazd Health Study is a longitudinal study conducted to determine the prevalence of non-communicable disease and related risk factors. In a two-step cluster sampling, 10,000 adults aged 20–69\\u2009years (200 clusters) were selected. In the recruitment phase, DM was considered if the patients had been either diagnosed DM by a physician or had fasting blood glucose\\u2009≥\\u2009126\\u2009mg/dL. Chi square test was used for categorical variables to evaluate the differences and logistic regression model was applied to determine the predictors of diabetes.. P-value <\\u20090.05 considered statistically significant.', metadata={'splits_id': '0', 'document_id': 'PMC6998152_abstract.txt'}),\n",
              " Document(page_content='Of the 9965 individuals recruited, the crude self-reported prevalence of DM was 14.1% (95% CI: 13.4–14.7). The prevalence was higher in women than men (15.6 vs.12.4%), significantly. The age-standardized prevalence of DM was 8%. The prevalence was 14.9% in Yazd local people and 8.6% in those residents migrated from other provinces (P\\u2009<\\u20090.0001). We showed a significant association between DM prevalence and age, education, marital status, unemployment, insurance status, and positive family history (P\\u2009<\\u20090.0001). The prevalence of DM diagnosed by phycisians was 16.1% in participants (age-standardized prevalence: 8.3%). The subset analysis showed that 4.8% of patients were not aware of their disease. The prevalence of pre-diabetes was 25.8%. Of those with diabetes, 58.3% were not adequately controlled, which is not statistically significant with socio-economic status.', metadata={'splits_id': '1', 'document_id': 'PMC6998152_abstract.txt'}),\n",
              " Document(page_content='The current study showed a high prevalence of DM in Yazd Greater Area which is closely related to some socio-demographic factors. The high prevalence of pre-diabetes is alarming. Effective strategies for DM prevention should be introduced. The majority of people with diabetes are aware, but half of them are not controlled. The ineffective care plan currently in use, should be reviewed. Patients needs to be encouraged to improve their lifestyle. Active follow-up of patients is recommended to ensure continuity of care.', metadata={'splits_id': '2', 'document_id': 'PMC6998152_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus is a common disease in patients with cancer. It is a risk factor for certain cancers such as pancreatic, liver, colon, breast, and endometrial cancer. Furthermore, several new cancer treatments or the use of steroids may unmask underlying diabetes or aggravate preexisting diabetes. Evidence suggests that patients with cancer and diabetes have higher cancer-related mortality. Moreover, concurrent complications associated with diabetes in patients with cancer may influence the choice of cancer therapy. This review highlights the relationship between diabetes and cancer and various aspects of the management of diabetes in patients with cancer.', metadata={'splits_id': '0', 'document_id': 'PMC8616213_abstract.txt'}),\n",
              " Document(page_content='Background: Diabetes mellitus and cancer are commonly coexisting illnesses, and the global incidence and prevalence of both are rising. Cancer patients with diabetes face unique challenges. This review highlights the relationship between diabetes and cancer and various aspects of the management of diabetes in cancer patients. Methods: A literature search using keywords in PubMed was performed. Studies that were published in English prior to July 2021 were assessed and an overview of epidemiology, cancer risk, outcomes, treatment-related hyperglycemia and management of diabetes in cancer patients is provided. Results: Overall, 8–18% of cancer patients have diabetes as a comorbid medical condition. Diabetes is a risk factor for certain solid malignancies, such as pancreatic, liver, colon, breast, and endometrial cancer. Several novel targeted compounds and immunotherapies can cause hyperglycemia. Nevertheless, most patients undergoing cancer therapy can be managed with an appropriate', metadata={'splits_id': '1', 'document_id': 'PMC8616213_abstract.txt'}),\n",
              " Document(page_content='cancer therapy can be managed with an appropriate glucose lowering agent without the need for discontinuation of cancer treatment. Evidence suggests that cancer patients with diabetes have higher cancer-related mortality; therefore, a multidisciplinary approach is important in the management of patients with diabetes and cancer for a better outcome. Conclusions: Future studies are required to better understand the underlying mechanism between the risk of cancer and diabetes. Furthermore, high-quality prospective studies evaluating management of diabetes in cancer patients using innovative tools are needed. A patient-centered approach is important in cancer patients with diabetes to avoid adverse outcomes.', metadata={'splits_id': '2', 'document_id': 'PMC8616213_abstract.txt'}),\n",
              " Document(page_content='We investigated the serum levels of cytokines, including interleukin 1β (IL-β), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), and growth factors, including brain-derived neurotrophic factor, vascular endothelial growth factor, and insulin-like growth factor 1, and their association with major depression in patients with and without type 2 diabetes mellitus. We also investigated the response to antidepressant treatment in both groups.', metadata={'splits_id': '0', 'document_id': 'PMC8820450_abstract.txt'}),\n",
              " Document(page_content='Forty-one patients with major depression were recruited at the University Hospital of Occupational and Environmental Health. All patients were diagnosed with major depression using the Diagnostic and Statistical Manual for Mental Disorders, Fifth Edition. Type 2 diabetes mellitus was diagnosed according to the criteria of the Japan Diabetes Society. Six healthy controls with no history of psychiatric or physical diseases were also enrolled. Serum levels of several cytokines, growth factors, and high-sensitivity C-reactive protein (hs-CRP) were measured. The clinical symptoms of patients with major depression were assessed using the Montgomery-Asberg Depression Rating Scale.', metadata={'splits_id': '1', 'document_id': 'PMC8820450_abstract.txt'}),\n",
              " Document(page_content='Significant differences in cytokines, growth factors, and hs-CRP were observed between the major depression and healthy control groups. Serum TNF-α levels were significantly higher in patients with major depression and type 2 diabetes mellitus than in those without type 2 diabetes mellitus. In the major depression group, serum IL-6 and hs-CRP levels tended to be higher in patients with type 2 diabetes mellitus than in those without. Several correlations among cytokines, growth factors, and hs-CRP were observed in patients with major depression with and without type 2 diabetes mellitus. Responses to pharmacological interventions for major depression did not differ between patients with and without type 2 diabetes mellitus.', metadata={'splits_id': '2', 'document_id': 'PMC8820450_abstract.txt'}),\n",
              " Document(page_content='Serum levels of TNF-α, hs-CRP, and IL-6 were different between patients with major depression with and without type 2 diabetes mellitus. Also, correlations were found between serum levels of cytokines, growth factors, and hs-CRP in patients with major depression. Inflammatory factors, which may be associated with growth factors, may be involved in the pathophysiology of major depression, particularly among patients with comorbid type 2 diabetes mellitus.', metadata={'splits_id': '3', 'document_id': 'PMC8820450_abstract.txt'}),\n",
              " Document(page_content='Neonatal diabetes mellitus (NDM) is noted as a genetic, heterogeneous, and rare disease in infants. NDM occurs due to a single-gene mutation in neonates. A common source for developing NDM in an infant is the existence of mutations/variants in the KCNJ11 and ABCC8 genes, encoding the subunits of the voltage-dependent potassium channel. Both KCNJ11 and ABCC8 genes are useful in diagnosing monogenic diabetes during infancy. Genetic analysis was previously performed using first-generation sequencing techniques, such as DNA-Sanger sequencing, which uses chain-terminating inhibitors. Sanger sequencing has certain limitations; it can screen a limited region of exons in one gene, but it cannot screen large regions of the human genome. In the last decade, first generation sequencing techniques have been replaced with second-generation sequencing techniques, such as next-generation sequencing (NGS), which sequences nucleic-acids more rapidly and economically than Sanger sequencing. NGS', metadata={'splits_id': '0', 'document_id': 'PMC8455689_abstract.txt'}),\n",
              " Document(page_content='and economically than Sanger sequencing. NGS applications are involved in whole exome sequencing (WES), whole genome sequencing (WGS), and targeted gene panels. WES characterizes a substantial breakthrough in human genetics. Genetic testing for custom genes allows the screening of the complete gene, including introns and exons. The aim of this review was to confirm if the 22 genetic variations previously documented to cause NDM by Sanger sequencing could be detected using second generation sequencing techniques. The author has cross-checked global studies performed in NDM using NGS, ES/WES, WGS, and targeted gene panels as second-generation sequencing techniques; WES confirmed the similar variants, which have been previously documented with Sanger sequencing. WES is documented as a powerful tool and WGS as the most comprehensive test for verified the documented variants, as well as novel enhancers. This review recommends for the future studies should be performed with second', metadata={'splits_id': '1', 'document_id': 'PMC8455689_abstract.txt'}),\n",
              " Document(page_content='future studies should be performed with second generation sequencing techniques to identify the verified 22 genetic and novel variants by screening in NDM (PNDM or TNMD) children.', metadata={'splits_id': '2', 'document_id': 'PMC8455689_abstract.txt'}),\n",
              " Document(page_content='Neonatal diabetes mellitus (NDM), First-generation sequencing, DNA-Sanger sequencing, Second-generation sequencing, Next-generation sequencing (NGS), Exome sequencing (ES), Whole exome sequencing (WES), Whole genome sequencing (WGS), Targeted gene panels', metadata={'splits_id': '3', 'document_id': 'PMC8455689_abstract.txt'}),\n",
              " Document(page_content='Globally, diabetes is a major public health burden that results in more than 3.2 million adult deaths per year. Currently, diabetes is increasingly becoming a major threat to global public health, particularly in Sub-Saharan Africa. Although previous studies emphasized knowledge and health beliefs about diabetes among patients living with diabetes, there is minimal evidence about knowledge and perception of risk for developing diabetes at the community level.\\nThis study aimed to assess the knowledge and perception of diabetes mellitus and its associated factors among people in Debre Berhan town, northeast Ethiopia.', metadata={'splits_id': '0', 'document_id': 'PMC7571671_abstract.txt'}),\n",
              " Document(page_content='A community-based cross-sectional study was conducted among 423 participants. The study was carried out from 25 February to 10 March 2019. Data were collected using a structured pretested questionnaire through face-to-face interviews. Data were entered into Epi data V 3.1 and exported to SPSS V 24 for analysis. A variable with p< 0.2 in bivariable analysis was entered into multivariable logistic regression. During multivariate analysis, variables with a p value of ≤ 0.05 were considered significantly associated.', metadata={'splits_id': '1', 'document_id': 'PMC7571671_abstract.txt'}),\n",
              " Document(page_content='A total of 237 (56.02%) participants had good general knowledge about diabetes mellitus. In the multivariable analysis, participants who were single (AOR = 9.08, CI: 1.72–48), had a family history of diabetes (AOR = 2.83; CI: 1.10–7.24), and had exposure to health education (AOR = 3.27; CI: 2.02–5.31) were associated with good knowledge. In this study, few respondents (20.1%) felt that they had a higher risk of developing diabetes. Two-thirds of respondents (62.4%) saw diabetes is a serious disease. On the other hand, approximately 67% agreed to the perceived benefits of screening.', metadata={'splits_id': '2', 'document_id': 'PMC7571671_abstract.txt'}),\n",
              " Document(page_content='Almost half of the Debre Berhan community was found to have inadequate knowledge of diabetes mellitus. Married, higher educational status, exposure to health education, and family history of diabetes mellitus were significantly associated with good knowledge. The perceived risk of developing diabetes was low at the community level, although many respondents felt that behavior change is important in the prevention of diabetes. Therefore, policy makers, healthcare managers, and healthcare workers need to work cooperatively to foster community knowledge towards diabetes mellitus.', metadata={'splits_id': '3', 'document_id': 'PMC7571671_abstract.txt'}),\n",
              " Document(page_content='To evaluate the impact of treatment with recombinant human growth hormone (rhGH; Omnitrope®) on the risk of diabetes mellitus in adults with growth hormone deficiency (GHD), using data from the ongoing PATRO Adults post-marketing surveillance study.\\nPATRO Adults is an ongoing post-marketing surveillance study being conducted in hospitals and specialized endocrinology clinics across Europe. All enrolled patients who receive ≥1 dose of Omnitrope® are included in the safety population. Patient profiles, containing all available study database information for each specific patient, were generated for all patients with adverse events (AEs) of diabetes mellitus while participating in the study. Diabetes mellitus was confirmed if fasting plasma glucose was ≥7.0\\u2009mmol/L or 2-h plasma glucose ≥11.1\\u2009mmol/L during oral glucose tolerance test or glycated hemoglobin ≥6.5%.', metadata={'splits_id': '0', 'document_id': 'PMC6907272_abstract.txt'}),\n",
              " Document(page_content='Up to July 2018, 1293 patients had been enrolled in the study, and 983 (76.0%) remained active. Just under half (n\\u2009=\\xa0687, 49.3%) of the patients were growth hormone (GH) treatment-naïve on entering the study, and most (n\\u2009=\\xa01128, 87.2%) had multiple pituitary hormone deficiency (MPHD). Diabetes mellitus/inadequate control (worsening) of diabetes mellitus was reported in 21 patients (22 events). The cases were newly diagnosed in 15 patients (age 29–84\\u2009years; incidence rate 3.61 per 1000 patient-years) and occurred in 6 patients with pre-existing diabetes mellitus at baseline (age 45–72\\u2009years). Most cases of newly diagnosed diabetes mellitus occurred in patients with adult-onset MPHD (n\\xa0=\\u200913); the remaining cases of new-onset diabetes mellitus occurred in a patient with childhood-onset MPHD who had previously received GH replacement therapy (n\\u2009=\\xa01), and a patient with adulthood-onset isolated GHD who was naïve to GH replacement therapy (n\\u2009=\\xa01). All cases of inadequate control/worsening', metadata={'splits_id': '1', 'document_id': 'PMC6907272_abstract.txt'}),\n",
              " Document(page_content='All cases of inadequate control/worsening of diabetes mellitus occurred in patients with adult-onset MPHD.', metadata={'splits_id': '2', 'document_id': 'PMC6907272_abstract.txt'}),\n",
              " Document(page_content='Based on this snapshot of data from PATRO Adults, Omnitrope® treatment is tolerated in adult patients with GHD in a real-life clinical practice setting. No signals of an increased risk for diabetes mellitus have been noted so far, although continued follow-up (both during and after rhGH therapy) is required to confirm this.\\nNot applicable.', metadata={'splits_id': '3', 'document_id': 'PMC6907272_abstract.txt'}),\n",
              " Document(page_content='To investigate the genetic etiology and evaluate the diagnostic application of next‐generation sequencing for diabetes/persistent hyperglycemia in children and adolescents.\\nPatients with diabetes/persistent hyperglycemia, presenting with at least one other clinical manifestation (other than diabetes) or with a family history of diabetes, were recruited. The clinical and laboratory characteristics of the patients were recorded. Next‐generation sequencing was carried out, and candidate variants were verified by Sanger sequencing. Variant pathogenicity was further evaluated according to the American College of Medical Genetics and Genomics guidelines.', metadata={'splits_id': '0', 'document_id': 'PMC7779271_abstract.txt'}),\n",
              " Document(page_content='This study included 101 potential probands, 36 of whom were identified as positive by genetic testing. A further 51.2 and 20.9% of variants were determined to be pathogenic or likely pathogenic, respectively. Variants associated with the disease were primarily identified in 21 genes and three regions of copy number variants. Among the 39 variants in 21 genes, 61.5% (24/39) were novel. The genetic diagnosis of 23 patients was confirmed based on genetic evidence and associated clinical manifestations. We reported GCK variants (21.7%, 5/23) as the most common etiology in our cohort. Different clinical manifestations were observed in one family with WFS1 variants.\\nOur findings support the use of next‐generation sequencing as a standard method in patients with diabetes/persistent hyperglycemia and provide insights into the etiologies of these conditions.', metadata={'splits_id': '1', 'document_id': 'PMC7779271_abstract.txt'}),\n",
              " Document(page_content='Few studies have focused on examining the genetic etiology of diabetes in Chinese children and adolescents. A total of 101 potential probands were included in this study to investigate the clinical and genetic features of monogenic diabetes and genetic syndromes associated with it, and evaluate the diagnostic use of next‐generation sequencing for diabetes/persistent hyperglycemia. Our findings expand the gene mutation spectrum and phenotypic spectrum of the rare monogenic diabetes and genetic syndromes associated with diabetes, and provide insights into the current understanding of the underlying etiologies of diabetes/persistent hyperglycemia and support the use of next‐generation sequencing as a diagnostic method in Chinese patients with diabetes/persistent hyperglycemia.', metadata={'splits_id': '2', 'document_id': 'PMC7779271_abstract.txt'}),\n",
              " Document(page_content='Wolfram syndrome (WFS) is a rare autosomal recessive disease with clinical manifestations of diabetes mellitus (DM), diabetes insipidus (DI), optic nerve atrophy (OA) and sensorineural hearing loss (SNHL). Although SNHL is a key symptom of WFS, there is limited information on its natural history using standardized measures. Such information is important for clinical care and determining its use as an outcome measure in clinical trials.\\nStandardized audiologic measures, including pure-tone testing, tympanometry, speech perception, and the unaided Speech Intelligibility Index (SII) were assessed in patients with confirmed WFS annually. Mixed model analyses were used to examine main effects of age, time or interactions for pure tone average (PTA), high frequency average (HFA) and SII.', metadata={'splits_id': '0', 'document_id': 'PMC6020390_abstract.txt'}),\n",
              " Document(page_content='Forty WFS patients were evaluated between 1 and 6 times. Mean age at initial enrollment was 13.5\\xa0years (SD\\u2009=\\u20095.6). Patients were classified as having normal hearing (n\\xa0=\\u200910), mild-to-severe (n\\xa0=\\u200924) or profound SNHL (n\\xa0=\\u20096). Mean age of diagnosis for SNHL was 8.3\\xa0years (SD\\u2009=\\u20095.1) with 75% prevalence. HFA worsened over time for both ears, and SII worsened over time in the worse ear, with greater decline in both measures in younger patients. Average estimated change over 1\\xa0year for all measures was in the subclinical range and power analyses suggest that 100 patients would be needed per group (treatment vs. placebo) to detect a 60% reduction in annual change of HFA over 3\\xa0years. If trials focused on just those patients with SNHL, power estimates suggest 55 patients per group would be sufficient.', metadata={'splits_id': '1', 'document_id': 'PMC6020390_abstract.txt'}),\n",
              " Document(page_content='Most patients had a slow progressive SNHL emerging in late childhood. Change over time with standard audiologic tests (HFA, SII) was small and would not be detectable for at least 2\\xa0years in an individual. Relatively large sample sizes would be necessary to detect significant impact on hearing progression in a clinical trial. Hearing function should be monitored clinically in WFS to provide appropriate intervention. Because SNHL can occur very early in WFS, audiologists and otolaryngologists should be aware of and refer for later emerging symptoms.\\nThe online version of this article (10.1186/s13023-018-0852-0) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '2', 'document_id': 'PMC6020390_abstract.txt'}),\n",
              " Document(page_content='The aim of the present study was to compare the clinical and genetic characteristics between people with type\\xa01 diabetes who were positive and negative for autoantibodies against glutamic acid decarboxylase (GADA) measured by enzyme‐linked immunosorbent assay (ELISA) with low‐titer GADA measured by radioimmunoassay.\\nAmong Japanese people with type\\xa01 diabetes in whom GADA were measured by both ELISA and radioimmunoassay, those who had low titers of GADA measured by radioimmunoassay (1.5–10\\xa0U/mL), regardless of positivity for GADA measured by ELISA, were studied. There were 65 participants with acute‐onset type\\xa01 diabetes and 30 participants with slowly progressive insulin‐dependent diabetes mellitus. Clinical characteristics and human leukocyte antigen types were compared in ELISA‐positive (≥5\\xa0U/mL) and ELISA‐negative participants. Endogenous insulin secretion was evaluated by C‐peptide index.', metadata={'splits_id': '0', 'document_id': 'PMC7078079_abstract.txt'}),\n",
              " Document(page_content='Among participants with slowly progressive insulin‐dependent diabetes mellitus, postprandial C‐peptide index was significantly higher in ELISA‐negative participants than in ELISA‐positive participants (r\\xa0=\\xa00.619, P\\xa0=\\xa00.002). Among 52 participants whose human leukocyte antigen typing was carried out, all of the participants with slowly progressive insulin‐dependent diabetes mellitus who had DRB1*09:01 were positive by GADA‐ELISA (P\\xa0=\\xa00.021). In acute‐onset type\\xa01 diabetes participants, there were no significant differences for the C‐peptide index and human leukocyte antigen genotypes.\\nThe difference in the positivity for GADA‐ELISA might reflect cytotoxicity toward pancreatic β‐cells and preservation of endogenous insulin secretion in people with slowly progressive insulin‐dependent diabetes mellitus. We also suggest that the difference in the GADA‐ELISA‐specific epitope depends on the human leukocyte antigen genotype.', metadata={'splits_id': '1', 'document_id': 'PMC7078079_abstract.txt'}),\n",
              " Document(page_content='Boxplots of p‐CPI of SPIDDM participants who were GADA‐ELISA‐positive (left) and GADA‐ELISA‐negative (right) are shown. Central lines show medians; the upper and lower boxes represent the 25th and 75th percentiles, respectively; whiskers indicate minimum and maximum values, respectively. p‐CPI of GADA‐ELISA‐negative SPIDDM participants was significantly higher (p=0.0008, Mann‐Whitney U test).', metadata={'splits_id': '2', 'document_id': 'PMC7078079_abstract.txt'}),\n",
              " Document(page_content='Background: Diabetes mellitus (DM) is a common chronic disorder in children and is caused by absolute or relative insulin deficiency, with or without insulin resistance. There are several different forms of childhood DM. Children can suffer from neonatal diabetes mellitus (NDM), type 1 diabetes (T1DM), type 2 diabetes (T2DM), Maturity Onset Diabetes of the Young (MODY), autoimmune monogenic, mitochondrial, syndromic and as yet unclassified forms of DM. The Middle East has one of the highest incidences of several types of DM in children; however, it is unclear whether pediatric diabetes is an active area of research in the Middle East and if ongoing, which research areas are of priority for DM in children.\\nObjectives: To review the literature on childhood DM related to research in the Middle East, summarize results, identify opportunities for research and make observations and recommendations for collaborative studies in pediatric DM.', metadata={'splits_id': '0', 'document_id': 'PMC6882272_abstract.txt'}),\n",
              " Document(page_content='Methods: We conducted a thorough and systematic literature review by adhering to a list recommended by PRISMA. We retrieved original papers written in English that focus on childhood DM research, using electronic bibliographic databases containing publications from the year 2000 until October 2018. For our final assessment, we retrieved 429 full-text articles and selected 95 articles, based on our inclusion and exclusion criteria.', metadata={'splits_id': '1', 'document_id': 'PMC6882272_abstract.txt'}),\n",
              " Document(page_content='Results: Our literature review suggests that childhood DM research undertaken in the Middle East has focused mainly on reporting retrospective review of case notes, a few prospective case studies, systemic reviews, questionnaire-based studies, and case reports. These reported studies have focused mostly on the incidence/prevalence of different types of DM in childhood. No studies report on the establishment of National Childhood Diabetes Registries. There is a lack of consolidated studies focusing on national epidemiology data of different types of childhood DM (such as NDM, T1DM, T2DM, MODY, and syndromic forms) and no studies reporting on clinical trials in children with DM.\\nConclusions: Investing in and funding basic and translational childhood diabetes research and encouraging collaborative studies, will bring enormous benefits financially, economically, and socially for the whole of the Middle East region.', metadata={'splits_id': '2', 'document_id': 'PMC6882272_abstract.txt'}),\n",
              " Document(page_content='Diabetes kills more than 4.9 million adults per year. It becomes rapidly increasing, non-communicable disease—a major threat to global public health particularly in Sub-Saharan Africa. Though previous studies among diabetic patients were focused in health institution, limited knowledge, attitude and practice were seen. There is no study conducted about diabetes related to knowledge, attitudes, practice and associated factors in the community level.\\nThe study assessed knowledge, attitude, practices, and its associated factors towards diabetes mellitus among non diabetic community members of Bale Zone, Ethiopia.', metadata={'splits_id': '0', 'document_id': 'PMC5289457_abstract.txt'}),\n",
              " Document(page_content='Community based cross-sectional study was conducted from November 15 to December 15, 2015 among 605 non diabetic community members of Bale Zone administrative towns. Data was collected using pretested structured face-to-face interview after taking informed written consent. Respondents were selected by systematic random sampling. The data was entered into EPI data version 3.1 and analyzed using Statistical package for social sciences version 20. Odds ratio and 95% confidence interval were calculated and P<0.05 was considered statistically significant. Finally, multivariable logistic regression analysis was performed to indicate the independent predictors of knowledge, attitude and practice.', metadata={'splits_id': '1', 'document_id': 'PMC5289457_abstract.txt'}),\n",
              " Document(page_content='Response rate of the study was 98.2%. About 52.5% of participants were knowledgeable, 55.9% and 56.6% had good attitude and practice respectively. Earning average monthly family income of ≤500 Ethiopian birr (AOR = 0.4, CI = 0.2, 0.6) and 501–1000 (AOR = 0.4, CI = 0.2, 0.7), heard about diabetes (AOR = 4.4, CI = 1.9, 10.2), had diabetes health education exposure (AOR = 5, CI = 2.5, 9.7) resulted to have good diabetes knowledge. Student, (AOR = 5.1, CI = 2.1,12), government/private employee (AOR = 3,CI = 1.4,6.7), merchant (AOR = 2,CI = 1.1,3.6) and Knowledgeable (AOR = 3, CI = 2.1, 4.7) subjects had positive attitude towards diabetes. Having college and above educational level (AOR = 0.33, CI = 0.16, 0.7), having good attitude towards diabetes (AOR = 2, CI = 1.3, 3) had good practiced.\\nConsiderable limited knowledge, attitude and practices were seen. A great emphasis on health education regarding symptoms and risk factors modification for diabetes are necessary.', metadata={'splits_id': '2', 'document_id': 'PMC5289457_abstract.txt'}),\n",
              " Document(page_content='Three‐dimensional (3D) speckle tracking echocardiography can identify subclinical diabetic cardiomyopathy without geometric assumption and loss of speckle from out‐of‐plane motions. There is, however, significant heterogeneity among the previous reports. We performed a systematic review and meta‐analysis to compare 3D strain values between adults with asymptomatic, subclinical diabetes mellitus (ie, patients with diabetes mellitus without known clinical manifestations of cardiac disease) and healthy controls.', metadata={'splits_id': '0', 'document_id': 'PMC8649137_abstract.txt'}),\n",
              " Document(page_content='After systematic review of 5 databases, 12 valid studies (544 patients with diabetes mellitus and 489 controls) were eligible for meta‐analysis. Pooled means and mean difference (MD) using a random‐effects model for 3D global longitudinal, circumferential, radial, and area strain were calculated. Patients with diabetes mellitus had an overall 2.31 percentage points lower 3D global longitudinal strain than healthy subjects (16.6%, 95% CI, 15.7–17.6 versus 19.0; 95% CI, 18.2–19.7; MD, −2.31, 95% CI, −2.72 to −2.03). Similarly, 3D global circumferential strain (18.9%; 95% CI, 17.5–20.3 versus 20.5; 95% CI, 18.9–22.1; MD, −1.50; 95% CI, −2.09 to −0.91); 3D global radial strain (44.6%; 95% CI, 40.2–49.1 versus 48.2; 95% CI, 44.7–51.8; MD, −3.47; 95% CI, −4.98 to −1.97), and 3D global area strain (30.5%; 95% CI, 29.2–31.8 versus 32.4; 95% CI, 30.5–34.3; MD, −1.76; 95% CI, −2.74 to −0.78) were also lower in patients with diabetes mellitus. Significant heterogeneity was noted between studies', metadata={'splits_id': '1', 'document_id': 'PMC8649137_abstract.txt'}),\n",
              " Document(page_content='heterogeneity was noted between studies for all strain directions (inconsistency factor [I2], 37%–78%). Meta‐regression in subgroup analysis of studies using the most popular vendor found higher prevalence of hypertension as a significant contributor to worse 3D global longitudinal strain. Higher hemoglobulin A1c was the most significant contributor to worse 3D global circumferential strain in patients with diabetes mellitus.', metadata={'splits_id': '2', 'document_id': 'PMC8649137_abstract.txt'}),\n",
              " Document(page_content='Three‐dimensional myocardial strain was reduced in all directions in asymptomatic diabetic patients. Hypertension and hemoglobin A1c were associated with worse 3D global longitudinal strain and 3D global circumferential strain, respectively.\\nURL: https://www.crd.york.ac.uk/prospero; unique identifier: CRD42020197825.', metadata={'splits_id': '3', 'document_id': 'PMC8649137_abstract.txt'}),\n",
              " Document(page_content='Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disorder characterized by diabetes mellitus (DM), optic atrophy (OA), central diabetes insipidus (CDI) and deafness (D).\\nThe phenotype of the disease has been associated with several mutations in the WFS1 gene, a nuclear gene localized on chromosome 4. Since the discovery of the association between WFS1 gene and Wolfram syndrome, more than 150 mutations have been identified in WS patients.\\nWe previously described the first case of perinatal onset of Wolfram syndrome newborn carrying a segmental uniparental heterodysomy affecting the short arm of chromosome 4 responsible for a significant reduction in wolframin expression.\\nHere we review and discuss the pathophysiological mechanisms that we believe responsible for the perinatal onset of Wolfram syndrome as these data strongly suggest a role for WFS1 gene in foetal and neonatal neurodevelopment.', metadata={'splits_id': '0', 'document_id': 'PMC4422421_abstract.txt'}),\n",
              " Document(page_content='We described a male patient of 30\\xa0weeks’ gestation with intrauterine growth restriction and poly-hydramnios.\\nDuring the first days of life, the patient showed a 19% weight loss associated with polyuria and hypernatremia. The presence of persistent hypernatremia (serum sodium 150\\xa0mEq/L), high plasma osmolarity (322\\xa0mOsm/L) and low urine osmolarity (190\\xa0mOsm/l) with a Uosm/Posm ratio < 1 were consistent with CDI. The diagnosis of CDI was confirmed by the desmopressin test and the brain magnetic resonance imaging (MRI) at 34\\xa0weeks of age, that showed the lack of posterior pituitary hyperintense signal. In addition, a bilateral asymmetrical optic nerve hypoplasia associated with right orbital bone hypoplasia was observed, suggesting the diagnosis of WF.', metadata={'splits_id': '1', 'document_id': 'PMC4422421_abstract.txt'}),\n",
              " Document(page_content='During the five years follow-up the patient did not developed glucose intolerance or diabetes mellitus. By the end of the second year of life, primary non-autoimmune central hypothyroidism and mild neurodevelopment retardation were diagnosed.\\nThe analysis of our case, in the light of the most recent literature, suggests a possible role for WFS1 gene in the development of certain brain structures during the fetal period.\\nWolfram syndrome should be considered in the differential diagnosis of the rare cases of congenital central diabetes insipidus developed in the neonatal period.', metadata={'splits_id': '2', 'document_id': 'PMC4422421_abstract.txt'}),\n",
              " Document(page_content='The prevalence of neuropathic lesions in young patients with type 1 diabetes mellitus (T1DM) at the time of transition from pediatric care to adult-oriented diabetes care is poorly studied. A comparative study with healthy volunteers to assess the possible neuropathic condition of this special population and to identify the potential early screening needs has not been performed yet. The results may provide important feedback to pediatric diabetes care and a remarkable baseline reference point for further follow up in adult diabetes care.\\nTwenty-nine young patients with T1DM [age: 22.4 ± 2.9 years; HbA1c: 8.5 ± 2.1%, diabetes duration: 12.2 ± 5.8 years; (mean ± SD)] and 30 healthy volunteers (age: 21.5 ± 1.6 years; HbA1c: 5.3 ± 0.3%) were involved in the study. Autonomic function was assessed by standard cardiovascular reflex tests. Complex peripheral neuropathic testing was performed by Neurometer®, Neuropad®-test, Tiptherm®, Monofilament®, and Rydel-Seiffer tuning fork tests.', metadata={'splits_id': '0', 'document_id': 'PMC8430208_abstract.txt'}),\n",
              " Document(page_content='T1DM patients had significantly higher diastolic blood pressure than controls (80\\xa0± 9 vs. 74 ± 8 mmHg, p < 0.01), but there was no significant difference in systolic blood pressure (127 ± 26 vs. 121 ± 13 mmHg). Cardiovascular reflex tests had not revealed any significant differences between the T1DM patients and controls. No significant differences with Neurometer®, Neuropad®-test, and Monofilament® were detected between the two groups. The vibrational sensing on the radius on both sides was significantly impaired in the T1DM group compared to the controls with Rydel-Seiffer tuning fork test (right: 7.5 ± 1.0 vs. 7.9 ± 0.3; left: 7.5 ± 0.9 vs. 7.9 ± 0.3, p < 0.05). The Tiptherm®-test also identified a significant impairment in T1DM patients (11 sensing failures vs. 1, p < 0.001). In addition, the neuropathic complaints were significantly more frequently present in the T1DM patient group than in the controls (9 vs. 0, p < 0.01).', metadata={'splits_id': '1', 'document_id': 'PMC8430208_abstract.txt'}),\n",
              " Document(page_content='In this young T1DM population, cardiovascular autonomic neuropathy and cardiac morphological alterations could not be found. However, Rydel-Seiffer tuning fork and Tiptherm®-tests revealed peripheral sensory neurological impairments in young T1DM patients at the time of their transition to adult diabetes care.', metadata={'splits_id': '2', 'document_id': 'PMC8430208_abstract.txt'}),\n",
              " Document(page_content='Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes.', metadata={'splits_id': '0', 'document_id': 'PMC5512820_abstract.txt'}),\n",
              " Document(page_content='The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy.', metadata={'splits_id': '1', 'document_id': 'PMC5512820_abstract.txt'}),\n",
              " Document(page_content='Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.', metadata={'splits_id': '2', 'document_id': 'PMC5512820_abstract.txt'}),\n",
              " Document(page_content='There is increasing evidence that the lung is a target organ of diabetes. This study aimed to examine in detail the association between diabetes mellitus and pulmonary function using a national cohort. We also aimed to explore the non-linear association between pulmonary function and blood glucose, insulin resistance, and C-reactive protein (CRP).\\nA total of 30,442 participants from the National Health and Nutrition Examination Survey from the period between 2007 and 2012 were included. The cross-sectional association between diabetes mellitus and pulmonary function was assessed using multiple linear regression. Where there was evidence of non-linearity, we applied a restricted cubic spline with three knots to explore the non-linear association. Partial mediation analysis was performed to evaluate the underlying mechanism. All analyses were weighted to represent the US population and to account for the intricate survey design.', metadata={'splits_id': '0', 'document_id': 'PMC7641838_abstract.txt'}),\n",
              " Document(page_content='A total of 8584 people were included in the final study population. We found that diabetes was significantly associated with reduced forced expiratory volume in one second (FEV1) and forced vital capacity. We further found L-shaped associations between hemoglobin A1c (HbA1c) and pulmonary function. There was a negative association between HbA1c and FEV1 in diabetes participants with good glucose control (HbA1c\\u2009<\\u20097.0%), but not in patients with poor glucose control. A non-linear association was also found with fasting plasma glucose, 2\\xa0h-plasma glucose after oral glucose tolerance test, insulin resistance, and CRP. Finally, we found that diabetes duration did not affect pulmonary function, and the deleterious effect of diabetes on pulmonary function was mediated by hyperglycemia, insulin resistance, low-grade chronic inflammation (CRP), and obesity.', metadata={'splits_id': '1', 'document_id': 'PMC7641838_abstract.txt'}),\n",
              " Document(page_content='Diabetes mellitus is non-linearly associated with pulmonary function. Our finding of a negative association between HbA1c and FEV1 in diabetes patients with good glucose control but not in patients with poor glucose control indicates that a stricter glycemic target should be applied to diabetic patients to improve pulmonary function. Given, the cross-sectional nature of this research, a longitudinal study is still needed to validate our findings.', metadata={'splits_id': '2', 'document_id': 'PMC7641838_abstract.txt'}),\n",
              " Document(page_content='Smoking is a strong risk factor for albuminuria in people with type 2 diabetes mellitus (T2DM). However, it is unclear whether this sequela of smoking is brought about by its action on cardiometabolic parameters or the relationship is independent. The aim of this systematic review is to explore this relationship.\\nElectronic databases on cross-sectional and prospective studies in Medline and Embase were searched from January 1946 to May 2018. Adult smokers with T2DM were included, and other types of diabetes were excluded.', metadata={'splits_id': '0', 'document_id': 'PMC6597612_abstract.txt'}),\n",
              " Document(page_content='A random effects meta-analysis of 20,056 participants from 13 studies found that the odds ratio (OR) of smokers developing albuminuria compared to non-smokers was 2.13 (95% CI 1.32, 3.45). Apart from smoking, the odds ratio of other risk factors associated with albuminuria were: age 1.24 (95% CI 0.84, 1.64), male sex 1.39 (95% CI 1.16, 1.67), duration of diabetes 1.78 (95% CI 1.32, 2.23), HbA1c 0.63 (95% CI 0.45, 0.81), SBP 6.03 (95% CI 4.10, 7.97), DBP 1.85 (95% CI 1.08, 2.62), total cholesterol 0.06 (95% CI −\\u20090.05, 0.17) and HDL cholesterol −\\u20090.01 (95% CI −\\u20090.04, 0.02), triglyceride 0.22 (95% CI 0.12, 0.33) and BMI 0.40 (95% CI 0.00–0.80). When the smoking status was adjusted in a mixed effect meta-regression model, the duration of diabetes was the only statistically significant factor that influenced the prevalence of albuminuria. In smokers, each year’s increase in the duration of T2DM was associated with an increased risk of albuminuria of 0.19 units (95% CI 0.07, 0.31) on the', metadata={'splits_id': '1', 'document_id': 'PMC6597612_abstract.txt'}),\n",
              " Document(page_content='of 0.19 units (95% CI 0.07, 0.31) on the log odds scale or increased the odds approximately by 23%, compared to non-smokers. Prediction from the meta-regression model also suggested that the odds ratios of albuminuria in smokers after a diabetes duration of 9\\xa0years and 16\\xa0years were 1.53 (95% CI 1.10, 2.13) and 5.94 (95% CI 2.53, 13.95), respectively.', metadata={'splits_id': '2', 'document_id': 'PMC6597612_abstract.txt'}),\n",
              " Document(page_content='Continuing to smoke and the duration of diabetes are two strong predictors of albuminuria in smokers with T2DM. With a global surge in younger smokers developing T2DM, smoking cessation interventions at an early stage of disease trajectory should be promoted.\\nThe online version of this article (10.1007/s00592-019-01293-x) contains supplementary material, which is available to authorized users.', metadata={'splits_id': '3', 'document_id': 'PMC6597612_abstract.txt'}),\n",
              " Document(page_content='Asprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type\\xa02 diabetes mellitus.\\nWe recruited 60 patients with type\\xa02 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75‐g oral glucose tolerance test. Fasting and 2‐h postprandial serum asprosin concentrations were measured by the enzyme‐linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes.', metadata={'splits_id': '0', 'document_id': 'PMC7078095_abstract.txt'}),\n",
              " Document(page_content='Both fasting and postprandial asprosin levels were significantly higher in patients with type\\xa02 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type\\xa02 diabetes mellitus after multiple adjustment (odds ratio 2.329, P\\xa0=\\xa00.023). Asprosin correlated negatively with change in blood glucose (r\\xa0=\\xa0−0.502, P\\xa0<\\xa00.001) and change in C‐peptide (r\\xa0=\\xa0−0.467, P\\xa0<\\xa00.001) in individuals with NGT, but not in type\\xa02 diabetes mellitus patients.\\nSerum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type\\xa02 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type\\xa02 diabetes mellitus patients might be one of the reasons for the onset of type\\xa02 diabetes mellitus.', metadata={'splits_id': '1', 'document_id': 'PMC7078095_abstract.txt'}),\n",
              " Document(page_content='We found that serum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with normal glucose tolerance, whereas this circadian oscillation was disturbed in type\\xa02 diabetes patients. The response of asprosin to glucose fluctuation was impaired in type\\xa02 diabetes patients, which might be one of the reasons for the onset of type\\xa02 diabetes.', metadata={'splits_id': '2', 'document_id': 'PMC7078095_abstract.txt'}),\n",
              " Document(page_content='The treatment of asymptomatic hydronephrosis due to ureteropelvic junction obstruction (UPJO), as well as the timing and indications for surgical intervention, remain controversial. Diabetes insipidus (DI) is a rare disease in infants that is known to cause non-obstructive hydronephrosis, while its association with obstructive hydronephrosis has not been reported. Some studies have found that increased water intake is a predisposing risk factor of developing hydronephrosis. However, there are no studies or guidelines that indicate the specific follow-up intervals and surgical indications for mild hydronephrosis if predisposing risk factors persist. A 46-month-old boy was admitted to our Urology Department with a history of Society of Fetal Urology (SFU) Grade 2 prenatal left hydronephrosis, which was stable at SFU Grade 1–2 at regular postnatal follow-ups. The patient developed polydipsia and polyuria three months prior to admission, then he was considered as primary polydipsia by', metadata={'splits_id': '0', 'document_id': 'PMC8261591_abstract.txt'}),\n",
              " Document(page_content='then he was considered as primary polydipsia by endocrinology and was treated with fluid restriction while the examination was negative. Renal ultrasound at follow-up demonstrated severe left hydronephrosis with an anterior-posterior diameter (APD) of 6.25 cm three months after symptom onset. Diuretic renography (DR) revealed a renal function of 13.7% with a glomerular filtration rate (GFR) of 11.25 mL/min. The patient was otherwise asymptomatic without any abdominal pain or vomiting. He underwent left pyelostomy immediately as well as laparoscopic left dismembered ureteropelvioplasty after three months, and a diagnosis of UPJO was confirmed. The patient had an uncomplicated postoperative recovery and the result of follow-up renal ultrasound was stable. However, the symptoms of polydipsia and polyuria did not improve significantly. He underwent pituitary magnetic resonance imaging (MRI) and pathological examination, the results of which were consistent with central DI caused by', metadata={'splits_id': '1', 'document_id': 'PMC8261591_abstract.txt'}),\n",
              " Document(page_content='which were consistent with central DI caused by Langerhans cell hyperplasia four months postoperatively. This case indicates the need to pay attention to children with mild hydronephrosis undergoing regular observation and conservative treatment, as a sudden aggravation of the hydronephrosis and a rapid decline of renal function may occur if DI persists.', metadata={'splits_id': '2', 'document_id': 'PMC8261591_abstract.txt'}),\n",
              " Document(page_content='Permanent neonatal diabetes mellitus (PNDM) presents with dehydration and hyperglycemia, which usually occurs during the first 12 months of life. Activating mutations of beta-cell adenosine triphosphate-sensitive potassium [KATP] channel subunits that cause opening of the channel are associated with PNDM. Some patients with PNDM respond to administration of a sulfonylurea derivative, which has long action on blood glucose even during hypoglycemia and has an apoptotic effect on beta cells. However, there have been no reports regarding treatment with meglitinide (repaglinide), which has rapid and short duration of action during the rise in blood glucose after meals that is more similar to beta cell function. It has no effects during hypoglycemia, so it does not cause neurological damage, and has no apoptotic effect on beta cells. We report herein the effects of repaglinide administration in the management and clinical outcome of two patients with PNDM during 9 and 10 years of follow-up.', metadata={'splits_id': '0', 'document_id': 'PMC8543822_abstract.txt'}),\n",
              " Document(page_content='Two Iranian infants were brought to our institution with poor general condition, dehydration, lethargy, and poor feeding. They had diabetic ketoacidosis at 52 days and 3.5 months of age, respectively. Their genetic analysis revealed mutations in the KCNJ11 gene encoding KIR6.2, so they both had PNDM. After treatment of diabetic ketoacidosis with insulin, they responded to sulfonylurea (glibenclamide) treatment, but were switched to repaglinide because of blood sugar fluctuations in terms of hyper- and hypoglycemia. Repaglinide was administered with the dosage of 0.04 mg/kg/day divided before every meal. \\nThe patients were 10 and 9 years old at the last visit, with normal growth parameters. The values of self-monitored blood glucose were well-controlled, and the hemoglobin A1C (HbA1C) levels ranged from 3.6 to 6.4% during the follow-up period. There was no complication of diabetes, neurological disorder, or adverse effects related to repaglinide.', metadata={'splits_id': '1', 'document_id': 'PMC8543822_abstract.txt'}),\n",
              " Document(page_content='In every neonate or infant < 6 months of age with diabetes mellitus, PNDM should be considered. A trial of oral repaglinide can be performed and substituted for glibenclamide for prevention of hypoglycemia, neurological damage, and apoptosis of beta cells during long-term administration.', metadata={'splits_id': '2', 'document_id': 'PMC8543822_abstract.txt'}),\n",
              " Document(page_content='The worldwide prevalence of diabetes mellitus has been increasing over the past decades, particularly in developing countries. Because of the lack of information regarding changes in diabetes mellitus prevalence, awareness, treatment and control in rural China, we assessed these trends – overall and in the context of related health conditions – to explore the impact of these primary health issues on these rates in a poorly educated, rural population.\\nDiabetes mellitus prevalence, awareness, treatment and control rates were compared between two surveys carried out in 1992 and 2011. The residents of three villages, aged 35–64\\xa0years, were recruited for this study.', metadata={'splits_id': '0', 'document_id': 'PMC6944834_abstract.txt'}),\n",
              " Document(page_content='In 1992, 1,091 individuals were interviewed and, in 2011, 2,338 individuals were interviewed. Between the two surveys, the overall diabetes mellitus prevalence in the study population was lower in 1992 than that in 2011 (P\\xa0<\\xa00.001); among men, the prevalence was 5.2‐fold higher in 2011 than in 1992 (10.5 vs 1.7%) and nearly 4.3‐fold higher (11.2 vs 2.1%) among women. Men aged 35–44\\xa0years, with >6\\xa0years of education, stage\\xa0I hypertension and being overweight, had a higher prevalence of diabetes mellitus in 2011 than in 1992. Similarly, for the same time periods, there was also a higher diabetes mellitus prevalence among women aged 55–64\\xa0years, with 1–6\\xa0years of education, stage\\xa0III hypertension and who were overweight. However, there were no significant changes in diabetes mellitus awareness, treatment or control in this population.', metadata={'splits_id': '1', 'document_id': 'PMC6944834_abstract.txt'}),\n",
              " Document(page_content='These results suggest that particular efforts must be made to enhance diabetes mellitus prevention, control and public awareness in rural communities in China.\\nThe overall prevalence of diabetes mellitus increased significantly both in men and in women over the past two decades. In men, the prevalence of diabetes mellitus increased most significantly for those aged 35–44\\xa0years, with >6\\xa0years of education, having stage\\xa0I hypertension and being overweight; but for those aged 55–64\\xa0years, with 1–6\\xa0years of education, having stage\\xa0III hypertension and being overweight in women. However, there were no significant changes in diabetes mellitus awareness, treatment or control in this population.', metadata={'splits_id': '2', 'document_id': 'PMC6944834_abstract.txt'}),\n",
              " Document(page_content='To systematically review the risk factors for new‐onset diabetes mellitus after kidney transplantation, and to provide a theoretical basis for the prevention and management of new‐onset diabetes mellitus after kidney transplantation.\\nWe searched PubMed, Web of Science, Embase, the Cochrane Library databases and other databases for case–control studies related to risk factors for new‐onset diabetes mellitus after kidney transplantation published between January 2005 and July 2019. A meta‐analysis of data on risk factors for new‐onset diabetes mellitus after kidney transplantation from the included studies was carried out. A narrative review of risk factors for new‐onset diabetes mellitus after kidney transplantation was also carried out.', metadata={'splits_id': '0', 'document_id': 'PMC7779280_abstract.txt'}),\n",
              " Document(page_content='A total of 24 case–control studies were included in the meta‐analysis, with a total of 7,140 patients. There were 1,598 patients with new‐onset diabetes mellitus after kidney transplantation, and 5,542 patients without new‐onset diabetes mellitus after kidney transplantation. The meta‐analysis results showed that age, polycystic kidney disease, family history of diabetes, body mass index, acute rejection, tacrolimus use, hepatitis\\xa0B virus infection, hepatitis\\xa0C virus infection and hypertension were associated with new‐onset diabetes mellitus after kidney transplantation, whereas sex, sirolimus use, cyclosporin\\xa0A use, steroid use and cytomegalovirus infection were not associated with new‐onset diabetes mellitus after kidney transplantation.', metadata={'splits_id': '1', 'document_id': 'PMC7779280_abstract.txt'}),\n",
              " Document(page_content='Older age, body mass index, family history of diabetes, tacrolimus use, history of hypertension, polycystic kidney disease, acute rejection, hepatitis\\xa0B virus infection and hepatitis\\xa0C virus infection are risk factors for new‐onset diabetes mellitus after kidney transplantation. Therefore, the clinical implications of these factors warrant attention.\\nOlder age, body mass index, family history of diabetes, tacrolimus use, history of hypertension, polycystic kidney disease, acute rejection, hepatitis\\xa0B virus infection and hepatitis\\xa0C virus infection are risk factors for new‐onset diabetes mellitus after kidney transplantation. Therefore, the clinical implications of these factors warrant attention.', metadata={'splits_id': '2', 'document_id': 'PMC7779280_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 44
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "splitted_docs[:2]"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Ucp09gL9FUkx",
        "outputId": "0eba3f98-a5c7-4f66-cbbb-67babf861809"
      },
      "execution_count": 45,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetes mellitus is a group of diseases associated with various metabolic disorders, the main feature of which is chronic hyperglycemia due to insufficient insulin action. Its pathogenesis involves both genetic and environmental factors. The long‐term persistence of metabolic disorders can cause susceptibility to specific complications and also foster arteriosclerosis. Diabetes mellitus is associated with a broad range of clinical presentations, from being asymptomatic to ketoacidosis or coma, depending on the degree of metabolic disorder.\\nNote: Those that cannot at present be classified as any of the above are called unclassifiable.\\nThe occurrence of diabetes‐specific complications has not been confirmed in some of these conditions.\\nThe occurrence of diabetes‐specific complications has not been confirmed in some of these conditions.', metadata={'splits_id': '0', 'document_id': 'PMC4020724_abstract.txt'}),\n",
              " Document(page_content='\\u2002A scheme of the relationship between etiology (mechanism) and patho‐physiological stages (states) of diabetes mellitus. Arrows pointing right represent worsening of glucose metabolism disorders (including onset of diabetes mellitus). Among the arrow lines,  indicates the condition classified as ‘diabetes mellitus’. Arrows pointing left represent improvement in the glucose metabolism disorder. The broken lines indicate events of low frequency. For example, in type\\u20032 diabetes mellitus, infection can lead to ketoacidosis and require temporary insulin treatment for survival. Also, once diabetes mellitus has developed, it is treated as diabetes mellitus regardless of improvement in glucose metabolism, therefore, the arrow lines pointing left are filled in black. In such cases, a broken line is used, because complete normalization of glucose metabolism is rare.', metadata={'splits_id': '1', 'document_id': 'PMC4020724_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 45
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## JohnSnowLabsLangChainEmbedder"
      ],
      "metadata": {
        "id": "P0pWrA2pZ6aq"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from johnsnowlabs.llm import embedding_retrieval\n",
        "\n",
        "embeddings =  embedding_retrieval.JohnSnowLabsLangChainEmbedder('en.embed_sentence.instructor_base',\n",
        "                                                                hardware_target=\"gpu\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "o8z4sBVYFpu-",
        "outputId": "204f778c-311f-418c-9f40-633b3824f49f"
      },
      "execution_count": 46,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Spark Session already created, some configs may not take.\n",
            "Warning::Spark Session already created, some configs may not take.\n",
            "Warning::Spark Session already created, some configs may not take.\n",
            "instructor_base download started this may take some time.\n",
            "Approximate size to download 387.7 MB\n",
            "[OK!]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# embeddings.embed_query('test for something')"
      ],
      "metadata": {
        "id": "6QaRHesTawmV"
      },
      "execution_count": 47,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Vector Databases"
      ],
      "metadata": {
        "id": "EBRHMgSbzPzD"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "%%time\n",
        "from langchain.vectorstores import FAISS\n",
        "\n",
        "db = FAISS.from_documents(splitted_docs, embeddings)\n",
        "faiss_retriever = db.as_retriever(search_kwargs={\"k\": 3})\n",
        "#!zip -r faiss_retriever.zip faiss_retriever"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Lo6eXmqwzHHd",
        "outputId": "d6835848-dc4c-41c6-ce2e-ed3c42c75f15"
      },
      "execution_count": 48,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Warning::Spark Session already created, some configs may not take.\n",
            "CPU times: user 244 ms, sys: 30.2 ms, total: 274 ms\n",
            "Wall time: 23.9 s\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "relevavant_docs = faiss_retriever.get_relevant_documents(\"causes of diabetes\")\n",
        "len(relevavant_docs)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "uZnLK8v9zZDN",
        "outputId": "54939458-ff86-40f6-a769-9cf1d3db9b9e"
      },
      "execution_count": 49,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "3"
            ]
          },
          "metadata": {},
          "execution_count": 49
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "relevavant_docs"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2IxVaPMh6Ci1",
        "outputId": "8fb62463-1c92-4a31-cd4a-19394942bfea"
      },
      "execution_count": 50,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetic patients, during the course of the disease, are most likely to experience depressive symptoms that might ultimately lead to suicidal ideation or suicide. The size of literature in diabetes depression/suicide is a good indicator of national and international efforts to address psychological co-morbidities associated with diabetes mellitus (DM). Therefore, the objective of this study was to give a comprehensive analysis, both quantitative and qualitative, of scientific literature in diabetes depression/suicide.\\nSciVerse Scopus was used to retrieve relevant literature up to 2016.', metadata={'splits_id': '0', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='Background: Diabetes mellitus (DM) is a common chronic disorder in children and is caused by absolute or relative insulin deficiency, with or without insulin resistance. There are several different forms of childhood DM. Children can suffer from neonatal diabetes mellitus (NDM), type 1 diabetes (T1DM), type 2 diabetes (T2DM), Maturity Onset Diabetes of the Young (MODY), autoimmune monogenic, mitochondrial, syndromic and as yet unclassified forms of DM. The Middle East has one of the highest incidences of several types of DM in children; however, it is unclear whether pediatric diabetes is an active area of research in the Middle East and if ongoing, which research areas are of priority for DM in children.\\nObjectives: To review the literature on childhood DM related to research in the Middle East, summarize results, identify opportunities for research and make observations and recommendations for collaborative studies in pediatric DM.', metadata={'splits_id': '0', 'document_id': 'PMC6882272_abstract.txt'}),\n",
              " Document(page_content='We present a case of central diabetes insipidus (DI) secondary to neurosarcoidosis. The path to final diagnosis was challenging. Along with reporting the case, we review the available medical literature relating to neurosarcoidosis and central diabetes insipidus\\xa0in this case report. Patient is a 56-year-old female with notable history of rheumatoid arthritis, anxiety, asthma, hypertension, spinal stenosis, and seizures of unknown etiology who presented to the emergency department for worsening headache for one week. She also endorsed decreased vision, photophobia, nausea, vomiting, gait abnormality, polyuria, and polydipsia over the past three months. Physical exam and neurological exam were unremarkable. Labs on presentation were notable for hypernatremia, increased serum osmolality and urine output of 5 L/day. Given her persistent headache and history of seizure, she underwent a CT head without contrast which showed a posterior suprasellar soft tissue fullness measuring 6 mm in the', metadata={'splits_id': '0', 'document_id': 'PMC7682679_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 50
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {},
          "inputWidgets": {},
          "nuid": "7802bbd1-8e62-4201-a797-5bba56a0b5f8",
          "showTitle": false,
          "title": ""
        },
        "id": "Saq9k56LiLfT"
      },
      "source": [
        "## OpenAI"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 51,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "2e76d286-2a28-4505-a4c4-5b2e212f5926",
          "showTitle": false,
          "title": ""
        },
        "id": "D925E-F8iN3p"
      },
      "outputs": [],
      "source": [
        "from langchain.chat_models import ChatOpenAI\n",
        "from langchain.chains import RetrievalQA\n",
        "\n",
        "# completion llm\n",
        "llm = ChatOpenAI(\n",
        "    openai_api_key=OPENAI_API_KEY,\n",
        "    model_name='gpt-3.5-turbo-16k',\n",
        "    temperature=0.0\n",
        ")\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 52,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "c789c17b-daa4-4a04-a9fc-e7c73f09d116",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NKYuq8KTbg-m",
        "outputId": "a136f678-cc4e-4771-a226-3acd043fb5d3"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The causes of diabetes can vary depending on the type of diabetes. \n",
            "\n",
            "Type 1 diabetes is believed to be caused by an autoimmune reaction in which the body's immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. The exact cause of this autoimmune reaction is not known, but it is thought to involve a combination of genetic and environmental factors.\n",
            "\n",
            "Type 2 diabetes is primarily caused by a combination of genetic and lifestyle factors. It is often associated with obesity, physical inactivity, and poor diet. Genetic factors can also play a role in determining a person's risk of developing type 2 diabetes.\n",
            "\n",
            "Other forms of diabetes, such as gestational diabetes and certain types of monogenic diabetes, have their own specific causes and risk factors.\n",
            "\n",
            "It's important to note that while certain factors can increase the risk of developing diabetes, it does not mean that everyone with these risk factors will develop the disease. Additionally, there may be other factors involved in the development of diabetes that are not yet fully understood.\n"
          ]
        }
      ],
      "source": [
        "qa_chain = RetrievalQA.from_chain_type(\n",
        "    llm,\n",
        "    retriever=faiss_retriever,\n",
        "    return_source_documents=True\n",
        "    )\n",
        "\n",
        "question = \"causes for diabetes?\"\n",
        "result = qa_chain({\"query\": question})\n",
        "\n",
        "print (result['result'])"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {},
          "inputWidgets": {},
          "nuid": "ecfe7a57-552e-4c9e-bb50-470dbc50797c",
          "showTitle": false,
          "title": ""
        },
        "id": "nFEGg-Qmrh7A"
      },
      "source": [
        "### PromptTemplate"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 53,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "f7042c40-5986-4128-8b6a-dd4183c9bbab",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 53
        },
        "id": "PgMFZ-92gqgy",
        "outputId": "8d8bf431-5ecd-4d26-f96f-3f71ade777b3"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"Use the following pieces of context to answer the user's question. \\nIf you don't know the answer, just say that you don't know, don't try to make up an answer.\\n----------------\\n{context}\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 53
        }
      ],
      "source": [
        "qa_chain.combine_documents_chain.llm_chain.prompt.messages[0].prompt.template\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 54,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "f8443450-1be5-4b2c-887d-b93c108d9210",
          "showTitle": false,
          "title": ""
        },
        "id": "dPhHjR5BhSYx"
      },
      "outputs": [],
      "source": [
        "from langchain.prompts import PromptTemplate\n",
        "\n",
        "new_template = \"\"\"\n",
        "Use the following pieces of context to answer the user's question. If you return an answer, end with 'It's my pleasure'.\n",
        "If you don't know the answer, just say that you don't know, don't try to make up an answer .\n",
        "{context}\n",
        "Question: {question}\n",
        "Helpful Answer:\"\"\"\n",
        "\n",
        "QA_CHAIN_PROMPT = PromptTemplate.from_template(new_template)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 55,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "0b803f1b-2814-418f-91d5-f5a0d8d50790",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Ditu0Im1gXGH",
        "outputId": "f0535225-4a95-4cbf-e231-5dc3fac897d6"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "The causes of diabetes can vary depending on the type of diabetes. Type 1 diabetes is believed to be caused by an autoimmune reaction where the body's immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. The exact cause of type 2 diabetes is not fully understood, but it is thought to involve a combination of genetic and lifestyle factors, such as obesity and lack of physical activity. It's my pleasure to help!\n"
          ]
        }
      ],
      "source": [
        "qa_chain = RetrievalQA.from_chain_type(\n",
        "    llm,\n",
        "    retriever=faiss_retriever,\n",
        "    return_source_documents=True,\n",
        "    chain_type_kwargs={\"prompt\": QA_CHAIN_PROMPT}\n",
        ")\n",
        "\n",
        "question = \"causes for diabetes?\"\n",
        "result = qa_chain({\"query\": question})\n",
        "\n",
        "print(result['result'])"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 56,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "cf72c679-5630-4407-a0a3-b5edbf86e096",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 143
        },
        "id": "ehUqOEZCjSiC",
        "outputId": "fecd94a9-c5fd-46ac-8e1d-d8339c3bdb5d"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "  splits_id              document_id\n",
              "0         0  PMC6198430_abstract.txt\n",
              "1         0  PMC6882272_abstract.txt\n",
              "2         0  PMC7054376_abstract.txt"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-dd2e9ad3-fe8a-405e-bd5a-2254c048df2d\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>splits_id</th>\n",
              "      <th>document_id</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>0</td>\n",
              "      <td>PMC6198430_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>0</td>\n",
              "      <td>PMC6882272_abstract.txt</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>0</td>\n",
              "      <td>PMC7054376_abstract.txt</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-dd2e9ad3-fe8a-405e-bd5a-2254c048df2d')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-dd2e9ad3-fe8a-405e-bd5a-2254c048df2d button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-dd2e9ad3-fe8a-405e-bd5a-2254c048df2d');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "<div id=\"df-1c988fae-0277-4add-bfe3-3d0bdd3422c0\">\n",
              "  <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-1c988fae-0277-4add-bfe3-3d0bdd3422c0')\"\n",
              "            title=\"Suggest charts\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "  </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "  <script>\n",
              "    async function quickchart(key) {\n",
              "      const quickchartButtonEl =\n",
              "        document.querySelector('#' + key + ' button');\n",
              "      quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "      quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "      try {\n",
              "        const charts = await google.colab.kernel.invokeFunction(\n",
              "            'suggestCharts', [key], {});\n",
              "      } catch (error) {\n",
              "        console.error('Error during call to suggestCharts:', error);\n",
              "      }\n",
              "      quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "      quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "    }\n",
              "    (() => {\n",
              "      let quickchartButtonEl =\n",
              "        document.querySelector('#df-1c988fae-0277-4add-bfe3-3d0bdd3422c0 button');\n",
              "      quickchartButtonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "    })();\n",
              "  </script>\n",
              "</div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"pd\",\n  \"rows\": 3,\n  \"fields\": [\n    {\n      \"column\": \"splits_id\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"0\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"document_id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 3,\n        \"samples\": [\n          \"PMC6198430_abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 56
        }
      ],
      "source": [
        "pd.DataFrame([doc.metadata for doc in result['source_documents']])"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "relevavant_docs"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "y5NPDn7X6_yC",
        "outputId": "425e2b31-8d68-4ba8-9dfb-1f7720b03553"
      },
      "execution_count": 57,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetic patients, during the course of the disease, are most likely to experience depressive symptoms that might ultimately lead to suicidal ideation or suicide. The size of literature in diabetes depression/suicide is a good indicator of national and international efforts to address psychological co-morbidities associated with diabetes mellitus (DM). Therefore, the objective of this study was to give a comprehensive analysis, both quantitative and qualitative, of scientific literature in diabetes depression/suicide.\\nSciVerse Scopus was used to retrieve relevant literature up to 2016.', metadata={'splits_id': '0', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='Background: Diabetes mellitus (DM) is a common chronic disorder in children and is caused by absolute or relative insulin deficiency, with or without insulin resistance. There are several different forms of childhood DM. Children can suffer from neonatal diabetes mellitus (NDM), type 1 diabetes (T1DM), type 2 diabetes (T2DM), Maturity Onset Diabetes of the Young (MODY), autoimmune monogenic, mitochondrial, syndromic and as yet unclassified forms of DM. The Middle East has one of the highest incidences of several types of DM in children; however, it is unclear whether pediatric diabetes is an active area of research in the Middle East and if ongoing, which research areas are of priority for DM in children.\\nObjectives: To review the literature on childhood DM related to research in the Middle East, summarize results, identify opportunities for research and make observations and recommendations for collaborative studies in pediatric DM.', metadata={'splits_id': '0', 'document_id': 'PMC6882272_abstract.txt'}),\n",
              " Document(page_content='We present a case of central diabetes insipidus (DI) secondary to neurosarcoidosis. The path to final diagnosis was challenging. Along with reporting the case, we review the available medical literature relating to neurosarcoidosis and central diabetes insipidus\\xa0in this case report. Patient is a 56-year-old female with notable history of rheumatoid arthritis, anxiety, asthma, hypertension, spinal stenosis, and seizures of unknown etiology who presented to the emergency department for worsening headache for one week. She also endorsed decreased vision, photophobia, nausea, vomiting, gait abnormality, polyuria, and polydipsia over the past three months. Physical exam and neurological exam were unremarkable. Labs on presentation were notable for hypernatremia, increased serum osmolality and urine output of 5 L/day. Given her persistent headache and history of seizure, she underwent a CT head without contrast which showed a posterior suprasellar soft tissue fullness measuring 6 mm in the', metadata={'splits_id': '0', 'document_id': 'PMC7682679_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 57
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 58,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "7179cb3b-62e5-4c78-8782-d7c0fc04741e",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "oUO3TbCUfELi",
        "outputId": "6ae29408-c254-4c44-ce14-a013bb5c89cc"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetic patients, during the course of the disease, are most likely to experience depressive symptoms that might ultimately lead to suicidal ideation or suicide. The size of literature in diabetes depression/suicide is a good indicator of national and international efforts to address psychological co-morbidities associated with diabetes mellitus (DM). Therefore, the objective of this study was to give a comprehensive analysis, both quantitative and qualitative, of scientific literature in diabetes depression/suicide.\\nSciVerse Scopus was used to retrieve relevant literature up to 2016.', metadata={'splits_id': '0', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='with SMBG three or more times daily and diabetes duration of 1 to <5\\xa0years.', metadata={'splits_id': '2', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes insipidus (DI) is a rare complication of pregnancy, usually developing in the third trimester and remitting spontaneously 4–6 weeks post-partum. It is mainly caused by excessive vasopressinase activity, an enzyme expressed by placental trophoblasts which metabolises arginine vasopressin (AVP). Its diagnosis is challenging, and the treatment requires desmopressin. A 38-year-old Chinese woman was referred in the 37th week of her first single-gestation due to polyuria, nocturia and polydipsia. She was known to have gestational diabetes mellitus diagnosed in the second trimester, well-controlled with diet. Her medical history was unremarkable. Physical examination demonstrated decreased skin turgor; her blood pressure was 102/63\\u200ammHg, heart rate 78\\u200abeats/min and weight 53\\u200akg (BMI 22.6\\u200akg/m2). Laboratory data revealed low urine osmolality 89\\u200amOsmol/kg (350–1000), serum osmolality 293\\u200amOsmol/kg (278–295), serum sodium 144\\u200ammol/l (135–145), potassium 4.1\\u200ammol/l (3.5–5.0),', metadata={'splits_id': '0', 'document_id': 'PMC4626653_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 58
        }
      ],
      "source": [
        "# Retrieve more documents with higher diversity\n",
        "# Useful if your dataset has many similar documents\n",
        "\n",
        "#lambda_mult – Number between 0 and 1 that determines the degree of diversity among the results with 0 corresponding to maximum diversity and 1 to minimum diversity. Defaults to 0.5.\n",
        "\n",
        "faiss_retriever_ = db.as_retriever(search_type=\"mmr\",\n",
        "    search_kwargs={'k': 6,\n",
        "                   'lambda_mult': 0.25})\n",
        "\n",
        "faiss_retriever_.get_relevant_documents(\"causes of diabetes\")[:3]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 59,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "56bd80b1-5f72-464d-8f08-46cda59608d4",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Qctprin7feVC",
        "outputId": "5023b41f-c74c-4df0-c806-e39db8a3410f"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Diabetic patients, during the course of the disease, are most likely to experience depressive symptoms that might ultimately lead to suicidal ideation or suicide. The size of literature in diabetes depression/suicide is a good indicator of national and international efforts to address psychological co-morbidities associated with diabetes mellitus (DM). Therefore, the objective of this study was to give a comprehensive analysis, both quantitative and qualitative, of scientific literature in diabetes depression/suicide.\\nSciVerse Scopus was used to retrieve relevant literature up to 2016.', metadata={'splits_id': '0', 'document_id': 'PMC6198430_abstract.txt'}),\n",
              " Document(page_content='with SMBG three or more times daily and diabetes duration of 1 to <5\\xa0years.', metadata={'splits_id': '2', 'document_id': 'PMC8015826_abstract.txt'}),\n",
              " Document(page_content='Gestational diabetes insipidus (DI) is a rare complication of pregnancy, usually developing in the third trimester and remitting spontaneously 4–6 weeks post-partum. It is mainly caused by excessive vasopressinase activity, an enzyme expressed by placental trophoblasts which metabolises arginine vasopressin (AVP). Its diagnosis is challenging, and the treatment requires desmopressin. A 38-year-old Chinese woman was referred in the 37th week of her first single-gestation due to polyuria, nocturia and polydipsia. She was known to have gestational diabetes mellitus diagnosed in the second trimester, well-controlled with diet. Her medical history was unremarkable. Physical examination demonstrated decreased skin turgor; her blood pressure was 102/63\\u200ammHg, heart rate 78\\u200abeats/min and weight 53\\u200akg (BMI 22.6\\u200akg/m2). Laboratory data revealed low urine osmolality 89\\u200amOsmol/kg (350–1000), serum osmolality 293\\u200amOsmol/kg (278–295), serum sodium 144\\u200ammol/l (135–145), potassium 4.1\\u200ammol/l (3.5–5.0),', metadata={'splits_id': '0', 'document_id': 'PMC4626653_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 59
        }
      ],
      "source": [
        "# Fetch more documents for the MMR algorithm to consider\n",
        "# But only return the top 5\n",
        "# fetch_k – Number of Documents to fetch before filtering to pass to MMR algorithm.\n",
        "\n",
        "faiss_retriever_ = db.as_retriever(\n",
        "    search_type=\"mmr\",\n",
        "    search_kwargs={'k': 5, 'fetch_k': 50}\n",
        ")\n",
        "\n",
        "faiss_retriever_.get_relevant_documents(\"causes of diabetes\")[:3]"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "search_type=\"similarity_score_threshold\","
      ],
      "metadata": {
        "id": "ubnw7cwy8K24"
      },
      "execution_count": 60,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": 61,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "f9333e16-4569-42e2-a8af-84a5f8fe1148",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 105
        },
        "id": "MeZOpHZNhJ8u",
        "outputId": "54cf1a28-ce8f-43e5-b230-e7ac0df29492"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"The context provided suggests that there is a relationship between diabetes and obesity. The prevalence of Type 2 diabetes mellitus and obesity has increased over time, and there is a significant association between BMI increase and Type 2 diabetes mellitus prevalence. Additionally, the study mentioned in the context aims to analyze the literature on diabetes depression/suicide, indicating that psychological co-morbidities are associated with diabetes mellitus. Therefore, it can be inferred that there is a relationship between diabetes and obesity, with obesity being a risk factor for the development of Type 2 diabetes mellitus. It's my pleasure to help!\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 61
        }
      ],
      "source": [
        "question = \"relationship between diabetes and obesity\"\n",
        "\n",
        "qa_chain({\"query\": question})['result']"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 62,
      "metadata": {
        "application/vnd.databricks.v1+cell": {
          "cellMetadata": {
            "byteLimit": 2048000,
            "rowLimit": 10000
          },
          "inputWidgets": {},
          "nuid": "c3edcda3-b456-4684-851a-97e989c957f1",
          "showTitle": false,
          "title": ""
        },
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 53
        },
        "id": "11t6nF9Ci5D8",
        "outputId": "3f466381-ae06-4071-ccf8-0898b6366ebe"
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\"Based on the provided context, the information does not directly address the mortality rates of childhood diabetes. Therefore, it is unclear what the specific relationship is between childhood diabetes and mortality. It's my pleasure to assist you.\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 62
        }
      ],
      "source": [
        "question = \"childhood diabetes and mortality\"\n",
        "\n",
        "qa_chain({\"query\": question})['result']"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Zephyr"
      ],
      "metadata": {
        "id": "bDaJyd_09pyg"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.llms import CTransformers\n",
        "from langchain.callbacks.streaming_stdout import StreamingStdOutCallbackHandler\n",
        "\n",
        "llm = CTransformers(model=\"TheBloke/zephyr-7B-beta-GGUF\",\n",
        "                    model_file = 'zephyr-7b-beta.Q4_0.gguf',\n",
        "                    model_type=\"mistral\",\n",
        "                    temperature = 0.01,\n",
        "                    max_new_tokens = 250,\n",
        "                    context_length = 500,\n",
        "                    lib=\"avx2\", #for CPU use\n",
        "                    callbacks=[StreamingStdOutCallbackHandler()])"
      ],
      "metadata": {
        "id": "b4I3rPRh8Y3u"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "db = FAISS.from_documents(splitted_docs, embeddings)\n",
        "faiss_retriever = db.as_retriever(search_kwargs={\"k\": 1})"
      ],
      "metadata": {
        "id": "iMo1VNY6_9CY"
      },
      "execution_count": 81,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "qa_chain_faiss = RetrievalQA.from_chain_type(\n",
        "    llm=llm,\n",
        "    retriever=faiss_retriever,\n",
        "    return_source_documents=True,\n",
        "    chain_type_kwargs={\"prompt\": QA_CHAIN_PROMPT}\n",
        ")"
      ],
      "metadata": {
        "id": "nwegY1gEHvGQ"
      },
      "execution_count": 82,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "question = \"relationship between diabetes and obesity\"\n",
        "\n",
        "qa_result = qa_chain_faiss({\"query\": question})['result']"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "E8IKfg1W9zRF",
        "outputId": "3e922e20-6f3a-4304-ccc2-2534fe836b45"
      },
      "execution_count": 85,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " Yes, there is a strong relationship between diabetes and obesity. Over the past several decades, both the prevalence of diabetes and obesity have increased rapidly, and studies have consistently shown that obesity is a major risk factor for developing diabetes. In fact, it's estimated that up to 90% of people with type 2 diabetes are overweight or obese. This suggests that addressing obesity through lifestyle changes such as diet and exercise may be an effective way to prevent and manage diabetes."
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "faiss_retriever.get_relevant_documents(question)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Zzt9yFcb93J1",
        "outputId": "6971df88-9094-4947-bb0e-008951da0db8"
      },
      "execution_count": 75,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Over 1978–2013, Type 2 diabetes mellitus prevalence increased from 1.2% to 19.6% in men (2.3% per 5 years), and from 2.2% to 19.5% in women (2.2% per 5 years). Obesity prevalence increased from 27.7% to 53.1% in men (3.6% per 5 years) and from 44.4% to 76.7% (4.5% per 5 years) in women. Type 2 diabetes mellitus and obesity prevalences increased in all age groups. From period trends, Type 2 diabetes mellitus prevalence in 2020 is projected to be 26% in men and women. Projected obesity prevalence is projected to be 59% in men and 81% in women. Type 2 diabetes mellitus period trends attributable to BMI increase are estimated as 31% (men) and 16% (women), after adjusting for age.', metadata={'splits_id': '1', 'document_id': 'PMC5411261_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 75
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Llama-2"
      ],
      "metadata": {
        "id": "ilznJsWrLK1G"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "Split size (k) cannot be set larger than 2-3 due to the context limit of LLama-2 (max context = 4096) as we join all the splits and send to LLM along with system prompt andf query. That's why we could only set k=3."
      ],
      "metadata": {
        "id": "WNxopHQxLJwT"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain.prompts import PromptTemplate\n",
        "\n",
        "new_template = \"\"\"\n",
        "Use the following pieces of context to answer the user's question. If you return an answer, end with 'It's my pleasure'.\n",
        "If you don't know the answer, just say that you don't know, don't try to make up an answer .\n",
        "{context}\n",
        "Question: {question}\n",
        "Helpful Answer:\"\"\"\n",
        "\n",
        "QA_CHAIN_PROMPT = PromptTemplate.from_template(new_template)\n",
        "\n",
        "\n",
        "from langchain.llms import CTransformers\n",
        "from langchain.callbacks.streaming_stdout import StreamingStdOutCallbackHandler\n",
        "\n",
        "llm = CTransformers(model=\"TheBloke/Llama-2-7B-Chat-GGUF\",\n",
        "                    model_file = 'llama-2-7b-chat.Q4_0.gguf',\n",
        "                    model_type=\"llama\",\n",
        "                    config={'temperature': 0.01,\n",
        "                            'max_new_tokens': 512,\n",
        "                            'context_length': 500\n",
        "                            },\n",
        "                    callbacks=[StreamingStdOutCallbackHandler()]\n",
        "                    )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 81,
          "referenced_widgets": [
            "f21302207e0146d7be7734e6d9cfcfd8",
            "4f4265ac12dc483f87f559b131f32b76",
            "1419cf2aef4343a49555b4b01d06230e",
            "47f61aca78004636b9bb48f5d86f1594",
            "4a89a05fa79d4104bc3e723ec49b23e1",
            "58a25e5ba197445397598cac5539a1fe",
            "59193fdd30134684a5d02d3788da6715",
            "b22865d149ba4ce99986bf0df507c13a",
            "291f02dbd90741899def31d164a37f56",
            "0e8810540e6643728ee71b2142ef5fca",
            "6ee403ddc58e49e39df8cb3cdae317dc",
            "446b49a3fb294014ab5f731280626527",
            "8a4360f56e51436a846ed008d84a61ea",
            "95782e837a384a588d11f50469cc7231",
            "9ee925afe77c4dca94a2cbd205683035",
            "284002f8dce5412dba9b1cec6a234bbc",
            "9e4aa572fef44fd9b53e8453520d2469",
            "be91ac0a99684828a1db722d1f210eac",
            "7315c82c6020408aaa85ee72844a6cee",
            "7108cd99da8e409a917dfe85ea04849f",
            "107aeded299b4fdf87d996c9323c5ddd",
            "4e75b56b93b1441eabac0591e124d9e9"
          ]
        },
        "id": "mveRFpV5LHtp",
        "outputId": "8c5d5db3-9cec-49d6-b52a-e93be1a9382b"
      },
      "execution_count": 78,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Fetching 1 files:   0%|          | 0/1 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "f21302207e0146d7be7734e6d9cfcfd8"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Fetching 1 files:   0%|          | 0/1 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "446b49a3fb294014ab5f731280626527"
            }
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "from langchain.chains import RetrievalQA\n",
        "\n",
        "qa_chain_faiss = RetrievalQA.from_chain_type(\n",
        "    llm=llm,\n",
        "    retriever=faiss_retriever,\n",
        "    return_source_documents=True,\n",
        "    chain_type_kwargs={\"prompt\": QA_CHAIN_PROMPT}\n",
        ")\n",
        "\n",
        "question = \"relationship between diabetes and obesity\"\n",
        "\n",
        "qa_chain_faiss({\"query\": question})['result']"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 142
        },
        "id": "MqLanHcALHq6",
        "outputId": "739b4d69-d548-45b7-950f-4fff604834a1"
      },
      "execution_count": 79,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " It's my pleasure to help you with that! According to the given data, there is a strong positive correlation between diabetes and obesity. The prevalence of Type 2 diabetes mellitus increases significantly with increasing obesity prevalence in both men and women. In fact, based on the period trends, it's projected that by 2020, the prevalence of Type 2 diabetes mellitus will be 26% in both men and women, and the obesity prevalence is projected to be 59% in men and 81% in women. This suggests a strong association between obesity and"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:ctransformers:Number of tokens (501) exceeded maximum context length (500).\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            " an"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "WARNING:ctransformers:Number of tokens (502) exceeded maximum context length (500).\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "\" It's my pleasure to help you with that! According to the given data, there is a strong positive correlation between diabetes and obesity. The prevalence of Type 2 diabetes mellitus increases significantly with increasing obesity prevalence in both men and women. In fact, based on the period trends, it's projected that by 2020, the prevalence of Type 2 diabetes mellitus will be 26% in both men and women, and the obesity prevalence is projected to be 59% in men and 81% in women. This suggests a strong association between obesity and an\""
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 79
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "faiss_retriever.get_relevant_documents(question)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "dBZ0JcQ7Q_FI",
        "outputId": "657f4ba7-ccb6-43b6-cf38-ed71325a130d"
      },
      "execution_count": 86,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[Document(page_content='Over 1978–2013, Type 2 diabetes mellitus prevalence increased from 1.2% to 19.6% in men (2.3% per 5 years), and from 2.2% to 19.5% in women (2.2% per 5 years). Obesity prevalence increased from 27.7% to 53.1% in men (3.6% per 5 years) and from 44.4% to 76.7% (4.5% per 5 years) in women. Type 2 diabetes mellitus and obesity prevalences increased in all age groups. From period trends, Type 2 diabetes mellitus prevalence in 2020 is projected to be 26% in men and women. Projected obesity prevalence is projected to be 59% in men and 81% in women. Type 2 diabetes mellitus period trends attributable to BMI increase are estimated as 31% (men) and 16% (women), after adjusting for age.', metadata={'splits_id': '1', 'document_id': 'PMC5411261_abstract.txt'})]"
            ]
          },
          "metadata": {},
          "execution_count": 86
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [],
      "metadata": {
        "id": "9cFQk5wBSr-g"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}